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The main focus of this PhD thesis is the study of iminosugars as potential 
glycosidases inhibitors. Two main classes of these carbohydrates mimics have been taken 
into consideration, namely polyhydroxylated pyrrolidines and piperidines, which were 
treated from different point of view, in particular in terms of Multivalency, one of the main 
issues studied in this work. If iminosugars is the pivotal class of molecules under deep 
examination, different types of glycosidases target have been screened, accordingly to the 
azasugar nature and to the final application consequently. 
 
Since the key role played in nature by chemical process of recognition between 
carbohydrates and glycosidases is known, several efforts have been done in the field of 
carbohydrate chemistry. Glycosidases indeed are key hydrolytic enzymes involved in many 
physiological functions, such as intestinal digestion, post-translational processing of the 
sugar chain of glycoproteins, quality-control systems in the endoplasmic reticulum (ER) and 
ER-associated degradation mechanism and the lysosomal catabolism of glycoconjugates. 
For this reason, the inhibition of those enzymes could be very important in several, not only 
biomedical, but also industrial applications. A branch of glycoscience concerns in fact the 
synthesis of carbohydrates mimics, such as iminosugars, a class of natural compounds in 
which a nitrogen atom replaces the endocyclic oxygen of sugars. They are demonstrated to 
be excellent glycosidases inhibitors because of their structural resemblance to the terminal 
sugar moiety in the natural substrates (the non-reducing end of polysaccharides). Starting 
from this point is possible to design new iminosugar-based drugs for the treatment of 
different pathologies by employing themselves as bioactive moiety or as ‘carbohydrate 
targeting-probe’, but also in the crop protection field as novel insecticides and fungicides.  
 
More recently, a new revaluation of iminosugars application to glycosidases inhibition 
arose following the possibility to create multivalent structures in which more than one unit 
of bioactive moiety are linked together onto a common scaffold. Since the first decade of 
2000’s indeed, the multivalency has been predominantly exploited for the study of the 
interaction between multivalent ligands and lectins. Nowadays it can be applied to increase 
the biological response towards enzymes with a deep enzyme cavity. 
 
Chapter 1 gives an overview of iminosugars, ranging from their natural occurrence and their 
classification to the synthetic methodologies and their application. In the 1970’s their 
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biological activity as potent glycosidases inhibitors became known, and this opened up a 
great interest towards a deep investigation about the mechanisms involved. However, 
large amounts of starting material are required for biological studies and the need to find 
new ways to synthesize them grew, being still now a hot topic in this branch of 
glycoscience. Lot of efforts were done in the total synthesis of iminosugars, since it is an 
important tool both for the structural confirmation of the natural compounds and to 
furnish new synthetic analogs with increased biological activity. Moreover, biological 
iminosugars’ target is a wide range of glycosidase enzymes, depending on the molecule’s 
structure, and consequently they could be used as drugs in the treatment of different kind 
of pathologies. 
 
Chapter 2 moves to a different application of iminosugar glycomimetics, having the 
synthesis of new potent and selective insecticides the final goal: the synthesis of new 
pseudodisaccharide mimetics based on pyrrolidine iminosugars as inhibitors of trehalases.  
These enzymes are retaining α- glucosidases that cleave the glycosidic bond converting 
trehalose in two units of glucose. This disaccharide has several functions in different 
organisms such as fungi, mycobacteria, and insects.  
The synthesis of new pseudodisaccharide mimetics using a stereoselective -glucosylation 
is presented, and allowed the preparation of a small library of new α,β-mixtures and -
pseudodisaccharides. Their biological evaluation towards insect trehalase of midge larvae 
of C. riparius and porcine kidney trehalase was also reported.  
 
Chapter 3 has the multivalency as the key concept and illustrates the synthetic strategies 
developed in our group at the University of Florence to build up new multivalent 
architectures exploiting different types of scaffolds, from gold nanoparticles to dendrimeric 
scaffolds. Starting from commercially available carbohydrates precursors, azido key 
intermediate structures were synthesized, from enantiopure cyclic nitrones and were then 
anchored onto different platforms. With those intermediates a small library of multivalent 
structures based on pyrrolidine and piperidine iminosugars have been obtained exploring 
Copper (I) catalyzed Azide-Alkyne Cycloaddition (CuAAC) with propargylated scaffolds 
characterized by different structure and valency. Moreover, a novel copper-free route 
consisting of subsequently repeated 1,3-dipolar cycloadditions was explored, in order to 





Chapter 4 deals with the synthesis of new monovalent and multivalent systems based on 
sugars and on iminosugar glycomimetics, in order to identify a new class of 
inhibitors/activators with a selectivity profile with respect to the different isozymes of 
carbonic anhydrases (CAs). The most potent CAs inhibitors are sulphonamides that could 
be functionalized with structures able to interact with prostetic group and providing so an 
adequate selectivity towards the different CAs families. Here the possibility to differentiate 
different CAs families exploiting different sugar or iminosugar ‘tails’ is reported. While the 
importance of the sugar component is already known, the effect of an iminosugar on the 
enzyme has never been studied. Moreover, also the concept of multivalency applied to 
those class of metalloenzymes is explored. For this reason, the synthesis of a small library 
of monovalent compounds that contain sugar or iminosugar moiety bound with different 
linkers to the sulphonamide moiety is here reported. 
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1.1 Iminosugars: natural glycomimetics 
In the wide glycomimetics world, a significant role is held by iminosugars, sugar 
mimics in which a nitrogen atom with basic properties replaces the endocyclic oxygen 
(Figure 1.1). 
 
Figure 1.1: General carbohydrate structure compared with general iminosugar 
structure. 
Many iminosugars are present in nature. Isolated from plants and microorganisms, 
iminosugars, or polyhydroxylated alkaloids, can be classified considering different aspects 
of their nature; the most common manner is to divide them into five classes, depending on 
the structure of their carbon skeleton: piperidine, pyrrolidine, indolizidine, pyrrolizidines 
and nortropanes. In figure 1.2 some examples of iminosugars well known in the literature, 
divided by the kind of structure are shown. 
 
Figure 1.2: Structure-based classification of iminosugars and some examples. 
Considering the natural hydrolytic process catalysed by glycosidases in many important 
biological processes and its transition state, it is easy to understand how iminosugars 
became, since their discovery in 1960s, one of the most privileged class of glycosidases 
Iminosugars as glycosidases inhibitors  
__________________________________ 
10 
inhibitors. Indeed their structural resemblance to the terminal sugar moiety in the natural 
substrates (polysaccharides) makes them able to interact with human glycosidases, other 
proteins and sugar receptors.1 The key of their potency is that at physiological pH the 
nitrogen atom of the iminosugar results protonated and the cationic species formed are 
able to perfectly mimic the oxocarbenium ion involved in the transition state of the 
hydrolysis catalysed by glycosidase enzymes (Figure 1.3).  
 
Figure 1.3: Example of an inverting glycosidase mechanism: an oxocarbenium ion like transition 
state is always involved in the hydrolytic process. 
Their therapeutic applications go back a long time ago, starting from the traditional Chinese 
medicine in which iminosugars were used in the treatment of diseases such as diabetes 
and bacterial infections, to the 17th century when a similar drug based on iminosugars was 
produced in industrial scale.2 However, we can fix the begin of scientific story of iminosugar 
in the 1960s, when the first synthesis of 1-deoxynojirimycin (DNJ, 1, Figure 1.4) was 
reported by Paulsen and coworkers3 and almost simultaneously the group of Prof. Inouye 
discovered the antibiotic properties of nojirimycin (NJ, 8, Figure 1.4) by isolating it from 
Streptomyces bacteria.4 Hence the interest towards this class of compounds could only 
increase, especially after that the inhibitory activity against an -glucosidase of DNJ was 
for the first time announced: it was the starting point for the discovery of hundreds of 
polyhydroxylated alkaloids, known also as iminosugars.5 
 
1 Compain P., Martin O. R., Iminosugars: from synthesis to therapeutic applications, Wiley-VCH, Weinheim, 
2007. 
2 Aerts J. M. F. G., Proc. European Working Group for the Study of Gaucher Disease, 2006. 
3 Paulsen H., Angew. Chem. Int. Ed. Engl., 1966, 5, 495-511. 
4 Inouye S., Tsurouka T., Niida T., J. Antibiot. Ser., 1966, A19, 288–292. 
5 Stütz A. E., Iminosugars as Glycosidase Inhibitors. Nojirimycin and Beyond, Wiley-VCH, Weinheim, Germany, 
1999.  





Figure 1.4: Deoxynojirimycin, DNJ and nojirimycin, NJ. 
One of the biggest challenges in this field is the efficient isolation of enantiomeric pure 
compounds, since a large amount of material is necessary to perform biological studies. 
Indeed the complexity of iminosugars structures, characterized on one hand by lot of 
hydroxyl groups and on the other by the basic nature of the endocyclic nitrogen atom, 
makes the synthesis not a trivial task.  
The glycosidases inhibition field offers such a wide range of topics, considering that 
according to the different structures of iminosugar, different type of glycosidases can be 
inhibited, and different therapeutic and industrial applications are possible.6 
 
1.2 Glycosidases and therapeutic glycomimetics 
1.2.1 Glycosidase enzymes 
Why is inhibiting glycosidases so important?                
Since glycosidases are involved in different processes, their inhibition represents a 
powerful tool both to clarify the biological mechanisms and to develop treatments for 
different types of diseases. As mentioned before, iminosugars represent excellent 
glycosidases inhibitors, due to their ability to mimic the oxocarbenium ion like transition 
state. Great efforts have been made in recent years to design and synthesize inhibitors of 
glycosidases. Given their multitude of roles in vivo indeed, inhibition of these enzymes is 
extremely attractive in the developing of new potential drugs to be used in the treatment 
of viral infections,7 diabetes8 and lysosomal storage disorders.9 
 
 
6 For a recent review see: Compain P., Chem. Rec. 2019, 19, 1–14. 
7 Mehta A., Zitzmann N., Rudd P. M., Block T. M., Dwek R. A., FEBS Lett., 1998, 430, 17–22. 
8 Krentz A. J., Bailey C. J., Drugs, 2005, 65, 385–411. 
9 Fan J.-Q., Ishii S., Asano N., Suzuki Y., Nat. Med., 1999, 5, 112–115. b) Sawkar A. R., Cheng W.-C., Beutler E., 
Wong C.-H., Balch W. E., Kelly J. W., Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 15428–15433. 
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Glycoside hydrolases (GHs; EC 3.2.1.-), well known as glycosidases, are enzymes 
responsible for the hydrolysis of the glycosidic linkage in carbohydrate compounds such as 
di-, oligo- and polysaccharides essential to life.1,10 In order to understand the significance 
of those enzymes we can just think to the variety of biological processes in which they are 
involved, such as catabolism of glycoconjugates (particular emphasis in this thesis will be 
given to the lysosomal one), intestinal digestion, post-translational processing of the sugar 
chain of glycoproteins, quality-control systems in the endoplasmic reticulum (ER) and ER-
associated degradation mechanisms. All these processes rely at the basis of life in 
organisms such as humans, animals and plants. Regarding the structural diversity of 
carbohydrates and the extreme stability of the glycosidic bond, glycosidases have been 
considered the most specific and proficient of catalysts, indeed they could enhance the 
reaction rate until 1017 fold over the uncatalysed reaction.11 They are part of the so-called 
“carbohydrate-active enzymes” (CAZymes) and represent from 1 to 3% of the proteins 
encoded by the genomes of most organisms.12 This classification is based on amino acid 
sequence similarity and to date 156 sequence-distinct families of glycosidases are present, 
and they are constantly increasing (they can be found on the online database 
http://www.cazy.org). Enzymes within a sequence-related family catalyze the cleavage of 
the glycosidic bond by the same mechanism and share a similar overall structural fold.13 
The reaction catalyzed by glycosidases is formally a nucleophilic substitution at the 
saturated carbon of the anomeric position and can take place with either retention or 
inversion of the anomeric stereochemistry (Figure 1.5), giving so two basic types of 
glycosyl-transferring enzymes: "retaining" and "inverting".14 
 
10 a) Gloster T. M. and Davies G. J., Org. Biomol. Chem. 2010, 8, 305–320; b) Stütz A. E. and Wrodnigg T. M., 
Adv. Carbohydr. Chem. Biochem. 2011, 66, 187-298. 
11 Wolfenden R., Lu X. D., Young G., J. Am. Chem. Soc. 1998, 120, 6814–6815. 
12 Davies G. J., Gloster T. M., Henrissat B., Curr. Opin. Struct. Biol., 2005, 15, 637-645.   
13 Cantarel B. L., Coutinho P. M., Rancurel C., Bernard T., Lombard V., Henrissat B., Nucleic Acids Res., 2008, 37, 
D233-238.   
14 Rempel B. P., Withers S. G., Glycobiology, 2008, 18, 570–586. 




Figure 1.5: (a) Mechanism for an inverting β-glucosidase. (b) Mechanism for a 
retaining β-glucosidase. 
The bond cleavage performed by GHs is catalysed by the action of two acidic residues in 
the enzymatic active site. In “inverting glycosidases” the nucleophilic attack on the 
anomeric position is done by the water molecule, deprotonated by one of the acids that 
works as a base. At this point the removal of the -OR group is catalysed by the other 
carboxylic acid. The steps of breaking-formation of the glycosidic bonds occur through a 
concerted oxocarbenium ion-like transition state, in which the positive charge is partially 
stabilized by the ring oxygen. In inverting glycosidases, the product has the opposite 
configuration at anomeric position with respect to the starting substrate. For the “retaining 
glycosidases” instead, the mechanism differs from the first one by the formation of a 
covalently bound glycosyl-enzyme intermediate, and hence proceeds through two 
oxocarbenium ion-like transition states. It is important to note that the proton delivered 
during general acid catalysis is delivered in either a syn- or anti-fashion, depending on the 
specific enzyme. Moreover, glycosidases can be further divided according to whether the 
sugar is in a five-membered (furanose) or a six-membered (pyranose) ring (Figure 1.6). In 
the case of pyranosyl-transferring enzymes it is also useful to distinguish whether, in the 
preferred conformation, the leaving group is equatorial or axial. 15 
 
15 Sinnott ML., Chem Rev., 1990, 90, 1171–1202. 




Figure 1.6: Example of pyranosyl and furanosyl-transferring hydrolases mechanism. 
Carbohydrates represent one of the most abundant family of natural compounds, with 
different type of linkages. Since the mode of action of glycosidases involves the cleavage of 
glycosidic bonds between sugar molecules, individual glycosidases show specificity for 
certain sugar molecules and for a specific anomeric configuration of that sugar. In that 
sense sometimes, it can be useful talk about - or -glycosidases. Polyhydroxylated 
alkaloids can be extremely potent and specific inhibitors of glycosidases by mimicking the 
pyranosyl or furanosyl moiety of their natural substrates.  
As structural and mechanistic studies have become more sophisticated, it is possible to 
acquire more and more information about different mode of actions and mechanisms and 
the study of the interactions substrate-enzyme complexes become easier. For example, 
other mechanisms have been proposed for small subsets of glycoside hydrolases that are 
substantially different from the inverting/retaining glycosidases, and this information help 
the inhibitor designing for these enzymes. Several families containing glycosidases which 
hydrolyse substrates containing N-acetylhexosamine with retention of configuration 
(which are classified into families GH18, GH20, GH56, GH84, GH85, and is likely for GH25)16 
have been shown to lack a conventional catalytic nucleophile, but instead use a substrate-
assisted catalytic mechanism (Figure 1.7). The acetamido group at the C-2 position of the 
substrate acts as a nucleophile to attack the anomeric carbon to create an enzyme-
stabilized oxazoline intermediate. The intermediate is hydrolysed by a water molecule, 
which is activated by a residue acting as a general base. In most cases, a second 
carboxylate-containing residue orients and polarizes the 2-acetamido group to increase its 
nucleophilicity. 
 
16 a) Macauley M. S., Whitworth G. E., Debowski A.W., Chin D., Vocadlo D. J., J. Biol. Chem., 2005, 280, 25313-
25322; b) Umekawa M., Huang W., Li B., Fujita K., Ashida H., Wang L., Yamamoto K. J., Biol. Chem., 2008, 283, 
4469-4479.   




Figure 1.7: Substrate-assisted mechanism proposed for families 18, 20, 56, 84, 85 and possibly 
25. 
Glycosidases are synthesized in the endoplasmic reticulum where they adopt their native 
conformations and are transported into the lysosomes through the Golgi apparatus.17 If a 
mutation in genes encoding for enzymes (such as integral membrane proteins and 
transport proteins, all with lysosomal localization) is present, a defect of one or more of 
the different functions of lysosomes can take place. For example, a protein may not be 
synthesized, or it can be synthesized with a defect, being in that way recognized as altered 
by the quality control systems of the cell and for this reason degraded. The consequence is 
the inability to metabolize a specific substrate (sphingolipids, glycosaminoglycans, 
glycoproteins and glycogen), which accumulates in lysosomes, provoking after a series of 
events, cell death and tissue and organ damage. When this series of event occurs, we have 
the so-called Lysosomal Storage Disorders. 
1.2.1 Lysosomal Storage Disorders  
Lysosomal Storage Disorders (LSDs) are a group of about 70 hereditary metabolic diseases 
caused by mutations in genes that code for enzymes, integral proteins of membrane and 
transport proteins with lysosomal localization. The mutation prevents the enzyme to 
overcome the efficient quality control of the endoplasmic reticulum, causing a reduced 
lysosomal activity, and therefore an abnormal accumulation of not metabolised substrate 
in the lysosomes. 18  Thus, the wide range of symptoms in LSDs may be explained by the 
activation of several deleterious processes, such as the release of acid hydrolases into the 
cytoplasm causing cellular damage, the dysregulation of apoptosis or the abnormal 
 
17 Parenti G., Andria G., Ballabio A., Annu. Rev. Med., 2015, 66, 471-486. 
18 Ortolano S., Viéitez I., Navarro C., Spuch C., Pat. Endocr. Metab. Immune Drug. Discov., 2014, 8, 9-25. 
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accumulation of lipids causing defective transport of substrates into and out of the 
lysosomes (Figure 1.8).19  
 
 Figure 1.8: The pathogenic cascade in lysosomal storage disorders (LSDs). 
Their symptomatology depends on the stored substrate and organs affected by this 
accumulation. LSDs can be classified on the base of the involved enzymes and consequently 
on the abnormally accumulated substrate (Figure 1.9). 
Although individually very rare, the incidence of LSDs as a group is estimated to be as high 
as 1 in 4000 in some countries,20 even if the exact prevalence is difficult to estimate, 
considering the clinical heterogeneity of LSDs, which may lead to missed diagnoses. 
According to Medical Genetics Service of the Hospital de Clínicas de Porto Alegre data, the 
investigation of high-risk subjects led to 3,512 LSD diagnoses in Brazil from 1982 to 2017.21 
Most of LSDs are neuronopathic, with Central Nervous System (CNS) involvement, 
progressive neurodegeneration and cognitive impairment. The most severe forms occur in 
infants with onset in utero (i.e. Sialidosis, Galactosialidosis, GM1 gangliosidosis, Gaucher 
type II, MPSIVA) or within 6 months and outcome in the second year of life, while in the 
 
19 Platt F.M., Nat. Rev. Drug Discov., 2018, 17, 133–150. 
20 Giugliani R., Federhen A., Michelin-Tirelli K., Riegel M., Burin M., Genet. Mol. Biol., 2017, 40, 31-39. 
21 Poswar F. O., Vairo F., Burin M., Michelin-Tirelli K., Brusius-Facchin A. C., Kubaski F., Fischinger C.,  Souza M., 
Baldo G., Giugliani R., Genet. Mol. Biol., 2019, 42, 165-177. 
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less severe forms, clinical symptoms eventually appear during adulthood and are the cause 
of reduced life expectation. 
DISEASE GENE ENZYME STORAGE PRODUCT 
Tay-Sachs HEX A -Hexosaminidase A GM2, Condroitin sulfate 
Sandhoff HEX B -Hexosaminidase A/B GL4, GA2 GM2 
Fabry GLA -Galactosidase A Gb3 LysoGb3 
Gaucher GBA -Glucosidase Glucocerebroside 
GM1 Gangliosidosis GLB1 - Galactosidase GM1 
Krabbe GALC Galactosylcerebrosidase GalCer, Psychosine 
Pompe GAA -Glucosidase Glycogen 
MPS I IDUA Iduronidase Dermatin sulfate, Heparin sulfate 
MPS II IDS Iduronate sulfatase Dermatin sulfate, Heparin sulfate 




MPS III B NAGLU -N-Acetylglucosaminidase Heparan sulfate 








MPS IV A GALNS N-Acetylglucosamine 6 sulfatase 
Keratan sulfate, Chontroitin sulfate, Keratin 
sulfate 
MPS IV B GALB1 - Galactosidase GM1-ganglioside and Keratan sulfate 




MPS VII GUSB - Glucoronidase Chondroitin sulfate 




Niemann-Pick C NPC1-2 NPC-1 and NPC-2 Cholesterol, lipids 
Infantile NCL (CLN1) CLN1(PPT1) Palmitoyl-protein thioesterase 1 Lipopigments 
Late Infantile NCL (CLN2) CLN2(PPT1) Tripetiyl-peptidase 1 Lipopigments 
MLD ARSA Arylsulfatase A Sulfatides 
Figure 1.9: Molecular basis of frequent lysosomal storage diseases. 
The first therapeutic strategies directed towards the treatment of these diseases were 
introduced in the early 1990s, and since then several new approaches have become 
available or tested in preclinical studies. The first approach raised from the simplest 
intuition based on the subministration (or the restoring) of the deficient enzyme activity, 
the so-called Enzyme replacement therapy (ERT). Available since 1996, until now ERT is 
approved for the treatment of 7 kind of LSDs and under clinical trial for other seven.17 It 
consists in an infusion of a recombinant enzyme (similar to the natural one), which is taken 
up into the cell through membrane receptors (typically mannose-6-phosphate receptors) 
and replaces the catalytic action of the missing or non-functional lysosomal enzyme.22 
However, this approach is limited by several disadvantages: first recombinant enzymes are 
 
22 Brady R. O., Annu. Rev. Med., 2006, 57, 283-96. 
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very expensive. It requires lifelong, repeated infusions of large quantities of the respective 
exogenous enzyme and not all patients may benefit from them. Furthermore, ERT relies on 
active transport to eventually enter the cell and then the lysosome. These are likely rate-
limiting steps; thus, despite massive infusions of recombinant enzyme, only a small 
proportion may actually make it into the lysosome. Moreover, following a continuous 
infusion of an ‘external’ system in to the body, the risk of an immune response against the 
administrated enzyme is high.21 To finish, the biggest limitation of this therapy is that the 
infused enzyme is unable to cross the blood brain barrier. For this reason, ERT is useful only 
in diseases without neuropathic involvement.     
 Other alternative treatments are present to date, the Substrate Reducing Therapy 
(SRT) and the Gene Therapy. The first one inhibits specific steps in the biosynthetic 
pathways of substrates to restore the equilibrium between the synthesis of substrates and 
their degradation by lysosomal enzymes,23 using small-molecule enzyme inhibitors that are 
involved in substrate biosynthesis. The Gene Therapy instead, is directed toward increasing 
or restoring defective enzyme activity in patients’ cells and tissues by delivering a wild-type 
copy of the defective gene.24 Unfortunately they both have disadvantages, most of whom 
similar to those already seen for ERT.       
 The development of new strategies to effectively target the brain and bone is of 
primary importance to guarantee a better quality of life for patients affected by LSDs.    
In that sense a promising frontier is the emergent active-site-specific chaperone (ASSC) 
therapy, or pharmacological chaperone therapy (PCT).25 PC is a small molecule with high 
affinity for the active site of the target protein that reach the mutated enzyme specifically 
binding itself to the protein and acting as a folding template. Certain mutations in LSDs 
cause the synthesis of improperly folded proteins that are retarded in endoplasmic 
reticulum (ER) and degraded by “quality control” mechanism, called ER-associated 
degradation (ERAD). At subinhibitory concentrations, a small molecule able to act as potent 
competitive inhibitor, catalyzes the restoring of native-like conformation, avoiding or 
decelerating in this way the degradation of the enzyme by ERAD in the cell. The enzyme is 
so able to retain full or partial activity being correctly folded, and it can reach its normal 
site of action. The most attractive aspects in this type of therapy, are that those ASSCs can 
be administrated orally and presumably can gain access to most cell types and CNS (central 
nervous system).  
 
23 Platt F.M., Jeyakumar M., Acta Paediatr., 2008, 97, 88–93. 
24 Sands M.S., Davidson B.L., Mol. Ther., 2006, 13, 839–49. 
25 Fan J.-Q., Trends Pharmacol. Sci. 2003, 24, 355–360. b) Desnick R. J., Schuchman E. H., Nat. Rev. Genet, 2002, 
3, 954–966. 




Figure 1.10: Endoplasmic reticulum (ER) quality-control system and active-site-specific 
chaperone (ASSC) therapy.1 
Compounds called to act as chaperones are those that show high affinity to target protein, 
and who better than reversible enzymatic inhibitors? Once the enzyme/substrate complex 
is formed and goes out of the ER, the inhibitor at subinhibitory concentrations can be easily 
replaced by the natural substrate that is nearby in high level of concentration, because it 
results still not metabolized (Figure 1.10). According to what has been reported until now, 
iminosugars represent the ideal candidates to be used as pharmacological chaperones. As 
we will deepen later, also SRT based-drugs already approved for the treatment of lysosomal 
storage disorders have iminosugars as fundament.  
 
1.2.2 -Glucosidase – Gaucher Disease 
 One of the most diffuse LSD is Gaucher Disease, related to -glucosidase, a 
glycoside hydrolase enzyme (EC 3.2.1.45). Also known as glucocerobrosidase or GCase, -
glucosidase, it is a peripheral membrane protein that catalyses the hydrolysis of 
glucoceramide (GlcCer, 9, Figure 1.11) to -glucose (10) and ceramide (11) in presence of 
the modulator protein saposin C and lipid (Figure 1.11).26   
 
26 Lieberman R.L.,Wustman B.A., Huertas P., Powe A.C. Jr., Pine C.W., Khanna R., Schlossmacher M.G., Ringe D., 
Petsko G. A., Nat. Chem. Biol., 2007, 3, 101–107. 
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Figure 1.11: Scheme of the reaction performed by GCase. 
Total or partial GCase enzyme deficiency leads to an abnormal accumulation of GlcCer (9) 
inside microphages lysosomes, with serious consequences that are symptoms of the LSDs 
called Gaucher Disease (GD). GD is a systemic disorder that presents with a various degree 
of systemic and neurological manifestations; to date, more than 400 mutations have been 
identified in the GBA1 gene and all of these cause the total or partial absence of enzymatic 
activity of the GCase protein. In this situation GCase is not properly folded and accumulates 
in the endoplasmic reticulum (ER), where it is degraded by the proteasome: GCase is not 
transported to the lysosome and, consequently, an accumulation of glucosylceramide is 
found there. Gaucher disease can be divided into 3 phenotypes based on the presence or 
absence of neurological manifestations and on the rate of its progression. In type 1 (GD1), 
the mildest and most common of the three clinical forms of Gaucher’s disease (90-95% of 
cases), patients suffer from bone pain, skeletal lesions, anaemia and liver or spleen damage 
without any neuronal involvement. Type 2 Gaucher (<5% of cases) is characterized by 
severe and early neurological involvement that develops in newborns starting at 3-6 
months of age. Splenomegaly and hepatosplenomegaly are almost always present while 
growth retardation may be the first sign of the disease. Also called subacute neurological 
GD, the type 3 Gaucher form (5% of cases) shows the visceral manifestations described in 
GD1, usually combined with neurologic-oculomotor involvement. Among all the LSDs, the 
Gaucher possesses the broader alternative therapies, counting at least two approved 
therapies based on different approaches (ERT and SRT) on the market, and one on clinical 
trial based on the use of PC (Figure 1.12).  




Figure 1.12: The major sites of action of the current lysosomal storage disorder therapeutics. 
Indeed, Gaucher disease is the first lysosomal storage for which the recombinant human 
-glucocerebrosidase enzyme was developed and approved by the FDA in 1991 
(Imiglucerase, Cerezyme®).27 Moreover, other two drugs based on ERT are now on the 
market: Taliglucerase alfa (Elelyso®) and Velaglucerase (Vpriv®).20 The other main 
therapeutic approach for treating GD and currently available is to reduce the amount of 
substrate entering the lysosome, thereby compensating for the catabolic defect. This 
approach (SRT) is now in clinical practice for the treatment of mild-to-moderate type 1 
Gaucher disease, and it is based on the use of N-butyldeoxynojirimycin (NB-DNJ 12, 
Miglustat, Zavesca®, figure 1.13). It inhibits GlcCer synthase (Ki, 7.4 M) if the N-alkyl chain 
is at least three carbon atoms in length28 and is a competitive inhibitor for ceramide able 
to lower the rates of synthesis of all GlcCer-based glycolipids, thus reducing glycolipid 
accumulation.29 
 
27 Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., 
Parker R.I., Argoff C.E., N. Engl. J. Med., 1991, 324, 1464-1470. 
28 Platt F.M., Neises G.R., Dwek R.A., Butters T.D., J. Biol. Chem., 1994, 269, 8362–8365. 
29 Lachmann R.H., Curr. Opin. Investig. Drugs., 2003, 4, 472–479. 




Figure 1.13: NB-DNJ. 
An approach that has recently attracted much interest in the treatment of Gaucher Disease 
is the one that uses PCs. The chaperoning activity of an iminosugar already known as potent 
-glucocerebrosidase inhibitor, N-nonyl-deoxynojirimycin (NN-DNJ, figure 1.13), was 
demonstrated for the firs time in 2002 by Sawkar and co-workers. Indeed, if subministrated 
at subinhibitory concentrations, it enhanced about two-fold the residual activity in mutated 
N370S enzyme (the most frequent mutation involved in Gaucher Disease).30 From this 
starting point, other groups discovered other iminosugars able to act as ASSCs, paving the 
way for the research in this field. In Figure 1.14 are reported some examples of potential 
chaperones iminosugar-based for GD. 
                                                          
Figure 1.14: Structures of some potential ASSCs in GD treatment. 
 
30 Sewkar A.R, Cheng W.C, Beutler E., Wong C.H., Balch W.E, Kelly J.W., Proc. Natl. Acad. Sci USA, 2002, 99, 
15428-15433. 
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For example, the synthetic 1-N-iminosugar isofagomine (IFG, 2), underwent a clinical trial 
against GD under the name of PliceraTM.31  
Following the pioneering work on NB-DNJ and NN-DNJ, several examples of N-alkylated 
iminosugar frameworks have been proposed as pharmacological chaperones for GD, again 
following the common concept to conjugate an iminosugar with a lipophilic moiety: the 
former may mimic the sugar part or the transition state towards glycosidic cleavage and 
the latter may mimic the ceramide aglycone of the natural substrate, glucosylceramide (9, 
Figure 1.11).  An example is another N-alkylated piperidine iminosugar synthetized in our 
research group in 2015. It showed measurable chaperone activity with human fibroblasts 
derived from Gaucher patients bearing the N370/RecNcil mutation (17, Figure 1.15) and it 
can increase 1.25-fold GCase activity at 100μM concentration.32  
Inhibition IC50 Rescue of GCase activity
(at 1mM)
98%
30 1 1.25 fold at 100 nM
 
Figure 1.15: Inhibition, IC50 and chaperoning activity for compound 17. 
Just for mentioning, structure–activity relationship studies indicated that a simple 
1,2-shift of the alkyl chain from the endocyclic nitrogen to the “anomeric” carbon could 
lead to more potent glucosidase inhibitors.33 Indeed, relevant examples have been 
reported for two C-alkylated analogues of IFG (2), compounds 18 and 19 (Figure 1.16), for 
which a 1.50-fold34 and a remarkable 1.80-fold35 GCase activity enhancements at 10 nM in 
N370S GD fibroblasts were observed, respectively. Interestingly, compounds 18 and 19 
have the opposite configuration of the alkylated carbon atom, showing that both 
configurations are able to achieve the biological activity.  
 
31 Steet R.A., Chung S., Wustman B., Powe A., Do H., Kornfeld S.A., Proc. Natl. Acad. Sci. USA, 2006, 103, 3813–
13818. 
32 Parmeggiani C., Catarzi S., Matassini C., D’Adamio G., Morrone A., Goti A., Paoli P., Cardona F., Chem. Bio. 
Chem., 2015, 16, 2054−2064. 
33 Godin G., Compain P., Martin O. R., Ikeda K., Yu L., Asano N., Bioorg. Med. Chem. Lett. 2004, 14, 5991 –5995. 
34 T. Hill, M. B. Tropak, D. Mahuran, S. G. Withers, ChemBioChem 2011, 12, 2152-2154. 
35 P. Compain, O. R. Martin, C. Boucheron, G. Godin, L. Yu, K. Ikeda, N. Asano, ChemBioChem 2006, 7, 1356-
1359. 




Figure 1.16: Two examples of C-alkylated chaperones. 
Moreover recently, a series of C-alkylated iminosugars varying the alkyl chain length was 
reported in our research group (Figure 1.17), giving interesting chaperoning activity.36  
 
 
Figure 1.17: New C-alkylated chaperones. 
 
1.2.4 Sulfatases – Mucopolysaccharidosis II and IV A  
Another class of glycosidases of our interest are sulfatases, enzymes which catalyse the 
hydrolysis of sulfuric acid esters from a wide variety of substrates, including 
glycosaminoglycans (GAGs, mucopolysaccharides), glycolipids and steroids. Eleven 
different mammalian sulfatases have been identified; eight in lysosomes and three 
associated with microsomal membranes. Anyway, the residues of the active site are highly 
conserved thus indicating that they all have common structures. This similarity is 
guaranteed by the presence of a cysteine residue that is first post-traslationally modified 
into a formyglycine and then hydroxylated into an activated hydroxylformyglycine, 
necessary for sulfatase activity of the enzyme (Figure 1.18).37  
 
36 Clemente F., Matassini C., Goti A., Morrone A., Paoli P., Cardona F., ACS Med. Chem. Lett., 2019, 10, 621−626. 
37 Schmidt B., Selmer T., Ingendoh A., von Figura.K., Cell, 1995, 82, 271–278. 
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Figure 1.18: Scheme for the post-translational modification of the essential active-site cysteine 
residue.38 
When this process does not occur, because of a deficiency of a specific lysosomal sulfatase, 
the degradation of substrates is not possible and leads in this way to rare inherited clinical 
disorders called mucopolysaccharidoses (MPS) belonging to LSDs.  
Clinical manifestations of the mucopolysaccharidoses depend on the specific enzyme 
deficiency, the end organ affected, and the accumulation of glycosaminoglycans in the 
affected organs. For example brain can be affected, minimizing in this case other somatic 
manifestations, whereas in diseases in which the brain is not involved, there is no mental 
retardation. MPS disorders share many common clinical features to variable degrees. These 
include coarse facial features, short stature, skeletal dysplasia (dysostosis multiplex), joint 
stiffness, organomegaly, cardiac valve disease, corneal clouding, hearing loss, airway 
obstruction, and respiratory infections.39 
Specific degradative lysosomal enzyme deficiencies have been identified for all the 
mucopolysaccharidoses (Figure 1.19). The glycosaminoglycans that are stored and excreted 
in the urine of the various mucopolysaccharidoses are dermatan sulfate, heparan sulfate, 
keratan sulfate, and chondroitin 4/6 sulfates.40  
 
38 Bond C.S., Clements P.R., Ashby S.J., Collyer C.A., Harrop S.J., Hopwood J.J., Guss J.M., Structure, 1997, 5, 
277-289. 
39 Neufeld E., Muenzer J., The Mucopolysaccharidoses, McGraw-Hill, 2014. 
40 Yu C., Lysosomal storage disorders: Mucopolysaccharidoses, Elsevier, 2017, 191-209. 




Figure 1.19: The catabolism of GAGs. Enzyme deficiencies in different MPS types are shown in 
parentheses. 
Nondegraded or partially degraded fragments of GAGs are excreted in the urine, which can 
be used for screening and diagnosis of MPS disorders. Various enzyme replacement 
therapies (ERTs) have been developed or are under investigation for treatment of MPS. 
 
Mucopolisaccharidose IV A (Morquio A syndrome): it is caused by a deficiency in the enzyme 
N-acetylgalactosamine-6-sulfatase (GALNS) that cleaves the C-6 sulfate group from the N-
acetylgalactosamine-6-sulfate residue of chondroitin-6-sulfate (Figure 1.19). It is estimated 
that incidence for this disease ranges from one to 76,000 births in Northern Ireland and 
one to 640,000 births in Western Australia.41 The disease presents two phenotypes 
depending on its severity: a mild form, which generally allows the patient a full life span, 
and a severe form, which often results in death before the second decade of life.42 There is 
no definitive cure for Morquio syndrome, indeed the current standard of care is medical 
and surgical management of the involved systems with the goal of palliation, prevention, 
and slowing of the progression of complications.43 Currently in the treatment of Morquio 
A syndrome an ERT therapy based on elosulfase alfa (Vimizim®, BioMarin) is used, recently 
 
41 Solanki G. A., Martin K. W., Theroux M. C., Lampe C., White K. K., Shediac R., Lampe C. G., Beck M., Mackenzie 
W. G., Hendriksz C. J., Harmatz P. R., J. Inherited Metab. Dis., 2013, 36, 339. 
42 Northover H., Cowie R. A., Wraith J. E., J. Inherited Metab. Dis., 1996, 19, 357–365. 
43 Davison J.E., Kearney S., Horton J., Foster K., Peet A.C., Hendriksz C.J., J. Inherit. Metab. Dis. Epub., 2012. 
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approved by the FDA (Food and Drug Administration) and by the EMA (European Medicines 
Agency). Not being effective for CNS involvement, again there is a need for the 
identification of compounds which can act as PCs for this orphan disease. Recently Garman 
and co-workers determined the three-dimensional structure of the enzyme 
acetylgalactosamine-6-sulphatase (GALNS) and demonstrated its dimeric nature.44 With 
this structural information in hands, we contributed to the field by synthetizing pyrrolidine-
based inhibitors (deeply discussed in Chapter 3).45  
 
Mucopolisaccharidose II A (Hunter syndrome): it is caused by a deficiency of iduronate-2-
sulfatase (IDS), which cleaves the C-2 sulfate from L-iduronic acid residues at the 
nonreducing ends (NREs) of heparin, heparan sulfate, and dermatan sulfate (Figure 1.19). 
More than 500 mutations have been identified to date, approximately 40% of which are 
deletions, duplications, insertions, indels, or complex rearrangements mechanisms 
(Human Gene Mutation Database (HGMD)).40 It is chronicle and progressive and patients 
with MPS II are often classified as severe MPS II or a more mild attenuated form 
(attenuated MPS II). The most severe form of MPS II is characterized by progressive 
cognitive impairment, progressive airway disease, and heart disease. Death usually occurs 
in the first, second, or third decades of life. Those with an attenuated form of MPS II 
typically have no-to-minimal cognitive involvement, living well into adulthood. It is 
probably an underestimated incidence of 1.3 per 100,000 newborn males46 and the most 
common symptoms are problems with internal organs such as liver and heart, hearing loss, 
motor difficulties and skeletal deformations. Idursulfase based ERT therapy (Elaprase®, 
Shire Human Genetic Therapy, Inc., Cambridge, MA), which has been on the market since 
2006, is now available in more than 40 countries.  
To date still little investigated, these two pathologies constitute an interesting test bench 
for the development of PCs that can be used as such or in combination with ERT therapy, 
already available for both. It has been shown that the combined use of a PC with ERT 
therapy is able to increase the life time of the conformationally stable form of the enzyme, 
reducing the need to undergo enzymatic administration therapy. Also for this reason it is 
necessary to research and develop new PCs. 
Considering these concepts and considering also our interest in the synthesis of 
nitrogenating glycomimetics, our research group contributed to the field with a preliminary 
investigation of the potential inhibitory activity of some multivalent pyrrolidine-based 
 
44 Rivera Colón Y., Schutsky E. K., Zita A. K., Garman S. C., J. Mol. Biol., 2012, 423, 736-751. 
45 (a) Matassini C., Parmeggiani C., Cardona F., Goti A., Tetrahedron Lett. 2016, 57, 5407. (b) Matassini C., Vanni 
C., Goti A., Morrone A., Marradi M., Cardona F., Org. Biom. Chem., 2018, 16, 8604. 
46 Beck M., Wijburg F. A., Gal A., Eur. J. Hum. Genet., 2012, 20. 
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iminosugars to be tested against these two types of sulfatases.47 The aspect of multivalency 
will be deeply discussed in Chapter 3, entirely devoted to this topic, the most studied in 
this PhD thesis. 
 
1.2.5 Golgi -Mannosidase – Anticancer applications 
α-Mannosidases hydrolyze terminal α-mannosidic linkages from glycan moieties of 
various glycoconjugates. In eukaryotes, they are involved in the processing and 
degradation of N-glycans by hydrolyzing the terminal α1–2-, α1–3- and α1–6-linked 
mannose residues from high-mannose, hybrid and complex type N-glycans present in 
glycoproteins. Initially, the -mannosidases were classified into three groups: 
acidic/lysosomal, intermediate/Golgi and neutral/cytosolic. A more recent 
classification categorizes those enzymes into two classes based on inhibition and 
sequence similarity: Class I α-mannosidase of glycosyl hydrolase (GH) family 47 present in 
the endoplasmic reticulum (ER α-man), and the Golgi apparatus (GM I) that hydrolyzes 
specifically α1–2-mannosidic linkages involved in maturation of N-glycans. These are 
classified as Class II α-mannosidases of GH family 38. In eukaryotic cells the N-glycosylation 
pathway is responsible for proper processing of proteins as they are synthesized in the 
endoplasmic reticulum (ER) and Golgi apparatus. It follows a well-defined series of steps 
and involves a considerable number of enzymes responsible for both the extension 
(glycosyl transferases) and trimming (glycosyl hydrolases) at various steps of the assembly 
process. The pathway begins with the assembly and transfer of Glc3Man9GlcNAc2 (where 
Glc is glucose, Man is mannose and GlcNAc is N-acetyl-glucosamine) oligo-saccharide 
precursor onto a newly formed polypeptide chain. Initial processing involves a series of 
trimming events by ER-resident glycosidases. As the pathway progresses through the Golgi, 
the trimming steps are followed by the action of some transferases and mannosidases, 
resulting in the mature glycosylation structure on the nascent protein destine for the cell 
surface, the lysosomes or secretion.48 Any kind of alterations are generally associated in 
cancer growth. New drugs aimed at the key enzymes involved in this pathway using sugar 
or iminosugars have opened up a new approach for anticancer therapies.49  
 
47 D’Adamio G., Matassini C., Parmeggiani C., Catarzi S., Morrone A., Goti A., Paoli P., Cardona F., RSC Adv., 
2016, 6, 64847-64851. 
48 van den Elsen J.M., Kuntz D.A., Rose D.R., EMBO J., 2001, 20(12), 3008–3017.  
49 Wrodnigg T.M., Steiner A.J., Ueberbacher B.J., Curr. Med. Chem. Anti-Cancer Agents, 2008, 8, 77-85. 




Figure 1.20: Swaisonine, -mannosidase inhibitor. 
Jack bean α-mannosidase (JBM) is a commercially available exo-glycosidase, widely used as 
a tool for glycan analysis that exhibits activity toward several different substrate, cleaving 
α1–2-, α1–3- and α1–6-linked mannose residues from various glycoprotein preparations.50 
Due to its properties similar to those of Golgi α-mannosidase II (an important therapeutic 
target), JBM serves as a model enzyme for structural and mechanistic studies for inhibitors. 
Until the first resolution of crystal structure of the apo structures of JB-man reported by 
Compain in 2018,51 interactions with inhibitors have been studied using indirect methods 
such as atomic force microscopy, dynamic light scattering, NMR or mass spectroscopy. 
These studies have led to a number of competing hypotheses and binding models involving 
large aggregates, additional interactions with enzyme subsites or formation of discrete 
cross-linked complexes, all of whom involving multivalent inhibitors (see Chapter 3).45a  
An example of GMII inhibitor is swaisonine (5, SW, figure 1.20),52 an indolizidine iminosugar. 
However, SW presents a problem of selectivity: it results a potent inhibitor also of 
lysosomal -mannosidase (LManII) and it can lead to many undesirable side effects (the 
symptoms of mannosidosis disease).53 In that sense, once again the concept of 
multivalency can help us (Chapter 3). 
 
1.2.6 Trehalase 
 Glycosidase enzymes are ubiquitous in nature, in a wide range of organisms. For 
example, in different organisms such as fungi, mycobacteria and insects, trehalases [EC 
3.2.1.28] are present. These glycosidases are responsible for the hydrolysis of ingested 
trehalose (-D-glucopyranosyl -D-glucopyranoside, 22 in figure 1.21), a disaccharide with 
a multifunctional physiological role in various organisms. Trehalose is particularly 
 
50 Li Y.T., J. Biol. Chem., 1996, 241, 1010–1012. 
51 Howard E., Cousido-Siah A., Lepage M. L., Schneider J. P., Bodlenner A., Mitschler A., Meli A., Izzo I., Alvarez 
H. A., Podjarny A., Compain P., Angew. Chem. Int. Ed., 2018, 57, 8002. 
52 Daniel P.F., Winchester B., Warren C.D., Glycobiology, 1994, 4, 551–566. 
53 Dantas A. F. M., Riet-Correa F., Gardner D. R., Medeiros R. M. T., Barros S. S., Anjos B. L., Lucena R. B., Toxicon, 
2007, 49, 111–116. 
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important for insects (it constitutes their major blood sugar)54 as it is hydrolysed into 
glucose, which is vital for insect flight. 
 
Figure 1.21: Hydrolysis of trehalose catalysed by -trehalase. 
Trehalose is not found in mammalian cells, although humans do possess a trehalase 
enzymes in intestinal villi and kidney brush border cells, probably to handle ingested 
trehalose. The absence of trehalose in the metabolism of mammals, together with the 
physiological relevance of trehalose hydrolysis in insects, makes insect trehalase inhibition 
a relevant target for the development of selective insecticides that are potentially non-
toxic to mammals.55 Compounds able to inhibit insect trehalase, without affecting the 
human one, are excellent candidates for insecticides not toxic for humans (green 
insecticides). Among the most powerful inhibitors of trehalases there are some natural 
pseudodisaccharides and analogues, such as validoxylamine A (23), trehazolin (24) and 
casuarine-6-O--D-glucoside (25) in which a glucose unit is bounded to a glycomimetic 
(Figure 1.22).56 
 
Figure 1.22: Some natural and non-natural trehalase inhibitors. 
 
54 Becker A., Schlöder P., Steele J. E., Wegener G., Experientia, 1996, 52, 433–439. 
55 Bini D., Cardona F., Gabrielli L., Russo L., Cipolla L., Carbohydr. Chem., 2012, 37, 259. 
56 Kato A., Kano E., Adachi I., Molyneux R. J., Watson A. A., Nash R. J., Fleet G. W. J., Wormald M. W., Kizu H., 
Ikeda K., Asano N., Tetrahedron: Asymmetry, 2003, 14, 325–331. 
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Inhibition studies revealed that these compounds are able to specifically block trehalase 
activity in a micromolar or submicromolar range. The extremely high affinity of the 
pseudodisaccharide inhibitors derives from the synergistic interactions of an alkaloid unit 
and a sugar moiety with two enzyme’s subsites. Indeed, the active site of trehalase contains 
two different substructures, one for catalysis and one for recognition; this hypothesis was 
confirmed in 2007 when Davies and co-workers solved the first three-dimensional 
structure of a bacterial trehalase.57 These findings allowed us to understand how casuarine-
based inhibitors place themselves inside the catalytic site in order to better mimic the 
natural configuration. Isolation and purification of these trehalose mimetics from natural 
sources are very difficult and expensive and afford only minute amount of compounds. In 
order to overcome these problems and generate highly potent trehalase inhibitors with 
potential insecticidal activity, several synthetic efforts have been done. In our research 
group the first total synthesis of casuarine-6-O--D-glucoside (25) was achieved,58 and 
casuarine glucoside derivatives bearing modifications at C-7 were synthesized (26 and 27, 
figure 1.23). 
 
Figure 1.23: 6-O--D-glucopyranosyl casuarine derivatives. 
Upon biological assays of the synthetized compounds, we found different biological 
activities, thus showing how slight modifications of C-7 of the B ring (OH, H, CH2OH) were 
able to influence both the potency and specificity of inhibition.59 From those results we 
were able to project and synthesize new selective trehalase inhibitors (See Chapter 2).  
 
1.2.7 Multivalency 
 Recently it has been demonstrated that the simultaneous introduction of several 
iminosugar units onto a common scaffold leads to a remarkable increase of the inhibitory 
activity towards some glycosidases. This phenomenon, known as the multivalent effect, 
 
57 Gibson R. P., Gloster T. M., Roberts S., Warren R. A. J., de Gracia S., García Á., Chiara J. L., Davies G. J., Angew. 
Chem. Int. Ed. 2007, 46, 4115-4119. 
58 Cardona F., Parmeggiani C., Faggi E., Bonaccini C., Gratteri P., Sim L., Gloster T. M., Roberts S., Davies G. J., 
Rose D. R., Goti A., Chem. Eur. J. 2009, 15, 1627-1636. 
59 Cardona F., Goti A., Parmeggiani C., Parenti P., Forcella M., Fusi P., Cipolla L., Roberts S. M., Davies G. J., 
Gloster T. M., Chem.Commun., 2010, 46, 2629-2631.   
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has been extensively studied for carbohydrate-lectin interactions, but only in recent years 
has it acquired increasing interest with regards to the inhibition of glycosidase.6,45(a),60 The 
multivalent effect (Multivalent Effect, MVE) is defined as the increasing in the biological 
response of compounds having multiple bioactive units linked together on a common 
scaffold, compared to the activity of the same unit in monomeric form. Since in biological 
processes the recognition of a substrate by an enzyme takes place through a very fast 
association/dissociation equilibrium, an increasing in the local concentration of the ligand 
in proximity of the active site, consequently increases the chances to form such a bond. 
 
Figure 1.24: Representation of the multivalent effect: increased activity towards the target 
enzyme when the epitops are covalently linked. 
However, if the concentration of the single monomer unit is increased, the same effect is 
not observed. This shows that the cluster of single units linked together in a multivalent 
structure is the one responsible to increases the relative power (relative potency, rp) of the 
structure. Here relies the key to understand the MVE. The MVE indeed, is defined positive 
when the ratio rp/n is greater than 1, where n represents the number of biological units 
grafted on the scaffold.  
This concept was deeply investigated in the field of lectins, where the presence of several 
carbohydrate-binding sites on the protein’s surface has inspired the design of a variety of 
glycoclusters with impressive binding affinity.61 On the contrary, the use of multivalent-
based strategy has been less explored in glycosidase inhibition, due to the monomeric 
nature of many of these carbohydrate-processing enzymes. Surprisingly, in the last decade 
it was demonstrated that also for enzymes with a single active site presentation affinity 
enhancement can occurs, since the high local concentration of the active moiety on the 
multivalent scaffold, close to the recognition site, may favor a mechanism of recapture, 
called “statistical rebinding”.45a From here, a variety of different scaffolds onto which 
multimerize different type of bioactive iminosugars are reported in literature, and also our 
research group contributed to the field designing different multivalent architectures, such 
 
60 (a) Gouin S. G., Chem. Eur. J. 2014, 20, 11616-11628; (b) Compain P., Bodlenner A., ChemBioChem., 2014, 15, 
1239-1251; (c) Zelli R., Longevial J.-F., Dumy P., Marra A., New J. Chem., 2015, 39, 5050-5074. 
61 Martinez A., Ortiz Mellet C., García Fernández J. M., Chem. Soc. Rev. 2013, 42, 4746-4773. 
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as dendrimers,32 gold glyconanoparticles45,b and resorcinarenes62 exploiting different 
synthetic methodologies (see Chapter 3). 
 
1.3 Aim of the work 
 The principal aim of this PhD thesis is the study of multivalent iminosugar 
glycomimetics to target enzymes for healthcare applications. The MVE has been studied by 
multimerizing iminosugar belonging to two classes (piperidines and pyrrolidines) onto 
different kind of scaffolds, to get an overview of the multivalent effect applied to different 
glycosidases involved in some Lysosomal Storage Disorders. We also compared the activity 
of some of the synthesized compounds with other non-lysosomal glycosidases, interesting 
for anticancer applications. The main strategy used to achieve multivalent compounds is 
the click chemistry reaction CuAAC (copper-mediated azide-alkyne cycloaddition),63 one of 
the most common method reported in literature to date in this field. Indeed, it is a very 
versatile and ultra-fast synthetic procedure that allows to easily obtain multimeric 
compounds with a high valency degree. On the other hand, it is associated with a general 
drawback, consisting in the possibility of complexation of copper that could occur by the 
several triazole moieties presents in dendrimers, producing a cytotoxicity of final products 
if traces of copper remain as impurities. For this reason, also alternative strategies were 
considered in the synthesis of final multimeric iminosugars. In particular, two different 
methodologies were investigated in this PhD thesis, the first one involving in the synthesis 
of Au glyconanoparticles, polyvalent nanoclusters based on self-assembled monolayers of 
thyol glycoconjugates attached to gold nanoparticles by Au-S ligation. The second, 
exploiting a sequence of 1,3-dipolar cycloaddition with a high stereo and regioselectivity. 
 Moving to a different application and changing the glycosidase target, I have dealt 
with the synthesis of selective trehalase inhibitors. The common thread are iminosugars, 
used in this case conjugated with a glucose unit in order to get a pseudodisaccharide able 
to mimic trehalose to be used as green insecticide. We combined the inhibition potency of 
some compounds with the selectivity of a similar derivatives that contained an inverted 
stereochemistry in a specific position (previously obtained results), getting new more 
potent and more selective pseudodisaccharides.      
 Again, interested in the study of iminosugar potentiality and in better 
understanding MVE, we started a project aimed at the synthesis of Carbonic Anhydrase 
 
62 Cardona F., Isoldi G., Sansone F., Casnati A., Goti A., J. Org. Chem., 2012, 77, 6980-6988. 
63 (a) Kolb H. C., Finn M. G., Sharpless K. B., Angew. Chem., Int. Ed., 2001, 40, 2004–2021; (b) Rostovtsev V. C., 
Green L. G., Fokin V. V., Sharpless K. B., Angew. Chem., Int. Ed., 2002, 41, 2596–2599; (c) Tornøe C. W., 
Christensen C., Meldal M., J. Org. Chem., 2002, 67, 3057–3064. 
Iminosugars as glycosidases inhibitors  
__________________________________ 
34 
(CAs) modulators. CAs enzymes are strongly inhibited by compounds bearing a 
pharmacophoric arylsulfonamide moiety. Even if in literature several examples of 
sulfonamide-sugars are reported, there are no data about some possible conjugation of 
the sulfonamide moiety with iminosugar derivatives. Moreover, the multivalent effect 
against CAs has been investigated just with reference to the sulfonamide function, without 
considering the hypothesis of multimerize the sugar ‘scaffold’ necessary to give the right 
selectivity towards some specific human isoforms to fill this gap. We synthesized a small 
library of monovalent compounds that contain sugar or iminosugar moiety bound with 
different linkers to the sulfonamide pharmacophore, and a preliminary example of 








Iminosugars as agrochemicals: 











 Trehalose (-D-glucopyranosyl -D-glucopyranoside, 22, Figure 2.1) is a 
disaccharide with a multifunctional physiological role in various organisms (e.g. bacteria, 
fungi, invertebrates and higher plants).64 
 
Figure 2.1: Trehalose structure. 
In order to use trehalose, insect tissues have the enzyme α,α-trehalase (EC 3.2.1.28), which 
promotes the irreversible hydrolysis of trehalose into two molecules of D-glucose with 
inversion at the anomeric configuration.65 Although insects possess two distinct forms of 
trehalases, a soluble one (localized in haemolymph) and a membrane-bound trehalase 
(localized in tissues), very little is known about this latter and the difference in function 
about soluble and membrane-bound trehalases.66 While trehalose is not present in 
mammalian cells, humans do possess the enzyme trehalase, only at intestinal level, 
probably to hydrolyze occasionally ingested trehalose. Indeed, intolerance to fungi has 
been correlated with the absence or deficit of trehalases in mammals.64 For the important 
role of trehalose-derived glucose in larvae survival and development, trehalase inhibitors 
have been considered in recent years an interesting target for the identification of novel 
insecticides and fungicides. However, due to the presence of trehalase also in mammals, 
specificity towards insect trehalase is crucial for the development of drugs that are safe for 
plants and mammals, and possibly also for insects that are of benefit in nature.67 
 As mentioned in the introduction, the most powerful inhibitors of trehalases are 
some natural pseudodisaccharides and analogs shown in Figure 2.2, such as validoxylamine 
(23), trehazolin (24) and some inhibitors containing iminosugar moieties, such as casuarine-
6-O-D-glucoside (25), a casuarine (6) derivative and its non-natural analogues 26 and 27. 
Casuarine and casuarine-6-O-D-glucoside were isolated for the first time in 1996 from the 
leaves of Eugenia jambolana Lam. (Myrtaceae) and from the bark of Casuarina equisetifolia 
 
64 Elbein A. D., Pan Y. T., Pastuszak I., Carroll D., Glycobiology, 2003, 13, 17R-27R. 
65 Defaye J., Driguez H., Henrissat B., Carbohydr. Res., 1983, 124, 265-273.   
66 Tang B., Chen X., Liu Y., Tian H., Liu J., Hu J., Xu W., Zhang W., BMC Mol. Biol., 2008, 9, 51-57.   
67 Bini D., Cardona F., Gabrielli L., Russo L., Cipolla L., Carbohydrate Chem., 2012, 37, 259-302. 
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L. (Casuarinaceae), two plants well known for their therapeutic action against diarrhoea, 
breast cancer, diabetes and bacterial infections.68 
They are well known inhibitors of the fungal glucoamylase from Aspergillus niger. 




Figure 2.2: Most potent trehalase inhibitors. 
The first investigated trehalase three-dimensional structure was the family 37 periplasmic 
enzyme from Escherichia coli (Tre37A), which was solved in complex with 23,57 with 
casuarine-6-O-D-glucoside 2558 and with non-natural analogue 27 (Figure 2.3).59 These 
findings were achieved in collaboration with Prof. Davies in 200758 and the presence of two 
enzymatic subsites was confirmed, showing that those compounds mimic the natural 
glucose configuration placing the A ring of pyrrolizidine nucleus in the primary catalytic site 
(figure 2.3).  
 
68 Wormald M. R., Nash R. J., Watson A. A., Bhadoria B. K., Langford R., Sims A., Fleet G. W. J., Carbohydr. Lett., 





Figure 2.3: 25 and Tre37A (E496 is the catalytic base, D312 the catalytic acid).  
It is worth remembering that the isolation from natural sources of those compounds is not 
a trivial task, and also when it is possible, the isolate amounts are so small that is much 
better to find a synthetic methodology to obtain them in order to perform more reliable 
biological tests. In those cases, the reasons of such complexity can be ascribed to the 
presence of highly complex and challenging structure of casuarine, but also to the fact that 
it is the most highly hydroxylated pyrrolizidine alkaloid and possesses six contiguous carbon 
stereocenters. An additional problematic issue in the synthesis of casuarine 6-O--
glucoside lies in the selectivity of glucosylation of the hydroxy group at C-6. Our focus was 
therefore to find an efficient and selective synthetic pathway.  The first synthesis of 
pseudodisaccharide 25 was achieved in our research group in 2009, and started with 
nitrone 30, available in multigram scale from 2,3,5-tri-O-benzylarabinofuranose, and 
exploited the sequence of a selective 1,3-dipolar cycloaddition, a reductive cleavage of the 
N-O bond69 with Zn in acetic acid followed by spontaneous N-cyclization and a Tamao-
Fleming oxidation. The compound was then obtained with a glucosylation reaction 
(Scheme 2.1).58 Moreover, following the same strategy, also casuarine glucoside derivatives 
bearing modifications on C-7, 26 and 27, were synthesized: they have a hydrogen atom and 
a hydroxymethyl group instead of hydroxyl moiety respectively. 
 
69 Cardona F., Faggi E., Liguori F., Cacciarini M., Goti A., Tetrahedron Lett., 2003, 44, 2315 –2318. 




Scheme 2.1: General procedure for the syntheses of pseudodisaccharides 25, 26 and 27. 
Compounds 25-27 were tested against trehalases from commercial porcine kidney, E. coli 
(Tre37A) and C. riparius and biological tests showed that the best inhibitor was casuarine 
glucoside 25, with a Ki in the nanomolar range. However, the most selective compound was 
7-homocasuarine glucoside 27; even if was less potent than compound 25, it was much 
more selective towards C. riparius with respect to porcine kidney trehalase that can be 
taken as a model for the human one (Table 2.1). Those results showed how slight 
modifications of C-7 of the B ring (OH, H, CH2OH) were able to influence both the potency 
and specificity of inhibition.  
Table 2.1: Inhibition towards different trehalases (taken from ref 59). n.d. stands for not 
determined. 
 
Compound Tre 37A Ki C. riparius Ki Porcine Kidney Ki 
Casuarine (6) 17 M 0.12 M 
 
Casuarine-6-O-a-D-glucoside (25) 12 nM 0.66 nM 11 nM 
7-deoxycasuarine-6-O-a-D-glucoside (26) 86 nM 22 nM 138 nM 
7-homocasuarine-6-O-a-D-glucoside (27) 2.8 μM 157 nM >10 μM 
(-)-uniflorine A (28) n.d 177 nM >1 mM 
7-deoxy-uniflorine A (29) n.d 175 nM >1 mM 
 
We reasoned that in the same way also modification on different positions of the 




In order to verify this hypothesis simpler natural (-)-uniflorine A (28) and non-natural 
analogue 7-deoxy-uniflorine A (29) were synthesized (figure 2.2). They both bear the 
opposite configuration in B ring at C-6 position with respect to casuarine, obtained with a 
Mitsunobu reaction.59 They actually showed an excellent inhibitory profile, being 
completely selective towards the insect trehalase (Table 2.1), much more with respect to 
compounds 25-27. Those results demonstrated that stereochemistry at C-6 has actually a 
key role in the specificity against insect trehalases. 
Following our interest in the identification of new more potent and selective trehalase 
inhibitors, we wanted to understand if by inverting the configuration at C-6 in the 
disaccharide 26, we could combine the high inhibition potency typical of 
pseudodisaccharide compounds 25-27 to the best selectivity obtained with uniflorine 
derivatives 28-29. For this reason, we designed the synthesis of the pseudodisaccharide 32 
(7-deoxyuniflorine A glucoside, figure 2.4), that possesses both the pseudodisaccharide 
structure and the same configuration at C-6 of uniflorine. Moreover, in order to reduce the 
overall number of synthetic steps required for the synthesis of disaccharides bearing the 
pyrrolizidine nucleus such as compounds 25-27 and 32 itself, we also thought about 
simplifying these structures by affording simpler pseudodisaccharide inhibitors 33-35 
(Figure 2.4), that bear the glucose unit linked to the pyrrolidine DAB-1 instead of the 
pyrrolizidine nucleus. Indeed DAB-1 possesses the same structure of ring A of the 
pyrrolizidine nucleus (Figure 2.4). Additionally, we had previously verified that DAB-1 is able 
to mimic glucose by imparting trehalase inhibition in pseudodisaccharide mimetics.70 
 
Figure 2.4: This thesis: synthesis of a new pseudodisaccharide mimetic 32 and of a series of 
more flexible disaccharide mimics 33-35 bearing the DAB-1 nucleus instead of the pyrrolizidine 
moiety. 
The choice to synthetize three different tether lengths (compounds 33-35) arose from the 
need to understand which was the most appropriate distance between the glucosyl moiety 
and the DAB-1 portion necessary to obtain the best flexibility of the pseudodisaccharide. 
 
70 Bini D., Cardona F., Forcella M., Parmeggiani C., Parenti P., Nicotra F., Cipolla. L., Beilstein J. Org. Chem., 2012, 
8, 514–521. 
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2.2 Results and discussion 
Part of the work described below was the object of previous works achieved in my 
research group. The key intermediate of the synthesis of both pyrrolizidine-based (32) and 
pyrrolidine-based (33-35) pseudodisaccharides is the enantiopure nitrone 30, readily 
available from D-arabinose in 5 steps (Scheme 2.2).71 However, while on one hand further 
5 steps are necessary to access the pyrrolizidine glucosyl acceptor (lactam 36),69 the 
hydroxypyrrolidine glucosyl acceptors 38-40 are in principle readily available from amine 
37. 72 Pyrrolidine 37, recently synthesized by some of us in a one-pot 2-steps sequence from 
nitrone 30 (Scheme 2.2),47 has the same stereochemical pattern of the hydroxyl groups of 
ring A in lactam 36, which is responsible for the key interactions within the enzyme active 
site of the final compounds. 58,58 Therefore, compound 37 is in principle able to mimic the 
more complex pyrrolizidine skeleton of lactam 36. We also reasoned that pyrrolidine 37 
could be easily functionalized at the endocyclic nitrogen atom to afford the desired glucosyl 
acceptors 38-40, allowing to probe different spatial lengths between the sugar and the 
iminosugar unit of the target pseudodisaccharides. 
 
Scheme 2.2: Synthetic steps to access pyrrolizidine lactam 36 and hydroxypyrrolidines 38-40 
from nitrone 30 through the key intermediate 37. 
 
71 (a) Cardona F., Faggi E., Liguori F., Cacciarini M., Goti A., Tetrahedron Lett., 2003, 44, 2315–2318. (b) Martella 
D., D'Adamio G., Parmeggiani C., Cardona F., Moreno‐Clavijo E., Robina I., Goti A., Eur. J. Org. Chem., 2016, 
1588-1598. 
72 (a) Overkleeft H.S., van Wiltenburg J., Pandit U.K.,Tetrahedron 1994, 50, 4215–4224. (b) Zhou X., Liu W.-J., 




The synthesis of compound 36 was achieved in a previous work in our research group73 
following the scheme below (Scheme 2.3). 
 
Scheme 2.3: Synthesis of lactam 36. 
 The OH group at C-6 was therefore employed as the acceptor in the glucosylation reaction 
with the benzyl protected glucopyranosyl trichloroacetimidate 43. The reaction, performed 
in diethyl ether at -20 °C, was highly selective in favour of the -anomer, as reported before 
for the casuarine derivatives,58,59 and afforded the  glucoside 44 as the major product 
(86% yield). Small amounts (4% yield) of the -anomer 44 were isolated and 
characterized. Reduction of the C=O bond in 44 with LiAlH4 in refluxing THF afforded 
compound 45 in excellent yield (90%). The final catalytic hydrogenation, followed by 
treatment with the ion exchange resin 50WX8-200 gave 7-deoxy-uniflorine A glucoside 32 
in 93% yield over two steps (Scheme 2.4). The  -configuration of the glucose moiety was 
confirmed by 1H NMR.  
 
73 D’Adamio G., Sgambato A., Forcella M., Caccia S., Parmeggiani C., Casartelli M., Parenti P., Bini D., Cipolla L. 
Fusi P., Cardona F., Org. Biomol. Chem., 2015, 13, 886-892. 




Scheme 2.4: Synthesis of the pseudodisaccharide 7-deoxyuniflorine A glucoside (32). 
In order to reduce the overall number of synthetic steps necessary to access the 
glucosyl acceptor in the final glucosylation with trichloroacetimidate 43, a series of 
pseudodisaccharide derivatives were prepared containing a DAB-1 nucleus and a remaining 
D-glucose unit linked through a 2, 3 or 4-carbon atoms spacer. The starting point was 
nitrone intermediate 30, that was reduced using NaBH4 followed by a N-O cleavage 
performed in Zn in acetic acid, to give pyrrolidine 37 in 98% overall yield. It was then N-
alkylated with an excess of 2-bromo-1-ethanol, 3-bromo-1-propanol and 4-bromo-1-
butanol in THF using Et3N as the base at room temperature, affording in this way alcohols 
38 (92% yield),72,b 39 (94% yield) and 40 (88% yield), that bear a free hydroxyl group at the 
end of the aliphatic chain, thus allowing selective glucosylation at this position (Scheme 
2.5).  
 







Using the glucosyl donor 4374, protected with benzyl groups, we obtained a mixture of the 
two : anomers, and only a small amount of a product was recovered (scheme 2.6). The 
corresponding mixture of deprotected ,β isomers 49-51 were obtained with a catalytic 
hydrogenation in acidic MeOH and Pd/C as hydrochloride salts, that were passed onto an 
ion exchange resin (DOWEX 50WX8-200) eluting successively with MeOH, H2O and 6% 
aqueous ammonia. The final elution with ammonia afforded pure glucosyl derivatives 49-
51 as a mixture of α and β anomers, in 32-40% yields as (49α,β, α:β 2:1; 50α,β, α:β 1:1; 
51α,β, α:β 1.2:1 as determined by 1H NMR analysis).75 
 
Scheme 2.6: Glucosylation reaction to afford pseudodisaccharides 46-48. 
Due to the impossibility to separate the α and β isomers both with benzylated and free 
hydroxyl groups, we decided to directly react the crude obtained by catalytic 
hydrogenation of 46–48α,β with an excess of acetic anhydride in pyridine affording the 
corresponding peracetylated compounds 52–54 as α,β mixtures. As expected, in all cases, 
the two isomers were separated by flash column chromatography, affording pure 
compounds 52α, 53α and 54α in 23%, 42% and 37% yields over two steps and β-isomers 
(52β, 53β and 54β in 3%, 12% and 9% yield) impure of some traces of the corresponding α-
isomers (Scheme 3). The α-isomers 52–54α were subsequently treated with strongly basic 
Ambersep 900 OH resin in MeOH, leading to pure polyhydroxylated α-pseudodisaccharides 
49–51α in quantitative yield.  
 
74 Stick R.V., Williams S.J., Eds. Elsevier, 2009, 1133–1202. 
75 D’Adamio G., Forcella M., Fusi P., Matassini C., Ferhati X., Vanni C., Cardona F., Molecules, 2018, 23, 436. 




Scheme 2.7: Synthesis of pseudodisaccharides 49-51. 
Synthesized compounds 32, 49α, 50α, 51α and the α/β mixture of compounds 49, 50 and 
51 were tested for their inhibitory activity against insect (C. riparius) and porcine kidney 
trehalases and the results are shown in Table 2.2, together with the previously published 









26 44 ± 1 nM 479 ± 45 nM 10 
28 177 ± 18 nM >1 mM  >5649 
29 175 ± 12 nM >1 mM >5714 
32 29.49 ± 7.26 M 190.60± 34.15 M 6 
49 2.30 ± 0.13 M 7.67 ± 3.91 M 3 
49 9.36 ± 1.49 M 27.64 ± 5.35 M 3 
49 0.784 ± 0.059 M 5.84 ± 0.26 M  
50 >1000 M n.d.3 ‐ 
50 >1000 M n.d.3 ‐ 
51 >1000 M n.d.3 ‐ 
51 >1000 M n.d.3 ‐ 
Table 2.2: Biological activity (IC50) towards C. riparius and porcine trehalases. 2Selectivity 
is the ratio between IC50 value against porcine trehalase and the IC50 value against C. 




The biological data reported in table 2.2 show that compound 32 was active only in the M 
range, even if a rather good selectivity was still observed with respect to porcine trehalase. 
We argue that the with such configuration at C-6, the pseudodisaccharide is not able to 
place the glucosyl moiety in the active catalytic site with favorable interactions. Among the 
pyrrolidinic series on the contrary, only compound 49 seems to possess the right distance 
between the glucosyl moiety and the iminosugar ring, while compounds with a longer 
linker chain completely lost their inhibitory properties (50-51). Thus, considering only the 
compounds 49, and 49, only the mixture of two anomers gave a good inhibitory and 
selectivity profile, suggesting us that probably the major contribution to inhibition towards 
C. riparius trehalase is given by the isolated  anomer. The data reported above are the 
object of previous work done in the research group. My contribution to this work inserts in 
this context, and it consists in finding a strategy to synthesize the pseudodisaccharide 
49 selectively, in order to verify our hypothesis in which we attribute the merit of the 
selectivity to the  anomer. Because of the impossibility to obtain the isolate  anomer 
applying the synthetic strategy used before (scheme 2.6), we decided to exploit the 
differentiation achievable by changing the protecting groups of the glucosyl donor. 
We employed the O-acetyl protected 1-α-trichloroacetimidate 57 (Scheme 2.8), which 
would in principle favor the formation of β-pseudodisaccharide 58 in the following 
glycosylation reaction through the orthoester procedure (1,2-trans glycosylation)74. 
Selective deprotection of 55 with ethylendiamine in acetic acid following the procedure 
reported by Sun et al.76 afforded in 86% yield compound 56, that was treated with 
trichloroacetonitrile to obtain 57 in 85% yield. Glycosylation reaction with 38 at 0 °C in dry 
CH2Cl2 in the presence of TMSOTF (1.5 equiv) afforded 39% yield of the β-glucoside 58 as 
the major compound, although impure of a partially deacetylated isomer. The 1H-NMR 
spectrum of compound 58 showed a dd at 5.05 ppm for H-2’ signal (appearing as a pseudo 
triplet), with coupling constants of 9.6 and 9.8 Hz. This indicates an axial-axial relationship 
with both H-1’ and H-3’, and therefore confirms the β-configuration of the glucose moiety. 
Deprotection of the benzyl groups by catalytic hydrogenation and of the acetyl groups by 
treatment with Ambersep 900-OH, allowed to isolate pure disaccharide 49β in 43% yield 
over 2 steps (Scheme 2.8).  
 
76 Sun Q., Yang Q., Gong S., Fu Q., Xiao Q., Bioorg. Med. Chem. 2013, 21, 6778–6787. 




Scheme 2.8: Synthesis of the pseudodisaccharide 49. 
Compound 49 was therefore tested against C. Riparius and porcine kidney trehalase, 
giving, to our delight and accordingly to our expectation, a 12-fold more potent inhibition 
towards C. riparius trehalase than its α-anomer, and it was the most potent insect trehalase 
inhibitor of the pseudodisaccharide pyrrolidine series, with an IC50 in the low micromolar 
range (IC50 = 0.784 μM, Table 2.2). Moreover, 49β showed also a good 7-fold selectivity 
towards the insect trehalase vs. the porcine enzyme. 
 
2.3 Conclusions 
 In this part of my PhD thesis the synthesis of new rather good and 
selectivetrehalase inhibitors was achieved. The hypothesis of the role of both 
pseudodisaccharide configuration and the importance of pyrrolidine-shape iminosugar 
bearing the same configuration of natural DAB-1, was confirmed. Moreover, the best 
tether length between glucose and iminosugar portions was found, suggesting that two 
carbon atom chain is the ideal distance to allow to all the pseudodisaccharide to place the 
glucose unit inside the active enzymatic site. 
Other investigations are in this moment object of study in our laboratories in collaboration 
with Prof. Cipolla research group (university of Milano-Bicocca) in particular as a future 




sulphate or a phosphate group on a position of our pyrrolizidine 29 (figure 2.2), in order to 
mimic the the sulphate ion that is found during the crystallization of the glycoside of 7-
homocasuarine within the enzyme (figure 2.3). 
 
2.4 Experimental Section 
Here are reported data dealing with the synthesis of the pure 49 anomer. The other 
experimental procedures can be found in this paper:   
D’Adamio G., Forcella M., Fusi P., Matassini C., Ferhati X., Vanni C., Cardona F.  
Probing the Influence of Linker Length and Flexibility in the Design and Synthesis of New 
Trehalase Inhibitors, Molecules, 2018, 23, 436.  
10.3390/molecules23020436 
 
General Experimental Procedures  
All the starting reactants, solvents, and catalysts were commercially available unless 
otherwise stated. All reactions were carried out under magnetic stirring and monitored by 
TLC on 0.25 mm silica gel plates (Merck F254). Column chromatographies were carried out 
on Silica Gel 60 (32–63 μm) or on silica gel (230–400 mesh, Merck). Yields refer to 
spectroscopically and analytically pure compounds unless otherwise stated. 1H NMR 
spectra were recorded on a Varian Mercury-400 or on a Varian INOVA 400 instruments at 
25 °C. 13C NMR spectra were recorded on a Varian Gemini-200 spectrometer. Chemical 
shifts are reported relative to TMS (1H: δ = 0.00 ppm) and CDCl3 (13C: δ = 77.0 ppm). 
Integrals are in accordance with assignments, coupling constants are given in Hz. For 
detailed peak assignments 2D spectra were measured (COSY, HSQC, NOESY, and NOE as 
necessary). Small scale microwave assisted syntheses were carried out in a microwave 
apparatus for synthesis (CEM Discover) with an open reaction vessel and external surface 
sensor. IR spectra were recorded with a BX FTIR Perkin-Elmer system spectrophotometer. 
ESIMS spectra were recorded with a Thermo Scientific™ LCQ fleet ion trap mass 
spectrometer. Elemental analyses were performed with a Perkin-Elmer 2400 analyzer. 
Optical rotation measurements were performed on a JASCO DIP-370 polarimeter. 
  
 Synthesis of 2,3,4,6-Tetra-O-acetyl-/ -D-glucopyranose 56:77 To a solution of 
ethylenediamine (93 mg, 1.54 mmol) in 10 mL of dry THF, acetic acid (102 μL, 1.79 mmol) 
 
77 Fernandez-Lorente G., Palomo J.M., Cocca J., Mateo C., Moro P., Terreni M., Fernandez-Lafuenteb R., 
Guisanb J.M., Tetrahedron, 2003, 59, 5705–5711. 
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was slowly added dropwise over 10 min and the reaction mixture was stirred under 
nitrogen atmosphere at room temperature for 1 h. Then 55 (500 mg, 1.28 mmol) was added 
and the mixture was stirred for 1 h, until TLC analysis (PE/EtOAc 3:2) showed the 
disappearance of the starting material (Rf = 0.48) and the formation of a new compound 
(Rf = 0.24). After washing with HCl 0.1 M (2 × 2 mL) and NaHCO3 (2 × 2 mL), the combined 
organic layers were dried on Na2SO4, concentrated at reduced pressure and the crude 
mixture was purified by FCC (PE/AcOEt 1:1) affording pure 56 (α/β 1:9 Rf = 0.30, PE/EtOAc 
1:1, 383 mg, 1.100 mmol, 86% yield). 1H-NMR (200 MHz, CDCl3): δ = 5.62 (d, J= 9.8 Hz 1H, 
H-1α), 5.55 (t, J= 3.8 Hz, 1H, H-3α), 5.36–5.27 (m, 1H, H-3β), 5.14 (t, J = 9.6 Hz, 1Hα + 1Hβ, 
H-4), 4.96 (dd, J= 9.8, 3.4 Hz, 1Hα + 1 Hβ, H-2), 4.80 (t, J= 8.1 Hz, 1H, H-1β), 4.37–4.12 (m, 
5H, H-6α, H-6 β, H-5α), 3.85–3.77 (m, 1H, H-5β), 2.16 (s, 3Hα + 3 Hβ, OAc), 2.15 (s, 3Hα + 3 
Hβ, OAc), 2.09 (s, 3Hα + 3 Hβ, OAc), 2.08 (s, 3Hα + 3 Hβ, OAc) ppm.   
Synthesis of 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyltrichloroacetimidate 57:78 A 
solution of 56 (383 mg, 1.10 mmol) in 8 mL of dry CH2Cl2 was cooled to 0 °C and DBU (32 
μL, 0.22 mmol) and trichloroacetonitrile (612 μL, 7.70 mmol) were added. The reaction 
mixture was stirred under nitrogen atmosphere at room temperature for 2.5 h, when a TLC 
analysis (Hex/EtOAc 1:1) showed the disappearance of the starting material (Rf = 0.26) and 
the formation of a new compound (Rf = 0.62). A saturated NH4Cl solution was added and 
the mixture was transferred to a separating funnel, washing with CH2Cl2. The organic layer 
was washed with water (3 × 5 mL) and dried over Na2SO4. After concentration under 
reduced pressure, the crude was purified by flash column chromatography on silica gel 
(Hex/EtOAc from 3:1 to 2:1) to afford pure 57 (Rf = 0.25 Hex/EtOAc 2:1, 461 mg, 0.939 
mmol, 85% yield). 1H-NMR (200 MHz, CDCl3): δ = 8.69 (s, 1H, NH), 6.56 (d, J = 3.7 Hz, 1H, H-
1), 5.57 (t, J = 9.8 Hz, 1H, H-4), 5.23–5.10 (m, 2H, H-2, H-3), 4.32–4.06 (m, 3H, H-5, H-6), 
2.08 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.02 (s, 3H, OAc) ppm.  
Synthesis of Compound 58: A solution of glucopyranosyl tricholoroacetimidate 57 (2 
equiv.) and alcohol 38 (1 equiv.) in dry CH2Cl2, was stirred for 10 min at room temperature 
under nitrogen atmosphere in the presence of 3 Å molecular sieves. After cooling to 0 °C 
trimethylsilyl trifluoromethanesulfonate (1.5 equiv.) was added and the mixture was 
stirred for 1.5 h, letting the temperature to rise. To the reaction mixture 1.8 mL of 
triethylamine was added and the mixture was transferred to a separating funnel, washing 
with CH2Cl2. The organic layer was washed with HCl 1M (3 × 3 mL), NaOH 1M (1 × 3 mL) and 
brine (2 × 3 mL). The combined organic layers were dried over Na2SO4 and the solvent was 
removed under reduced pressure. The resulting crude oil was dissolved in pyridine (3 mL), 
and acetic anhydride (2 mL) and DMAP (30 μL) were added. The solution was stirred at 
room temperature overnight, and after concentration under reduced pressure, the crude 
was purified by flash column chromatography on silica gel (Hex/EtOAc from 1:1 to 1:2) to 
 




afford the β compound 58 (Rf = 0.516 Hex/EtOAc 1:1, 34 mg, 0.044 mmol, 39% yield) as 
colorless oil, contaminated with small amounts of partially deacetylated glucoside. [α]21D= 
−15.2 (c = 0.80 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ=7.32–7.24 (m, 15H, HAr), 5.16 (t, J = 
9.5 Hz, 1H, H-4’), 5.05 (dd, J = 9.8, 9.6 Hz, 1H, H-2’), 4.97 (t, J = 9.6 Hz, 1H, H-3’), 4.54–4.43 
(m, 7H, H-Bn, H-1’), 4.23 (dd, J = 12.2, 4.7 Hz, 1H, Ha-6’), 4.09 (dd, J = 12.2, 2.2 Hz, 1H, Hb-
6’), 4.00–3.95 (m, 1H, Ha-8), 3.88 (d, J = 5.0 Hz, 1H, H-4), 3.81 (d, J = 3.8 Hz, 1H, H-3), 3.68–
3.58 (m, 2H, Hb-8, H-5’), 3.56–3.43 (m, 2H, H-6), 3.16 (d, J = 10.7 Hz, 1H, Ha-5), 3.10–3.04 
(m, 1H, Ha-7), 2.77 (q, J = 5.7 Hz, 1H, H-2), 2.69–2.61 (m, 2H, Hb-5, Hb-7), 2.06 (s, 3H, OAc), 
2.01 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.93 (s, 3H, OAc) ppm; 13C-NMR (100 MHz, CDCl3 ): δ = 
170.6, 170.2, 169.4, 169.3 (s, 4C, C=O), 138.3, 138.2, 138.1 (t, 3C, C-Ar), 128.3, 127.8, 127.7, 
127.6, 127.5 (d, 15C, C-Ar), 100.6 (d, C-1’), 84.7 (d, C-4), 81.6 (d, C-3), 77.4 (C-2’), 77.1 (d, 
C-3’), 73.2 (d, C-4’), 72.8 (d, C-2), 71.2, 71.1, 71.0 (s, 3C, C-Ar), 69.4 (d, C-5’), 68.9 (t, C-8), 
68.4 (t, C-6), 61.9 (t, C-6’), 58.4 (t, C-5), 54.0 (t, C-7), 20.7, 20.6, 20.6, 20.6 (q, 4C, CH3) ppm; 
IR (CDCl3): ν = 3031, 2945, 2866, 2360, 2331, 1755, 1497, 1454, 1375, 1231, 1171,1039 
cm−1. MS (ESI): m/z calcd (%) for C42H51NO13 777.33; found 800.63 (100%, [M+ Na]+). 
Synthesis of Compound 49: To a solution of 58 (43 mg, 0.055 mmol) in 10 mL of methanol, 
Pd/C (50%, w/w) and 0.5 mL of HCl 1 M were added under nitrogen atmosphere, then the 
mixture was stirred under hydrogen atmosphere at room temperature overnight, until an 
1H-NMR control showed the disappearance of the starting material. The mixture was then 
filtered through Celite® and the solvent was removed under reduced pressure. The crude 
was purified by flash column chromatography on silica gel (CH2Cl2/MeOH 10:1, Rf = 0.585) 
to afford 12 mg, which were dissolved in 10 mL of methanol, ion exchange resin Ambersep 
900-OH was added and the suspension was slowly stirred at room temperature for 16 h. 
The mixture was filtered through cotton and the solvent was removed under reduced 
pressure, affording pure 49β (8 mg, 0.024 mmol, 43% yield) as colourless oil. []19D = −28.5 
(c = 0.67 in H2O); 1H-NMR (400 MHz, D2O): δ = 4.34 (d, J = 8.0 Hz, 1H, H-1’), 4.02–3.98 (m, 
1H, H-4), 3.92 (ddd, J = 11.0, 6.4, 4.4 Hz, 1H, Ha-8), 3.82–3.81 (m, 1H, H-3), 3.77 (d, J = 2 Hz, 
1H, Ha-6’), 3.68–3.56 (m, 4H, Hb-8, H-6, Hb-6’), 3.38–3.21 (m, 3H, H-3’, H-4’, H-5’), 3.15 (t, 
J = 8.4 Hz, 1H, H-2’), 3.05–2.97 (m, 2H, Ha-7, Ha-5), 2.74 (dd, J = 11.4, 5.7 Hz, 1H, Hb-5), 
2.61–2.53 (m, 2H, Hb-7, H-2) ppm; 13C-NMR (100 MHz, D2O): δ = 102.32 (d, C-1’), 79.11 (d, 
C-3), 76.06 (d, C-3’), 75.79 (d, C-5’), 75.62 (d, C-4), 73.20 (d, C-2’), 72.01 (d, C-2), 69.78 (d, 
C-4’), 67.88 (t, C-8), 61.19 (t, C-6), 60.88 (t, C-6’), 58.94 (t, C-5), 54.04 (t, C-7) ppm; MS (ESI): 
m/z calcd (%) for C13H25NO9 339.15; found: 362.47 (100%, [M+ Na]+); elemental analysis 








To evaluate the inhibitory pattern, we performed kinetics measurements by varying the 
trehalose concentration, at two different concentrations of compounds 49 and 49. 
Results showed a pure competitive inhibitory pattern. To determine the inhibition type, 
data were plotted according to the Lineweaver-Burk plot, replots were built and an 
inhibition constant (Ki) was calculated equal to 2.56 ± 0.42 μM for 49 and 0.40 ± 0.022 μM 
for 49. 
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3.1 The Multivalent Effect 
3.1.1 Introduction  
From a long period, the therapeutic potentiality of iminosugars was known and 
during the last decades a large part of carbohydrate chemistry has been devoted to the 
study of new more efficient synthetic strategies to achieve those glycomimetics. In 
particular, large efforts were done in the search of monovalent iminosugars to target 
glycosidases. Until a certain point indeed, the basic concept to develop a specific enzyme 
inhibitor was to consider the lock-key mechanism as effective mode of recognition. Only 
recently it has been thought to extend to the field of glycosidase inhibition a concept 
known for a long time in the context of carbohydrate-lectin interactions. The reason is quite 
clear, indeed lectins are particularly prone for multivalent interactions, as they generally 
possess several carbohydrate recognition domains to counterbalance their intrinsic weak 
affinity for their ligands,79 while glycosidases are generally monomeric, and the 
oligosaccharides/catalytic sites interactions  are often associated with a monovalent 
process.60 Nevertheless, at the gates of the 2000s the first example of multivalent 
glycosidase inhibitors appeared in the literature (dimer 59, figure 3.1),80 paving the way for 
a new line of research: the study of multivalent glycosidases inhibitors.  
 
Figure 3.1: First example of multivalent structure, a dimer of DMJ. 
The Multivalent Effect (MVE) is defined as the increase in the biological response of 
compounds that show multiple bioactive units linked together onto a common scaffold, 
compared to the sum of contributions of the same units alone (see section 1.2.7, figure 
3.2). However, just by incrementing the concentration of the single binding units, an 
enhancement of activity (relative potency, rp) is observed due to the increasing of the local 
concentration, but not with the same effect observed for a multivalent cluster. Indeed, it’s 
only by the synergy obtained by grafting together several bioactive units, that we observed 
a real advantage (Figure 3.2). 
 
79 Lis H., Sharon N., Chem. Rev., 1998, 98, 637–674. 
80 Johns B. A., Johnson C. R., Tetrahedron Lett., 1998, 39, 749 –752. 




Figure 3.2: Representation of the multivalent effect: increased activity towards the target 
enzyme when the epitops are covalently linked. 
Winum and his collaborators affirmed that there is a positive multivalent effect when the 
ratio between the relative power (rp) and the number of bioactive units in the multivalent 
system (n) is greater than 1, or rp / n> 1 (the relative power rp is generally expressed in 
terms of Ki or IC50). Only in this case there is an effective advantage for the purposes of 
biological application to use multivalent systems rather than using a higher concentration 
of the monovalent ligand. Although the effects involved in the interaction between the 
glycosidases and the multivalent compounds responsible for MVE have not yet been clearly 
elucidated, affinity enhancements can be expected for enzymes with a single active site 
presentation, since the high local concentration of the active moiety on the multivalent 
scaffold, close to the recognition site, may favor a mechanism of recapture, called 
“statistical rebinding” (see section 3.1.2).       
 Many iminosugars display high affinity towards the active site of glycosidases, thus 
making them ideal candidates for the construction of multivalent architectures. Recently, 
the use of copper (I) azide-alkyne cycloaddition reaction (CuAAC)63 led to great progresses 
in the area of research on multivalent iminosugars, allowing the realization of different kind 
of clusters. For example, in 2009 Gouin and his group reported the systematic evaluation 
of some clusters of iminosugars as glucosidase inhibitors, providing for the first time also 
monovalent models to be able to quantify a possible multivalent effect.81 Indeed, two di- 
and trivalent derivatives of DNJ (1, Figure 3.3) were synthesized using CuAAC, with bi- and 
tridentate oligoetilene scaffolds (59, 60, Figure 3.3). In addition, the monovalent reference 
compound 59 was also synthesized. The trivalent derivative 60 in particular showed an rp/n 
= 2.2 with respect to the monovalent 61 towards α-mannosidase from Jack Bean (αManJB). 
 
81 Diot J., García-Moreno M. I., Gouin S. G., Ortiz Mellet C., Haupt K., Kovensky J., Org. Biomol. Chem., 2009, 7, 
357 363. 




Figure 3.3: Di- and trivalent derivatives of DNJ and monovalent reference compound. 
 
However, the first example of a truly remarkable MVE was obtained by Compain and 
Nierengarten in 2010, when they reported the synthesis of the fullerenic adduct 63 (Figure 
3.4),82 exploiting the synthetic strategy developed in the previous years.83 
 
82 Compain P., Decroocq C., Iehl J., Holler M., Hazelard D., Mena Barragn T., Ortiz Mellet C., Nierengarten J.-F., 
Angew. Chem. Int. Ed., 2010, 49, 5753 –5756. 
83 Iehl J., Nierengarten J.-F., Chem. Eur. J., 2009, 15, 7306 –7309. 




Figure 3.4: Multivalent Cluster C60 with N-alkylate DNJ. 
The multivalent structure consisting of a globular cluster (C60 fullerene), decorated with 12 
units of a N-alkylated derivative of the DNJ (63, in Figure 3.4), showed a significant 
multivalent effect (rp/n = 179) against the αManJB compared to the monovalent fee 62. 
Following the excellent results, other multivalent structures based on β-cyclodextrins (β-
CD)84 have been synthesized by Compain group. Compound 14-valent 65 (Figure 3.5) 
consists of 7 iminosugar units on the upper edge and 7 on the lower bound by a chain with 
9 carbon atoms to the triazole ring and showed a very high inhibitory activity (rp/n = 662, 
compared to the monovalent compound 64, taken as a reference). 21-valent cluster 67, 
obtained by reacting a trimer of DNJ with each of the seven alkyne functionalities of the β-
CD scaffold (and thus called second-generation), inhibits αManJB at nanomolar 
concentrations (the Ki is 19 ± 3 nM), while the other previously prepared multivalent 
compounds had Ki values in the order of micromoles. The interesting data for the purpose 
of rationalizing the multivalent effect is that the 2nd generation cluster 17 has a lower rp/n 
than its corresponding 14-valent 65 (rp/n = 470 vs 662), suggesting that the increase in 
multivalent effect does not grow linearly with valence, but stops at a plateau. 
 
84 (a) Decroocq C., Rodríguez-Lucena D., Russo V., Mena Barragán T., Ortiz Mellet C., Compain P., Chem. Eur. J., 
2011, 17, 13825 –13831; (b) Decroocq C., Joosten A., Sergent R., Mena Barragán T., Ortiz Mellet C., Compain 
P., ChemBioChem, 2013, 14, 2038 –2049. 




Figure 3.5: Multivalent cluster with scaffold β-CD decorated with N-alkylated DNJ. 
This aspect is also highlighted by a following work by Compain, which summarizes a series 
of cyclopeptoids of different valence (from 18 to 48 units of DNJ).85 Indeed also in this case 
the highest inhibition potential does not correspond to the highest valence number, which 
is instead obtained with the adduct 36-valent 68 (rp/n = 4747) (Figure 3.6). 
 
Figure 3.6: Multivalent cyclopeptoid. 
 
85 Lepage M. L., Schneider J. P., Bodlenner A., Meli A., De Riccardis F., Schmitt M., Tarnus C., Nguyen-Huynh N.-
T., Francois Y.-N., Leize-Wagner E., Birck C., Cousido-Siah A., Podjarny A., Izzo I., Compain P., Chem. Eur. J., 2016, 
22, 5151-5155. 
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Many other types of scaffolds have been synthesized and tested, such as linear or branched 
dextrans (DEX) based on polymeric iminosugars,86 porphyrins,87 or calixarenic structures.88 
Unlike the many types of scaffolds tested, the iminosugars used as biologically active units 
are almost exclusively DNJ and its analogue with D-mannose configuration (1-
deoxymannojirimicin, DMJ).        
 Since our research group has many years of experience in the synthesis of 
iminosugars, we thought to synthesize dendrimeric multivalent adducts with iminosugars 
which had never been used before, exploiting the CuAAC click chemistry. With this strategy 
we have synthesized both multivalent pyrrolizidines and piperidines. The first multimerized 
iminosugars were pyrrolizidines (Figure 3.7), since they already showed a remarkable 
inhibitory activity against amyloglucosidases, in particular of human maltase glucoamylase, 
in monovalent form.58 From the nitrone 30 (Figure 3.7) the derivative 69 (6-azido-6-epi-6,7-
dideoxycasuarine) of casuarine 6 was synthesized, which contains an azide moiety in 
position 6; this made it possible to carry out a CuAAC reaction to build the tetra- and 
nonavalent systems 70 and 71.89    
 
86 Brissonnet Y., Ladeveze S., Teze D., Fabre E., Deniaud D., Daligault F., Tellier C., Sestak S., Remaud-Simeon 
M., Potocki-Veronese G., Gouin S. G., Bioconjug. Chem., 2015, 26, 766-772. 
87 Fan J.-Q., Biol. Chem., 2008, 389, 1–11. 
88 (a) R. Zelli, J.-F. Longevial, P. Dumy and A. Marra, New J. Chem., 2015, 39, 5050-5074; (b) M. Marradi, S. 
Cicchi, F. Sansone, A. Casnati and A. Goti, Beilstein J. Org. Chem., 2012, 8, 951-957; (c) F. Cardona, G. Isoldi, F. 
Sansone, A. Casnati and A. Goti, J. Org. Chem., 2012, 77, 6980-6988. 
89 D’Adamio G., Parmeggiani C., Goti A., Moreno-Vargas A. J., Moreno-Calvijo E., Robina I., Cardona F., Org. 
Biomol. Chem., 2014, 12, 6250-6266. 




Figure 3.7: Tetra- e nonavalent pyrrolizidines with their Ki. 
Compound 71 was the first example of multivalent pyrrolizidine iminosugar with nine 
bioactive units. However unfortunately, biological enzymatic inhibition tests did not give 
satisfactory results: both multivalent adducts maintained their activity, but do not show an 
enhancement compared to their monomeric equivalents against the enzyme 
amyloglucosidase. Again, using the same scaffolds seen for pyrrolizidines, we prepared 
multivalent adducts based on piperidine iminosugars (Figure 3.8),90 exploiting the reductive 
double amination strategy on the aldehyde derivative 73 developed in our group and 
obtaining compound 74,91 enantiomer of the natural 72. A simple modification of the 
synthetic strategy allows to insert on the endocyclic nitrogen a terminal azido alkyl chain, 
obtaining the derivative 75 that we have exploited to build the structures 76 and 77 
through CuAAC. 
 
90 Matassini C., Mirabella S., Goti A., Robina I., Moreno-Vargas A. J., Cardona F., Beilstein J. Org. Chem., 2015, 
11, 2631-2640. 
91 Matassini C., Mirabella S., Goti A., Cardona F., Eur. J. Org. Chem., 2012, 3920-3924. 




Figure 3.8: Tetra- e nonavalent piperidines. 
 
3.1.2 Mechanistic hypothesis of the multivalent binding  
Even if the effects involved in the interaction between the glycosidases and the 
multivalent compounds responsible for MVE have not yet been unambiguously clarified, 
the following four mechanisms shown in figure 3.9 are considered possible: 1) Statistical 
effect (Figure 3.9 A), explainable through the increasing of the local concentration and 
therefore the consequent increase in the possibility to form the bond. 2) Chelating effect 
(Figure 3.9 B), which can attend only if the enzyme possesses more than one catalytic site. 
3) Secondary binding effect, which can derive from interactions with a non-catalytic site 
(Figure 3.9 C), or from a steric hindrance effect of the pocket to which the substrate is no 
longer able to access (Figure 3.9 D). 4) Cluster effect, in which the multivalent structure 
favors the aggregation of several enzymatic units (Figure 3.9 E) or is able to form a sort of 
cross-linked bonds with multimeric enzymes (Figure 3.9 F). 




Figure 3.9: Proposed binding models accounting for the multivalent effect. 
Several studies have been carried out with the aim of identifying the mechanism of 
interactions in place. Computational studies demonstrated that mechanism (d) can occur 
for fullerene-based nanoscale inhibitors of carbonic anhydrase possessing dimensions of 
the same order of magnitude of the opening of the enzyme cavity.92 To date the best results 
have always been obtained towards JBαMan,45 which is the enzyme most sensitive to the 
multivalent effect. This propensity can be explained by the dimeric nature hypothesized for 
this enzyme, which makes possible the involvement of various mechanisms such as the 
chelating effect (Figure 3.9 B) or the cluster effect (Figure 3.9 F). Furthermore, the results 
obtained suggest that the spatial distribution of iminosugars proves to be more relevant 
than the continuous increase in valence. This fact is particularly emphasized in the case of 
the JBαMan, where a plateau is reached after the repetition of a certain number of 
biologically active units. For this reason, one hypothesis is that a key role is also played by 
the multimeric nature of the enzyme itself, which seems to determine a MVE. Once the 
dimeric nature of the enzyme acetylgalactosamine-6-sulphatase (GALNS) has been 
demonstrated (see Chapter 1), we decided to test multivalent compounds based on 
pyrrolidine-based iminosugars inhibitors of this enzyme, whose deficiency causes the onset 
of a rare metabolic disease: Morquio A. syndrome. We decided to use a N-alkylated 
derivative of the iminosugar DAB-1, since it had already shown a high inhibitory activity 
(IC50 = 0.94 μM) against GCase, to achieve nonavalent compound 77.32 
 
92 Innocenti A., Durdagi S., Doostdar N., Strom T. A., Barron A. R., Supuran C. T., Bioorg. Med. Chem. 2010, 18, 
2822–2828. 
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Figure 3.10: Nonavalent pyrrolidine 78.  
The ratio rp/n = 9.2 of 78 confirms that also the nature of the enzymatic active site is of 
significant importance in MVE.        
 Other studies were carried on in our research group, in order to clarify this 
phenomenon, by investigating the binding mode of our multivalent pyrrolidine iminosugars 
with JBMan by a combined NMR/molecular modeling protocol.93 For the first time it was 
demonstrated that there is a specific interaction occurring between a multivalent inhibitor 
and the active site. Moreover, TEM (Transmittance Electron Microscopy) showed that 
aggregates of enzyme and ligand were formed during their interaction, involving a 
clustering effect (mode F, figure 3.9).   
 
3.1.3 Our approach to design multivalent architectures 
 This PhD thesis deals with the purpose to evaluate the MVE by exploiting different 
kind of scaffolds onto which two type of iminosugars were grafted. Combining our interest 
in the synthesis of bioactive iminosugars and in the rationalizing of multivalent effect 
indeed, we chose two kind of iminosugar (a piperidine and a pyrrolidine derivatives, 79 and 
80, figure 3.11) on the basis of the final enzymatic targets. The two azido derivatives were 
synthetized starting from intermediates 73 and 30, obtained from natural carbohydrates 
D-mannose and D-arabinose respectively. 
 
93 Mirabella S., D’Adamio G., Matassini C., Goti A., Delgado S., Gimeno A., Robina I., Moreno-Vargas A. J., Sestak 
S., Jimenez-Barbero J., Cardona F., Chem. Eur. J., 2017, 23, 14585 – 14596. 




Figure 3.11: Piperidine and pyrrolidine azido derivatives multimerized. 
The chapter on Multivalency can be divided in two main parts: the first describes our 
approach to design multivalent architectures based on the use of click chemistry reaction 
CuAAC. This synthetic strategy is an ultra-fast and very versatile procedure that allows to 
achieve a convergent and rapid valency increasing of a bioactive unit. On the other hand, 
it presents a disadvantage, given by the possible copper complexation by triazole rings and 
other N atoms that can contaminate the final product with the consequent cytotoxicity. 
For this reason, we considered alternative methods to avoid the use of copper during the 
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3.2 Dendrimeric architectures trough CuAAC 
3.2.1 Dendrimers  
The copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), described for the first 
time by Sharpless and Meldal,63 has been largely employed for the synthesis of multivalent 
compounds, due to its efficiency and versatility. Indeed, it allows the conjugation of a great 
numbers of azide-functionalized moieties on a single alkyl-armed multivalent scaffold with 
high yields and reduced reaction time. In this PhD thesis the preparation of a library of new 
multivalent piperidine compounds, by using different monovalent and dendrimeric alkyne 
scaffolds, is reported. The choice of the ‘bioactive warhead’ to be multimerized arise from 
the search of new potent inhibitors of the enzyme GCase. Moreover, following our goal to 
develop novel pharmacological chaperones to be used in the treatment of LSDs (Gaucher 
disease in this case), the first step to assess the affinity of our new molecules towards 
human GCase, is to evaluate their inhibitory activity against the target enzyme in cell lysate. 
Compounds showing IC50 in the micromolar range will be further investigated in ‘in vivo’ 
experiments.  
 




Figure 3.12: Propargylated multimeric and monomeric dendritic scaffolds. 
We chose the azido derivative 79, a trihydroxypiperidine N-alkylated with a 9-carbon chain, 
encouraged by very promising results in terms of inhibition and rescue of residual GCase 
activity, obtained with compound 17, that contains the same piperidine skeleton and a 8-
carbon chain on endocyclic nitrogen.32 In the search of the best valency to achieve our final 
goal, we explored dendrimeric alkynyl scaffold, differently branched, onto which 
multimerize piperidine derivative 79. 
To our support in the evaluation of the MVE of our dendrimers bearing the piperidine 
iminosugar moiety, the promising results in term of multivalency in previous works.47,93 
Indeed, the same piperidine bioactive core was exploited in the synthesis of multivalent 
architectures (76 and 77, figure 3.8). In that case a short alkyl chain (3 carbon atoms) was 
used as spacer between the scaffold and the iminosugar moiety. The resulting multivalent 
compounds were tested against a panel of eleven commercially available glycosidases, 
showing promising results in terms of inhibition towards amyloglucosidase. With the 
intention to expand our target to the human lysosomal enzyme GCase, we decide to 
elongate the length of alkyl linker, because of the excellent inhibitory activity obtained in 
the case of compound 17 that bears an 8-carbon chain on endocyclic nitrogen atom. 
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Moreover, it also showed a 1.25-fold rescue of GCase activity, thus indicating a very 
interesting chaperoning potential.  
 
3.2.1.1 Results and discussion  
 The intermediate N-alkylated trihydroxypiperidine was synthesized exploiting a 
well-known strategy reported in our research group, that allows to achieve the ‘masked’ 
aldehyde intermediate 73, easily synthesized in four steps and 80% overall yield from D-
mannose without the need of any chromatographic purification, by following a slight 
modification of the published procedure94 (scheme 3.1). 
 
Scheme 3.1: Synthesis of ‘masked’ dialdehyde 73 from D-mannose. 
To get the piperidine skeleton we exploited the DRA (Double Reductive Amination)91 on the 
intermediate 73, with benzylamine and H2 as a reducing agent in the presence of Pd(OH)2 
as catalyst (Scheme 3.2). 
 
Scheme 3.2: DRA on intermediate 73. 
Compound 73 was solubilized in dry MeOH in the presence of activated 3Å MS molecular 
sieves, then reacted with an equivalent of benzylamine for 50 minutes at room 
temperature under N2 atmosphere. The corresponding formed imine was reduced with H2 
 
94 Chen F.-E., Zhao J.-F., Xiong F.-J., Xie B., Zhang P., Carbohydr. Res. 2007, 342, 2461–2464. 
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in presence of Pd(OH)2/C as catalyst. After 7 days, piperidine 87 is formed and purified 
trough flesh column chromatography (FCC). 
 
Scheme 3.3: Hypothesized mechanism of piperidine formation. 
We hypothesize the reaction mechanism reported in scheme 3.3, in which, after the first 
nucleophilic attack performed by benzylamine and the consequent Schiff base formation 
with water elimination (from here the necessity to use molecular sieves in the reaction 
mixture), the reduction with H2 in presence of palladium hydroxide as catalyst produces an 
intermediate that is in equilibrium with his opened form. This specie undergoes in this way 
nucleophilic attack from the nitrogen atom of the primary amine formed (scheme 3.3). 
          
 With piperidine skeleton in hands, to introduce the azido moiety on the piperidine 
scaffold, we resumed our recently developed straightforward synthetic strategy to access 
N-functionalized pyrrolidine,45b trying to apply the same method to our piperidine (scheme 
3.4).  
 
Scheme 3.4: Alkylation of piperidine 87. 
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Compound 87 indeed, was reacted with bromo-azido alkyl chain 88 in CH3CN/H2O in the 
presence of K2CO3 under MW irradiation at 120°C to yield azide 89 (73%), that was then 
deprotected in acidic conditions in MeOH, affording the free-hydroxyl group piperidine 79 
(99%), necessary to build up the multimeric structures. 
 We chose a series of propargylated scaffolds with various geometry and number of 
alkyne moieties, from tri-, tetra- and hexavalents (Figure 3.12), in turn obtained by 
propargylation of the corresponding alcohols. The trivalent aliphatic scaffold 81 was 
synthesized from commercial TRIS (hydroxymethylaminomethane), following a reported 
procedure,95 while the aromatic trivalent 82 is a commercially available product. 
 The tetravalent scaffold 83 was prepared by propargylation of the commercial 
pentaerytritol, as previously reported, as well as hexavalent 85, obtained by coupling adipic 
acid with tris[(propargyloxy)methyl]aminomethane 81.89 Hexavalent 84 was achieved by 
propargylation reaction (figure 3.13).96  
 
95 Chabre Y. M., Contino-Pépin C., Placide V., Shiao T. C., Roy R., J. Org. Chem. 2008, 73, 5602-5605. 
96 Perez-Balderas F., Morales-Sanfrutos J., Hernandez-Mateo F., Isac-García J., Santoyo-Gonzalez F., Eur. J. Org. 
Chem. 2009, 2441–2453. 




Figure 3.13: Retrosynthesis of the trivalent, tetravalent and hexavalent scaffolds. 
To ‘click’ derivative 79 to the different scaffolds, we asked if it could be better use 
compound 89, perform the CuAAC and deprotect the final multivalent once grafted the 
bioactive unit, or directly react 79 with propargylated scaffolds avoiding the deprotection 
step on a very big structure such as a multivalent dendrimer. On the basis of previous 
works,90 in which the purification procedure resulted much less efficient with such a 
hydrophilic multivalent adducts with respect to several deprotected monovalent 
compounds synthesized, we directly applied the strategy a) reported in Scheme 3.5, 
avoiding in this way all the problems related to the isolation of free amines that we would 
recover from the DOWEX resin. Indeed, after the requested acidic condition in the 
deprotection for multivalents bearing protected piperidines, they would have been 
obtained as hydrochloride salts, therefore needing a treatment with an ion-exchange resin. 




Scheme 3.5: Two investigated routes for the synthesis of multivalent compounds. 
Following the first route (a, scheme 3.5), CuAAC reactions of the azido derivative 79 (always 
n.1 equivalent with respect to each alkynyl moieties number) with the scaffolds previously 
described were performed: trivalent compounds 81 (Scheme 3.6) and 82 (Scheme 3.7), 
tetravalent 83 (Scheme 3.8) and hexavalent 84 (Scheme 3.9) and 85 (scheme 3.10), 
following the same reaction conditions. A catalytic amount of CuSO4, sodium ascorbate, in 
THF/H2O =2: 1, under MW irradiation at 80 °C for 45 minutes afforded the multivalent 
compounds 90-94 that were first treated with a copper-scavenger resin (QuadraSil® MP 
resin, 1.0/1.5 mmol/g metal/resin loading) in order to remove every possible residual 
copper trace, and finally purified through exclusion size chromatography (SEC), using 
Sephadex LH-20. 




Scheme 3.6: Synthesis of trivalent piperidine 90. 
 
 
Scheme 3.7: Synthesis of trivalent piperidine 91. 
 




Scheme 3.8: Synthesis of tetravalent piperidine 92. 
 
 
Scheme 3.9: Synthesis of hexavalent piperidine 93. 
 




Scheme 3.10: Synthesis of trivalent piperidine 94. 
To evaluate the relative inhibitory activity enhancement of these new multimeric systems, 
giving in this way a quantification of the MVE (by calculating the rp/n), a proper monovalent 
counterpart was also synthesized. In particular, starting from azido-hydroxypiperidine 89, 
the CuAAC reaction was performed with propargylalchol in the presence of CuSO4/sodium 
ascorbate in THF/H2O = 2:1 at 80°C for 45 minutes, affording adduct 95 in 78% yield 
(Scheme 3.11). Final deprotection with MeOH/HCl and treatment with strongly basic resin 
Ambersep 900-OH, afforded the monovalent compound 96 in 95% yield. 
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3.2.1.2 Biological evaluation  
 Preliminary biological evaluation of all the new multivalent piperidines was carried 
out by measuring their inhibitory activity. All the multivalent compounds 90-94 as well as 
the corresponding monovalent iminosugar 96, were evaluated towards human GCase 
enzyme, thanks to a collaboration with Prof. Morrone (Meyer’s Children Hospital, Firenze).  
The compounds were screened in extracts from a pool of human leukocytes isolated from 
healthy donors (1 mM concentration of inhibitor, 37 °C and optimal pH conditions, see 







IC50 (µM) rp rp/n 
 96 1 69 500 ± 50 - - 
 
90 3 100 27 ± 3 19 6 
 
91 3 100 7 ± 1 71 24 
 
92 4 100 9 ± 4 56 14 
 
93 6 100 11 ± 3 45 8 
 
94 6 80 6 ± 1 83 14 
Table 3.1: Inhibitory activities of multivalent piperidine iminosugars 90, 91, 92, 93 
and 94, with monovalent reference compound 96, towards GCase -
glucocerebrosidase. Percentages of inhibition at 1mM of inhibitor and IC50 [μM] 
were reported. Relative potency (rp) and relative potency per active moiety (rp/n) 
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The results are summarized in Table 3.1, where the inhibition of the monovalent piperidine 
96 is also reported for sake of completeness. This one showed around 70% inhibition of 
GCase, while all the new multivalent piperidines inhibited the enzyme with percentages 
higher than 80%, suggesting that the simultaneous presentation of the active 2,3,4-
trihydroxypiperidine in a multimeric fashion leads to an enhancement of biological activity. 
As a matter of fact, IC50 value for monovalent 96 is higher than those of 90-94 which are in 
the low micromolar range, demonstrating that multivalent inhibitors are more potent than 
monovalent ones. The best inhibitor of the series is 94, showing an IC50 of 6 µM.  
To have a proof of concept about the potentiality of multivalent effect, we calculated the 
relative potency for all derivatives (rp, calculated as the IC50 ratio of the reference 
compound versus that of the corresponding multivalent compounds) that ranges from 19 
to 83, suggesting that the inhibitory activity enhancement is not simply due to a 
concentration effect. Moreover, a positive multivalent effect occurs in all cases (rp/n> 1, 
where n is the compound valency), in particular the best result is observed with compound 
91, for which a rp/n of 24 was calculated. Following our final goal to apply our iminosugars 
in the chaperoning activities, we performed chaperoning activity tests for the compounds 
showing the best values in term of inhibition and IC50. The ability of the multivalent 
trihydroxypiperidines 91, 92 and 93 to enhance the activity of GCase was so assayed in 





IC50 Rescue of GCase activity 
91 100 7 ± 1 1.21 at 10 M 
92 100 9 ± 4 1.26 at 10 M 
93 100 11 ± 3 1.21 at 50 M 
Table 3.2: Chaperoning activity assays. 
 
Interestingly, all new compounds showed a moderate increase in GCase activity (around 
1.2-fold), after incubation (4 days) with mutated fibroblasts, encouraging us in using 
multivalent architectures to design new inhibitors to be applied also as pharmacological 
chaperones. With reference to previous work,32 where compound 17 (figure 1.15), that 
bears an 8 atom carbon chain, showed an 1.25-fold GCase enhancement activity at 100 μM 
concentration, we have improved the chaperoning activity, demonstrating that there is 
actually an advantage in the multimerization of the bioactive trihydroxypiperidine. Indeed, 
the GCase activity rescue in this case is obtained at a concentration 10 fold lower. 
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3.2.1.3 Conclusions  
As introduced in the first part of section 3.2, our goal was to evaluate the biological 
activity of the new multivalent systems against human GCase enzyme, to find new selective 
inhibitors and, possibly, new pharmacological chaperones to use in the treatment of 
Gaucher disease. Moreover, we wanted also to define their multivalent potency in terms 
of rp/n in order to verify if an advantage in synthetizing multivalent compounds effectively 
exists. The synthesis of this small library of multivalent derivatives, including also the 
monovalent reference compound, was efficiently carried out by multimerizing our 
iminosugar onto different branched scaffolds through the CuAAC strategy, that allowded 
us to obtain multivalent 3,4,5-trihydroxypiperidines with a different degree of 
functionalized ‘bioactive arms’. Biological assays finally gave us promising results both in 
terms of inhibition and of chaperoning activity, with the best inhibitor/chaperone in the 
trivalent aromatic compound 91, that additionally shows the best value of rp/n revealing 
itself as the best multivalent iminosugar of the series. 
 
3.2.1.4 Experimental section 
 
For the general details see paragraph 2.4. 
 
Synthesis of piperidine 89: A solution of 87 (63 mg, 0.36 mmol), 1-azido-6-
bromohexane (88, 135 mg, 0.55 mmol) and K2CO3 (75 mg, 0.55 mmol) in 2.4 ml of a mixture 
CH3CN/H2O 5:1 was stirred in microwave at 120°C for 2 h, until a TLC analysis 
(CH2Cl2:MeOH:NH3 6:1:0.1) showed the disappearance of the starting material (Rf = 0.00) 
and the formation of a new product (Rf = 0.45). After filtration through Celite®, the solvent 
was removed under reduced pressure and the crude was purified by FCC (EtOAc: PE from 
1:1 to 2:1) affording pure 89 (Rf = 0.18, 89 mg, 0.26 mmol, 73% yield) as a yellow oil. [α]21D= 
−30.7 (c = 0.79 in MeOH); 1H-NMR (400 MHz, CD3OD): δ= 4.30 (dd, J = 8.3, 3.8 Hz, 1H, H-5), 
3.89-3.77 (m, 2H, H-3, H-4), 3.29 (t, J = 6.8 Hz, 2H, H-1’), 3.04 (d, J = 13.1 Hz, 1H, Ha-6), 2.76 
(pdd, J = 12.0, 4.0 Hz, 1H, Ha-2), 2.44 (dd, J = 13.3, 3.9 Hz, 1H, Hb-6), 2.39 (dd, J = 7.8, 2.7 
Hz, 2H, H-9’), 2.02 (dd, J = 11.4, 9.0 Hz, 1H, Hb-2), 1.62-1.51 (m, 6H, CH3), 1.36 (bs, 14H, 
from H-2’ to H-8’) ppm; 13C-NMR (50 MHz, CD3OD): δ= 110.1 (s, OC(CH3)2), 80.2 (d, C-4), 
74.5 (d, C-3), 70.4 (d, C-5), 59.2 (t, C-9’), 57.7 (t, C-6), 55.1 (t, C-2), 52.4 (t, C-1’), 30.5-27.8 
(t, 7C from C-2’ to C-8’), 27.5-26.6 (q, 2C, OC(CH3)2) ppm; IR (CD3OD): ν = 3022, 2989, 2934, 
2856, 2098, 1470, 1383, 1225, 1059 cm−1. MS (ESI): m/z calcd (%) for C17H32N4O3 340.25; 
found: 341.25 (100%, [M+ H]+), 363.25 (71%, [M+ Na]+).  
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Synthesis of piperidine 79: To a solution of 89 (152 mg, 0.45 mmol) in 18 mL of 
methanol, 20 drops of 37% HCl were added and the mixture was stirred at room 
temperature for 18 hours. After that a TLC analysis (CH2Cl2:MeOH 20:1) showed 
disappearance of the starting material (Rf = 0.44), the solvent was removed under reduced 
pressure. The crude was purified by FCC (CH2Cl2:MeOH:NH3 from 10:1:0.1 to 6:1:0.1) 
affording pure 79 (Rf = 0.19, 132 mg, 0.44 mmol, 99% yield) as a colourless oil. [α]26D= −21.6 
(c = 1.02 in MeOH); 1H-NMR (400 MHz, CD3OD): δ= 3.91 (q, J = 5.8 Hz, 1H, H-3), 3.80 (td, J 
= 7.9, 4.0 Hz, 1H, H-5), 3.42-3.39 (m, 1H, H-4), 3.29 (t, J = 6.8 Hz, 2H, H-1’), 2.84-2.76 (m, 
2H, Ha-6, Ha-2), 2.44-2.32 (m, 2H, Hb-6, Hb-2), 2.29 (d, J = 12.1 Hz, 1H, Ha-9’), 2.15-2.06 
(m, 1H, Hb-9’), 1.64-1.57 (m, 2H, H-2’), 1.54-1.51 (m, 2H, H-8’), 1.35 (bs, 10H, from H-3’ to 
H-7’) ppm; 13C-NMR (50 MHz, CD3OD): δ= 75.3 (d, C-4), 69.6 (d, C-5), 69.1 (d, C-3), 59.3 (t, 
C-9’), 58.2 (t, C-2), 57.6 (t, C-6), 52.4 (t, C-1’), 30.5-27.5  (t, 7C, from C-2’ to C-8’) ppm; IR 
(CD3OD): ν = 3690, 3585, 3429, 2932, 2856, 2817, 2098, 1469, 1068 cm-1. MS (ESI): m/z 
calcd (%) for C14H28N4O3 300.22; found: 301.33 (100%, [M+ H]+). Elemental analysis: 
C14H28N4O3 (300.40) calcd. C, 55.98; H, 9.40; N, 18.65; found C, 56.02; H, 9.32, N, 18.55. 
Synthesis of protected monovalent piperidine 95: To a solution of 89 (85 mg, 0.250 
mmol) in 3 ml of a 2:1 THF:H2O mixture were added CuSO4 (30 mol%), sodium ascorbate 
(60 mol%) and propargyl alcohol (1 equiv.). The reaction mixture was stirred in a MW 
reactor at 80 °C for 45 min until TLC analysis (DCM: MeOH 10:1) showed the disappearance 
of the starting material (Rf = 0.59) and formation of a new product (Rf = 0.00). After 
filtration through Celite®, the solvent was removed under reduced pressure and the crude 
was first treated with Quadrasil® MP resin then purified by FCC (CH2Cl2:MeOH:NH3 from 
30:1:0.1 to 6:1:0.1) affording pure 95 (Rf = 0.26, 77 mg, 0.19 mmol, 78% yield) as a 
colourless oil. [α]25D= + 11.5 (c = 0.90 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 7.51 (s, 1H, H 
triazole), 4.76 (s, 2H, CH2OH Ar), 4.31 (td, J = 7.1, 2.5 Hz, 2H, H-9’), 4.28-4.26 (m, 1H, H-5), 
4.04-4.01 (m, 1H, H-4), 3.95-3.92 (m, 1H, H-3), 3.27 (bs, 1H, OH), 2.72-2.68 (m, 1H, Ha-6), 
2.56 (d, J = 11.7 Hz, 1H, Ha-2), 2.44 (d, J = 11.1 Hz, 1H, Hb-2), 2.39 (dd, J = 12.0, 3.2 Hz, 1H, 
Hb-6), 2.35-2.31 (m, 2H, H-1’), 1.92-1.81 (m, 2H, H-8’), 1.48 (s, 3H, CH3), 1.45-1.37 (m, 2H, 
H-2’), 1.34 (s, 3H, CH3), 1.28-1.24 (m, 10H, from H-3’ to H-7’) ppm; 13C-NMR (50 MHz, 
CDCl3): δ= 147.9 (s, C-CH2OH Ar), 121.6 (d, CH triazole), 109.5 (s, OC(CH3)2), 76.6 (d, C-4), 
72.3 (d, C-5), 67.8 (d, C-3), 57.9 (t, C-1’), 56.7 (t, Ar-CH2OH), 56.0 (t, C-2), 55.7 (t, C-6), 50.5 
(t, C-9’), 30.4 (t, C-8’) 29.9-27.4 (t, 6C, from C-2’ to C-7’) 26.9-26.5 (q, 2C, OC(CH3)2) ppm; IR 
(CDCl3): ν = 3669, 3406, 3005, 2934, 2859, 2361, 1464, 1379, 1142, 1057, 926 cm-1. MS 
(ESI): m/z calcd (%) for C20H36N4O4 396.27; found: 397.53 (100%, [M+ H]+).  
Synthesis of deprotected monovalent piperidine 96: To a solution of 95 (73 mg, 
0.18 mmol) in 8 mL of methanol, 15 drops of 37% HCl were added and the mixture was 
stirred at room temperature for 18 hours. After that a TLC analysis (CH2Cl2:MeOH 10:1) 
showed disappearance of the starting material (Rf = 0.59), the solvent was removed under 
reduced pressure. The product, obtained as hydrochloric salt, was then treated with the 
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strongly basic resin Ambersep 900-OH to afford the final product 96 (62 mg, 0.18 mmol, 
95% yield) as a colourless oil. [α]27D= - 18.0 (c = 0.94 in CH3OH); 1H-NMR (400 MHz, CD3OD): 
δ= 7.90 (s, 1H, H triazole), 4.68 (s, 2H, CH2OH Ar), 4.39 (t, J = 6.4 Hz, 2H, H-9’), 3.90-3.89 (m, 
1H, H-3), 3.81-3.77 (m, 1H, H-5), 3.40-3.39 (m, 1H, H-4), 2.80-2.69 (m, 2H, Ha-6, Ha-2), 2.37-
2.32 (m, 2H, H-1’), 2.26 (d, J = 11.0 Hz, 1H, Hb-2), 2.14-1.99 (m, 1H, Hb-6), 1.91-1.88 (m, 2H, 
H-8’), 1.51-1.48 (m, 2H, H-2’), 1.31 (bs, 10H, from H-3’ to H-7’) ppm; 13C-NMR (50 MHz, 
CD3OD): δ= 148.8 (s, C-CH2OH Ar), 123.8 (d, CH triazole), 75.1 (d, C-4), 69.3 (d, C-5), 68.9 (d, 
C-3), 59.1 (t, C-1’), 58.0 ( t, C-2), 57.4 (t, C-6), 56.3 (t, Ar-CH2OH), 51.1 (t, C-9’), 31.1 (t, C-8’) 
30.3-27.3 (t, 5C, from C-3’ to C-7’) 27.7 (t, C-2’) ppm; MS (ESI): m/z calcd (%) for C17H32N4O4 
356.24; found: 379.52 (43%, [M+ Na]+), 357.52 (100%, [M+ H]+). Elemental analysis: 
C17H32N4O4 (356.47) calcd. C, 57.28; H, 9.05; N, 15.72; found C, 57.35; H, 8.99, N, 15.59.  
General procedure for CuAAC reaction to synthesize multivalent compounds: To 
a solution of 79 in a 2:1 THF:H2O mixture were added CuSO4 (30 mol%), sodium ascorbate 
(60 mol%) and alkyne 81-85 (1 equiv.). The reaction mixture was stirred in a MW reactor at 
80 °C for 45 min until TLC analysis (DCM: MeOH 10:1) showed the disappearance of the 
starting material (Rf = 0.21) and formation of the desired product. After filtration through 
Celite®, the solvent was removed under reduced pressure and the crude was first treated 
with Quadrasil® MP resin then purified through SEC (with Sephadex LH-20) to obtain the 
multivalent adducts 90-94. In the table below (table 3.3) are reported the piperidine 79 
equivalents required for each multivalent compound, with the yields of the final products. 
 
Multivalent compound Alkynyl scaffold (1eq.) Piperidine 77 (eq.) Yield % 
90 81 3.3 55 
91 82 3.3 89 
92 83 4.4 61 
93 84 6.6 85 
94 85 6.6 54 
 
Table 3.3: Multivalent final compounds with relative reaction conditions and yields. 
 
 
Aliphatic trivalent 90: Obtained as white waxy solid (47 mg, 0.04 mmol). [α]26D= - 
12.3 (c = 1.03 in CH3OH); 1H-NMR (400 MHz, CD3OD): δ= 7.98 (s, 3H, H triazole), 4.59 (bs, 
6H, H-), 4.40 (t, J = 7.0 Hz, 6H, H-9’), 3.99-3.95 (m, 3H, H-3), 3.87-3.83 (m, 3H, H-5), 3.55-
3.45 (m, 9H, H-4, H-), 3.35 (s, 2H, NH2), 2.93-2.86 (m, 6H, Ha-6, Ha-2), 2.55-2.47 (m, 9H, 
H-1’, Hb-2), 2.38-2.28 (m, 3H, Hb-6), 1.94-1.89 (m, 6H, H-8’), 1.56-1.55 (m, 6H, H-2’), 1.33 
(bs, 30H, from H-3’ to H-7’) ppm; 13C-NMR (50 MHz, CD3OD): δ= 145.5 (s, 3C, C-Ar triazole), 
125.0 (d, 3C, CH triazole), 74.3 (t, 3C, C-), 71.5 (d, 3C, C-4), 69.1 (d, 3C, C-5), 68.3 (d, 3C, C-
3), 65.4 (t, 3C, C-), 59.0 (t, 3C, C-1’), 57.3 (t, 3C, C-2), 56.8 (t, 3C, C-6), 51.4 (t, 3C, C-9’), 
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29.9 (t, 3C, C-8’) 31.2-27.4 (t, 15C, from C-3’ to C-7’) 26.9 (t, 3C, C-2’) ppm; MS (ESI): m/z 
calcd (%) for C55H101N13O12 1136.47; found: 1159.00 (100, [M+ Na]+), 379.83 (77, [(M/3)+ 
H]+). Elemental analysis: C55H101N13O12 (1136.47) calcd. C, 58.13; H, 8.96; N, 16.02; found C, 
58.19; H, 9.01, N, 15.89. 
Aromatic trivalent 91: Obtained as white waxy solid (48 mg, 0.04 mmol). [α]26D= - 
17.5 (c = 1.02 in CH3OH); 1H-NMR (400 MHz, CD3OD): δ= 8.46 (s, 3H, H-Ar), 8.29 (s, 3H, H 
triazole), 4.49 (t, J = 7.0 Hz, 6H, H-9’), 3.89 (dd, J = 5.5, 2.8 Hz, 3H, H-3), 3.80 (td, J = 7.7, 3.9 
Hz,  3H, H-5), 3.45-3.38 (m, 3H, H-4), 2.83-2.76 (m, 6H, Ha-6, Ha-2), 2.41-2.33 (m, 6H, H-1’), 
2.31-2.28 (m, 3H, Hb-2), 2.18-2.05 (m, 3H, Hb-6), 2.02-1.96 (m, 6H, H-8’), 1.54-1.44 (m, 6H, 
H-2’), 1.36-1.30 (m, 30H, from H-3’ to H-7’) ppm; 13C-NMR (50 MHz, CD3OD): δ= 148.0 (s, 
3C, C-Ar triazole), 133.4 (s, 3C, C-Ar), 123.3 (d, 3C, CH-Ar), 122.8 (d, 3C, CH triazole), 75.0 
(d, 3C, C-4), 69.4 (d, 3C, C-5), 68.8 (d, 3C, C-3), 59.2 (t, 3C, C-1’), 57.9 (t, 3C, C-2), 57.3 (t, 3C, 
C-6), 51.6 (t, 3C, C-9’), 31.2 (t, 3C, C-8’) 30.4-27.5 (t, 15C, from C-3’ to C-7’) 27.3 (t, 3C, C-2’) 
ppm; MS (ESI): m/z calcd (%) for C54H90N12O9 1050.70; found: 1073.92 (73, [M+ Na]+), 
526.58 (100, [(M/2)+ H]+), 351.42 (59, [(M/3)+ H]+). Elemental analysis: C54H90N12O9 
(1051.37) calcd. C, 61.69; H, 8.63; N, 15.99; found C, 61.45; H, 8.35, N, 16.08. 
Tetravalent 92: Obtained as white waxy solid (45 mg, 0.03 mmol). [α]23D= - 14.9 (c 
= 0.98 in CH3OH); 1H-NMR (400 MHz, CD3OD): δ= 7.98 (s, 4H, H triazole), 4.51 (s, 8H, H-), 
4.39 (t, J = 7.1 Hz, 8H, H-9’), 3.95 (dd, J = 3.9, 1.3 Hz, 4H, H-3), 3.84 (td, J = 7.1, 3.7 Hz, 4H, 
H-5), 3.47-3.44 (m, 12H, H-4, H-), 2.90-2.83 (m, 8H, Ha-6, Ha-2), 2.51-2.42 (m, 12H, H-1’, 
Hb-2), 2.32-2.23 (m, 4H, Hb-6), 1.94-1.87 (m, 8H, H-8’), 1.60-1.47 (m, 8H, H-2’), 1.32 (bs, 
40H, from H-3’ to H-7’) ppm; 13C-NMR (50 MHz, CD3OD): δ= 146.2 (s, 4C, C-Ar triazole), 
124.8 (d, 4C, CH triazole), 74.6 (t, 4C, C-), 70.0 (d, 4C, C-4), 69.3 (d, 4C, C-5), 68.5 (d, 4C, C-
3), 65.4 (t, 4C, C-), 59.1 (t, 4C, C-1’), 57.6 (t, 4C, C-2), 57.0 (t, 4C, C-6), 51.3 (t, 4C, C-9’), 
46.5 (t, 4C, C-8’) 31.3-27.4 (t, 20C, from C-3’ to C-7’) 27.1 (t, 4C, C-2’) ppm; MS (ESI): m/z 
calcd (%) for C73H132N16O16 1489.00; found: 756.92 (100, [(M+ Na)/2]+). Elemental analysis: 
C73H132N16O16 (1489.93) calcd. C, 58.85; H, 8.93; N, 15.04; found C, 58.98; H, 8.78, N, 14.49. 
Hexavalent 93: Obtained as white waxy solid (58 mg, 0.02 mmol). [α]23D= - 16.9 (c 
= 0.74 in CH3OH); 1H-NMR (400 MHz, CD3OD): δ= 7.92 (s, 6H, H triazole), 4.51 (s, 12H, H-), 
4.35 (t, J = 7.0 Hz, 12H, H-9’), 3.94-3.85 (m, 6H, H-3), 3.82-3.77 (m, 6H, H-5), 3.71 (s, 12H, 
H-), 3.46-3.37 (m, 6H, H-4,), 2.83-2.72 (m, 12H, Ha-6, Ha-2), 2.41-2.33 (m, 18H, H-1’, Hb-
2), 2.25-2.11 (m, 10H, Hb-6, H-10’, H-13’), 1.88-1.84 (m, 12H, H-8’), 1.57-1.41 (m, 16H, H-
2’, H-11’, H-12’), 1.28 (bs, 60H, from H-3’ to H-7’) ppm; 13C-NMR (100 MHz, CD3OD): δ= 
176.1 (s, 2C, C=O), 145.8 (s, 6C, C-Ar triazole), 124.9 (d, 6C, CH triazole), 74.7 (t, 6C, C-), 
69.3 (d, 6C, C-4), 68.6 (d, 6C, C-5), 65.3 (d, 6C, C-3), 61.3 (d, 2C, C-11’, C-12’), 59.2 (t, 6C, C-
), 57.7 (t, 6C, C-2, C-6), 57.2 (t, 6C, C-1’), 51.3 (t, 6C, C-9’), 31.3 (t, 6C, C-8’), 30.5-27.3 (t, 
30C, from C-3’ to C-7’) 26.4 (t, 6C, C-2’) ppm; MS (ESI): m/z calcd (%) for C116H208N26O26 
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2382.58; found: 1203.60 (100, [(M+ Na)/2]+), (84, [(M/2)+Na]+). Elemental analysis: 
C116H208N26O26 (2383.10) calcd. C, 58.46; H, 8.80; N, 15.20; found C, 58.29; H, 8.92, N, 15.46. 
Hexavalent 94: Obtained as white waxy solid (64 mg, 0.03 mmol). [α]23D= - 7.3 (c = 
0.95 in CH3OH); 1H-NMR (400 MHz, CD3OD): δ= 8.07, 8.01, 7.97 (s, 6H, H triazole), 4.76-4.57 
(s, 12H, H-), 4.39 (dd, J = 13.0, 6.6 Hz, 12H, H-9’), 4.17-4.05 (m, 6H, H-3), 4.02-3.87 (m, 
10H, H-5, H-), 3.85-3.65 (m, 10H, H-4, H-), 3.24-3.06 (m, 12H, Ha-6, Ha-2), 3.05-2.74 (m, 
24H, H-1’, Hb-2, Hb-6), 1.97-1.77 (m, 12H, H-8’), 1.77-1.75 (m, 12H, H-2’), 1.34-1.31 (m, 
60H, from H-3’ to H-7’) ppm; 13C-NMR (100 MHz, CD3OD): δ= 146.1 (s, 6C, C-Ar triazole), 
125.4 (d, 6C, CH triazole), 72.3 (t, 2C, C-), 69.9 (d, 6C, C-4), 68.1 (d, 4C, C-), 66.4 (d, 6C, C-
5), 65.2 (d, 6C, C-3), 63.7 (t, 6C, C-1’),  55.4 (t, 6C, C-2), 55.1 (t, 6C, C-6), 51.3 (t, 6C, C-9’), 
31.2 (t, 6C, C-8’), 30.1-27.4 (t, 30C, from C-3’ to C-7’) 25.6 (t, 6C, C-2’) ppm; MS (ESI): m/z 
calcd (%) for C108H194N24O24 2212.47; found: 1107.01 (57, [(M/2)+H]+), 738.54 (100, 
[(M/3)+H]+), 554 (69, [(M/4)+H]+). Elemental analysis: C108H194N24O24 (2212.84) calcd. C, 
58.62; H, 8.84; N, 15.19; found C, 58.88; H, 8.61, N, 15.25. 
 
Biochemical characterization with human GCase: The compounds were screened towards 
GCase from leukocytes isolated from healthy donors (controls). Isolated leukocytes were 
disrupted by sonication, and a micro BCA protein assay kit (Sigma–Aldrich) was used to 
determine the total protein amount for the enzymatic assay, according to the 
manufacturer instructions. Enzyme activity was measured in a flat-bottomed 96-well plate. 
Iminosugar solution (3 μL), 4.29 μg/μL leukocytes homogenate (7 μL), and substrate 4-
methylumbelliferyl-β-D-glucoside (3.33 mM, 20 μL, Sigma–Aldrich) in citrate/phosphate 
buffer (0.1:0.2, M/M, pH 5.8) containing sodium taurocholate (0.3%) and Triton X-100 
(0.15%) at 37 °C were incubated for 1 h. The reaction was stopped by addition of sodium 
carbonate (200 μL; 0.5M, pH 10.7) containing Triton X-100 (0.0025 %), and the fluorescence 
of 4-methylumbelliferone released by β-glucosidase activity was measured in SpectraMax 
M2 microplate reader (λex=365 nm, λem=435 nm; Molecular Devices). Percentage GCase 
inhibition is given with respect to the control (without iminosugar). 
IC50 determination: The IC50 values of inhibitors against GCase were determined by 
measuring the initial hydrolysis rate with 4-methylumbelliferyl-β-D-glucoside (3.33 mM). 























where Vi/Vo, represent the ratio between the activity measured in the presence of the 
inhibitor (Vi) and the activity of the control without the inhibitor (V0), “x” the inhibitor 
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concentration, Max and Min, the maximal and minimal enzymatic activity observed, 
respectively. 
 
Chaperoning activity assays 
Evaluation of the effect of multimeric iminosugars (90-94) on GCase activity in Gaucher 
patients’ cells: Fibroblasts with the N370S/RecNcil mutation from Gaucher disease patients 
were obtained from the “Cell line and DNA Biobank from patients affected by Genetic 
Diseases” (Gaslini Hospital, Genova, Italy). Fibroblasts cells (20 x104) were seeded in T25 
flasks with DMEM supplemented with fetal bovine serum (10 %), penicillin/streptomycin 
(1%), and glutamine (1%) and incubated at 37 °C with 5% CO2 for 24 h. The medium was 
removed, and fresh medium containing the multimeric iminosugars   was added to the cells 
and left for 4 days. The medium was removed, and the cells were washed with PBS and 
detached with tripsin to obtain cell pellets, which were washed four times with PBS, frozen 
and lysed by sonication in water. Enzyme activity was measured as reported above. 
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3.2.2 Study on the aggregation of trihydroxypiperidines  
Due to the biological properties of our trihydroxypiperidines, we wanted to 
investigate the aggregation behaviour, in aqueous solution, of those inhibitors. Indeed, it 
was expected that such amphiphilic compounds would form aggregates in solution, at 
given concentration. Understanding the aggregation state in water could be useful to 
clarify the mechanisms involved in the formation of enzyme-inhibitor complexes. Our aim 
was to determine if, at the concentration at which these compounds are biologically active 
(as inhibitors and/or as pharmacological chaperones) they do form aggregates (therefore 
presenting themselves as a multivalent dynamic micellar system) or they do not.  
To study this aspect, we synthesized piperidine 97 exploiting the DRA reaction already used 
to achieve the N-alkylated piperidine 17 (section 1.2.2) with a shorter carbon chain (figure 
3.14). Indeed, by elongating the alkyl chain, we enhanced the differentiation between the 




Figure 3.14: Synthetic strategy to obtain piperidine 97. 
Our hypothesis was initially based on the idea that, being the molecule formed by a 
hydrophilic portion and an apolar chain, and resembling in this way a ‘surfactant’, once in 
water there was a sort of a micellar rearrangement of the structures (figure 3.15). 




Figure 3.15: Our initial hypothesis: micellar aggregation of piperidine 97. 
To understand the self-assembly of the piperidine amphiphile, we collaborated with Prof. 
Lo Nostro of the Department of Chemistry of University of Florence, who performed the 
physico-chemical characterization.  
Compound 97 could be treated as a surfactant, due to its amphiphilic nature. Generally, 
the nature of the polar head of surfactants can be various: neutral, ionic and zwitterionic 
(figure 3.16). 
 
Figure 3.16: Possible forms of polar heads in surfactants: a) neutral; b) anionic; c) cationic; 
d) zwitterionic 
The double nature of the surfactants leads to peculiar behave in aqueous solution, causing 
a lowering of the surface tension. Indeed, some molecules of the surfactant are placed on 
the solution surface because of the energetically unfavourable interactions that occur 
between the alkyl chain of the amphiphile and the water. Increasing the concentration of 
the amphiphilic compound in solution also increases its amount at the interface, up to the 
point where the interface is saturated and adsorption is no longer possible; from this point 
onwards the added surfactant molecules will go into solution leading to an increase in the 
free energy of the system due to the unfavourable interactions between the surfactant tail 
and the water, until the so-called "critical micellar concentration" (CMC) is reached. From 
here, in order to "oppose" the increase in free energy of the system, the surfactant 
molecules start a process of self-assembly, leading to the formation of micelles (figure 
3.17).97 
 
97 Moroi Y., Plenum, J. Dispers. Sci. Technol., 1993, 14 (5), 603–604. 




Figure 3.17: Behaviour of a surfactant in aqueous solution. 
The process in which single molecules dispersed in a suitable solvent associate themselves 
to produce complex structures, is called self-assembly and it is caused by the great increase 
in entropy that occurs after self-association. Moreover, we defined a micellar critical 
concentration (CMC) the concentration above which the surfactant aggregates, while 
below the surfactant remains monodisperse in the solvent. Several types of micellar 
aggregation are known, depending on parameters such as the temperature of the system 
and the lipophilic chain’s length. Once reached the CMC, enhancing surfactant 
concentration, the micelles can remain spherical or, due to the growth of the volume, 
aggregate in other types of structures with considerable difference in symmetry with 
respect to the micellar one, for example assuming a lamellar form.98 It is possible to predict 
the type of aggregate that will occur in solution by evaluating the "packing parameter" P, 
obtained from the following relation: P = v / a0 l , where v and l are respectively the volume 
and the length of the hydrophobic chain, while 𝑎0 represents the surface occupied by a 
surfactant in the micelle-water interphase. We have the formation of spherical micelles if 
P < 1/3, while, if the value of P = 1 the lamellar aggregation occurs. Once estimated the 
packaging parameter empirically, SAXS measurements can effectuated for experimentally 
confirm the hypothesis, then to evaluate the crystalline structures, WAXS and FT-IR data 
can be recorded. Indeed, by correlating the experimental peaks with some parameters 
reported in literature,99 it is possible to understand the type of geometric organization 
assumed by the crystalline cell. Moreover, performing DSC (Differential Scanning 
Calorimetry) in the solution (at different concentrations) of the surfactant, we can 
 
98 Nagarajan R., Langmuir., 2002, 18, 31-38. 
99 Lo Nostro P., Tempestini E., Bucci M., Mastromartino V., Gori M., Tanini D., Ambrosi M., Fratini M., Capperucci 
A., ChemPhysChem., 2017, 18, 1400–1406. 
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investigate the interactions between water and amphiphilic substance molecules, 
understanding the self-assembly in water. 
 
The point was however that: if the micelle formation really occurs, at which 
piperidine concentration we have it? This is an important issue, because we wanted to 
understand the aggregation state in the same conditions of the biological tests, and 
therefore at inhibitory and sub-inhibitory (for the chaperoning activity) concentrations. If 
our piperidine aggregates in water in a micellar conformation, as we initially theorised, it 
could be considered as a kind of multivalent system, in which the micelle acts as a 
piperidine reserve. The main difference with respect to previous dendrimers, is that while 
they possess a well-defined number of active ‘warheads’ linked on a common scaffold with 
covalent bods, in this case the bioactive piperidines are held together by supramolecular 
forces, in a sort of dynamic equilibrium. For this reason, searching to clarify this concept, 
we thought to synthesize also a kind of covalently linked micelle, in which the dynamism of 
the micelle was hampered by the formation of covalent bonds (compound 98, figure 3.18), 
and to compare the activity of the polymer with that of monomer. 
 
 
Figure 3.18: Piperidine with unsaturated 11-carbon chain 98. 
But what about the role of the lipophilicity? Investigating this point could be useful to 
understand something about the nature of the enzymatic site of GCase: in our experience 
until now, the best results in terms of inhibition and chaperoning activity were obtained 
indeed with piperidines bearing a quite-long carbon chain (both on the N endocyclic atom, 
and on C-2).32,36 For this reason, to prove or confute the importance of a lipophilic portion, 
we carried on the synthesis of a molecule that contains the same trihydroxypiperidine 
skeleton and a water soluble more polar chain with a comparable length (compound 99, 
figure 3.19), but bearing a PEG chain instead of an alkyl chain. 




Figure 3.19: Trihydroxypiperidine 99 N-alkylated with a polar PEG-ylated chain. 
The final step in those preliminary studies was the evaluation of all those compounds as 
GCase inhibitors and, if they would show promising results, as chaperones. 
  
3.2.2.1 Results and discussion 
 For the synthesis of piperidine 97 we started from the same D-mannose derived 
dialdehyde intermediate 73, applying again the DRA strategy (scheme 3.12). We first 
remove the benzyl group of dialdehyde 73 affording 100,91 then, using dodecylamine in the 
double reductive amination, we got piperidine intermediate 101 that was finally 
deprotected in acidic conditions affording the final compound 97 (32% over 2 steps). 
 
 
Scheme 3.12: Synthetic strategy for compound 97. 
 
Physico-chemical characterization: 
The physico-chemical characterization of 97 was carried out by Prof. Lo Nostro group 
(Department of Chemistry, University of Florence). At first the packing parameter of 
compound 97 was estimated using Tanford formulas, through which it was possible to 
derive the volume and the length of the apolar tail of the compound 97. The area per polar 
head was found by approximating the piperidine polar heads with cylinders. 




Figure 3.20: Cylindric approximation of polar heads. 
The P value found is of about 0.9, for which the formation of a planar lamellar structure 
with the solvent distributed between the bilayers formed by the amphiphilic molecules is 
expected. This happens when we have a high amphiphile concentrations (see table 3.4). 
Moreover, through Tanford formulas the length of the polar head (lp) was calculated: it is 
of 6 Å; the length of the tails (lc) is about 15.4 Å. The structural unit (d) is composed of two 
tails and two heads that are placed at limited distance, in order to maximize the hydrogen 
bonds. Comparing the hydrocarbon thickness (d-2lh) with the length of the two tails, the 
degree of interdigitation G.I.% is obtained. The hypothesized structure, together with the 
G.I% formula, is reported in figure 3.21. 
 
 
Figure 3.21: Hhypothetical scheme of the structure envisaged by G.I%. 
Performing DSC measurements, a melting temperature of 64.37 °C with a Hfus of 75.03 J/g 
(248.89 kJ/mol) was found; moving towards higher temperatures another peak much 
smaller than the first is present, probably given by a polymorph or an improbable impurity 
remained following the synthesis (figure 3.22). 




Figure 3.22: DSC thermogram. 
The lamellar structure was then confirmed by SAXS experiments, in which two peaks at the 
scattering vector "q" value equal to 0.21 Å−1 and 0.43 Å−1 were obtain, relative respectively 
to the first and second reflection of the ‘lamella’. The thickness of a ‘lamella’ can be derived 
from the ratio q = 2π / d, which is therefore equal to 29.4 Å. Analyzing WAXS profile of the 
solid, a tricline type geometric organization of the crystalline cell was found, also confirmed 
by IR spectroscopy. Moreover, the sample was characterized by SAXS, WAXS and DSC 
techniques at various concentrations in aqueous solution, respectively at 8, 12, 20 and 40% 
w/w concentrations: it was possible to quantify the temperature at which there is a passage 
from a lamellar phase to a disordered gel-like phase (around 21°C), and to obtain the 
number of water molecules strongly linked to the polar heads of the surfactant (Wb), which 
do not freeze or melt during the heating/cooling cycles and the number of strongly bound 
molecules by the polar head of the surfactant (Nb) (table 3.4). Finding these values for 
several solutions at different concentrations (table 3.4) we note how the number of 
strongly bound molecules increases as the concentration of the dispersed 97 surfactant 
increases, while the number of molecules per polar surfactant head shows an opposite 
trend. 
 
W/W% Hfus ( J/g) Wb % Nb% 
7.9 331.1 0.81 6.82 
11.85 300.1 10.09 5.21 
19.53 271.6 18.63 2.57 
41.5 77 76.93 0.45 
Table 3.4: Values obtained by calorimetric experiments. 
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Moreover, aiming also to understand if the piperidine self-assemblies in micellar 
aggregates, we performed surface tension measurements. A 12 M value of CMC was 
found. This value can be compared to the IC50 graph in order to understand if our 
compound is active in monomeric form or the micellar aggregates, at least in part, are 
responsible of biological activity (see biological evaluation 3.2.2.2). 
 
For the synthesis of piperidine containing the terminal double bond 98, we investigated 
two different pathways: the first one in which 1,11-undecyl,bromo-nonane was directly 
reacted with piperidine 102, obtained through acidic deprotection and consequent 
treatment with strongly acid resin DOWEX, of compound 87 (scheme 3.13).91 
 
 
Scheme 3.13: Synthesis of compound 102. 
Compound 102 was reacted with 1,11-undecyl,bromo-nonane using the alkylation 
procedure already exploited in the synthesis of azido-piperidine 89 (see section 3.2.1.1), as 
described in scheme 3.14. 
 
Scheme 3.14: Synthesis of compound 98. 
We observed in this case, the formation of a byproduct in a consistent amount (66 mg, 0.23 
mmol, 28% yield), that we identified, through ESI-MS and NMR, in the bis-alkylated 
piperidine 103 (scheme 3.15). 




Scheme 3.15: Formation of byproduct 103. 
Trying to avoid to recover the bis-alkylated compound, we thought to perform the 
alkylation starting from the protected piperidine 87, and deprotect the product in the final 
step with an acidic cleavage of the hydroxyl groups on C-3 and C-4 (scheme 3.16), but also 
in this case, we obtained the corresponding protected bis-alkylated compound 105 (140 
mg, 0.32 mmol, 17%). 
 
Scheme 3.16: Alternative synthetic strategy. 
We reasoned that this problem was probably due to the terminal double bond that could 
provoke a sort of packaging, because in the case of the azido derivatives 79 and 89, we did 
not observe the same analogous by-product. Anyway, once obtained derivative 98, we 
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tried to perform a polymerization reaction exploiting the olefin moiety with several 
attempts. 
 We decided to perform the polymerization using AIBN (2,2’-azobisisobutyronitrile) as 
radical initiator and we planned the experiment in order to induce the micellar formation, 
dissolving amphiphile 98 in deuterium dioxide (to follow the reaction profile through NMR 
spectroscopy; concentration: 10 mg/0.1 ml) and adding drop by drop a solution of AIBN in 
methanol. According to our hypothesis compound 98 would dispose itself displaying the 
polar portion of the molecule outwards (showing a lipophobic nature) and the lipophile 
tails inwards; the initiator, dissolved in organic medium, would have reach the internal part 
of the micelle, performing its role and starting in that way the polymerization reaction, 
catalysed by the temperature (50°C) and helped by the use of UV radiation. To attest the 
formation of the polymer, we performed a 1H-NMR after one hour, but the situation 
seemed to be the same: the ratio between the integrals of H-3 (or H-4 or H-5) and H-7’ (the 
olefin proton) was still equal to 1, while, if the polymerization occurred, we expected at list 
a reduction of H-7’ integral. The same spectrum was observed after 4 hours and addition 
of AIBN (4% in mol with respect to initial 2%). We decided to add more AIBN (to reach a 
total percentage of 8%) and left the reaction for other 6 hours, but a further NMR control, 
showed again no decrease of olefin proton integrals. In the second attempt we changed 
some parameters, setting the temperature to 100°C for 15 minutes,100 but nothing 
happened also in this case. In the third and final procedure, we first tried to re-crystallize 
AIBN from methanol and then we enhanced the amount (10% in mol) of initiator and also 
the concentration of starting material in the solvent, passing from 100 mg/1 ml to 100 mg/2 
ml (see table 3.5). Unfortunately, even in these conditions the desired polymerization did 
not occurr, letting us think that for some reason it was no possible to achieve the covalently 
linked micelle. 
 
 T t C conditions 
2 50 °C 24 h 100 mg/ 1mL UV lamp 
3 100 °C 15 min 100 mg/ 1mL - 
4 100 °C 18 h 
from100 mg/ 1mL 
to 100 mg/ 2mL 
recrystallized AIBN from MeOH 
Purification with Sephadex® 
Table 3.5: Polymerization conditions. 
  
 
100 Krstina J., Moad G., Willing I., Danek S.K., Kelly D.P., Jones S.L., Solomon D.H., Eur. Polym. J., 1993, 29, 379-
388. 
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For the synthesis of ‘PEG-ylated’ piperidine 99, we followed the alkylation procedure 
already used in the synthesis of azido-piperidine 89 (see section 3.2.1.1), reported in 
scheme 3.17: the trihydroxypiperidine 87 was reacted with tetraethylene glycol p-
toluenesulfonate respectively, in CH3CN/H2O in the presence of K2CO3 under MW 
irradiation at 120°C to yield piperidine 106 (64%), that was then deprotected in acidic 




Scheme 3.17: Synthesis of piperidine 99. 
 
3.2.2.2 Biological evaluation  
 The inhibitory activity of all the synthesized piperidines was evaluated towards 
GCase enzyme, moreover chaperone activity of piperidine 97 was assayed on human 
fibroblasts derived from Gaucher patients bearing the N370/RecNcil mutation, thanks to a 
collaboration with Prof. Morrone (Meyer’s Children Hospital). First of all, compounds 97, 
98, and 103 were screened in extracts from a pool of human leukocytes isolated from 
healthy donors (1 mM concentration of inhibitor, 37 °C and optimal pH conditions, see 
experimental section 3.2.1.4), using 4-methylumbelliferyl -D-glucopyranoside as 
substrate. 
Piperidine 97 showed great inhibition value (99% at 1mM) and excellent results in terms of 
IC50 (Table 3.6), for this reason it was also tested as pharmacological chaperone revealing 
itself as the best chaperone of the series of N-alkylated trihydroxypiperidines synthesized 
in our group.32 Indeed, compound 97 was able to rescue the GCase activity of 1.3 fold at 
100 nM when incubated with fibroblasts bearing the N370/RecNcil mutation, for four days. 









3.4 µM 1.3 fold at 100 nM
 
 
Table 3.6: Biological data for piperidine 97. 
 
From the superficial tension measurements, we found a critical micellar concentration 
(CMC) of 12 M, 1 magnitude order higher than the IC50 concentration, thus suggesting 
that our compound is probably active in the monomeric form. However, further 
investigations are ongoing addressing this issue. 
We assayed also the two piperidines with unsatured 11 carbons chain 98 and 103, that 
revealed a good inhibitory profile and good IC50 values, especially for monoalkylated 
compound 98 (table 3.7). 
 
Piperidine Inhibition IC50
98 97 % 4.0 ± 0.7 M
103 98 % 20.0 ± 7.0 M
 
Table 3.7: Biological inhibition and IC50 data for piperidines 98 and 103. 
The good inhibition results achieved for bis-alkylated piperidine 103 lead us reasoned on 
the role played by the protonation of endocyclic nitrogen atom. Indeed, this compound 
results permanently charged, due to the formation of four bonds. Consequently, we asked 
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ourselves what could happen if we were able to give to piperidine the possibility to accept 
a proton donation from the enzymatic site and to be consequently positively charged in a 
reversible way, but still continuing to maintain the double chain on the piperidine N, a 
necessary condition to well mimic the natural substrate glucosyl ceramide (9, figure 3.23). 
Thus, as a future plan we aim to synthesize a 3,4,5-trihydroxypiperidine substituted on the 
endocyclic N with a bifurcate alkyl chain, that however has the possibility to be protonate 
in a reversible way during the interaction with the enzyme, such as the derivative showed 
in figure 3.23. 
 
Figure 3.23: Natural GCase substrate glucosyl ceramide 9. 
In order to understand the importance of a lipophilic portion in such inhibitors, we tested 
piperidine 99 that contains a polar chain (due to the presence of oxygen atoms instead of 
carbons), and effectively it showed no inhibition power (table 3.8), thus demonstrating that 
the cavity of the enzymatic site of GCase seems to be prone to accept preferentially 
lipophilic molecules. This result can be useful in the future design of new more potent 
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3.2.2.3 Conclusions  
In conclusion, in this part of the project trihydroxypiperidines differently 
functionalized at the nitrogen atom were synthesized and assayed as 
inhibitors/chaperones against GCase enzyme. Moreover, in order to understand the 
aggregation mode in water of the most active piperidine of the series (compound 97), we 
characterized it through physical-chemical techniques. Through different kind of 
measurement, we found that our piperidine self-assemblies in water in a lamellar 
conformation. 
New synthesized compounds (97, 98, 103) have revealed to be excellent GCase 
inhibitors, especially piperidine N-alkylated with C-12 carbon chain (compound 95) that is 
also able to restore the catalytic activity of the enzyme bearing the N370/RecNcil mutation. 
Moreover, it shows the best chaperoning activity between all the N-alkylated piperidines 
ever synthesized in our research group.   
Thanks to the synthesis and the biological evaluation of piperidine 99, that is 
substituted on the N endocyclic atom with a polar chain, we also were able to confirm that 
the enzymatic cavity of the GCase enzyme prefers to interact with a lipophilic moiety. 
To better understand the structure-activity relationship between 
trihydroxypiperidines and GCase, docking studies will be object of future investigation in 
our laboratories, together with the synthesis of a derivative bearing a bifurcate alkyl chain 
that allowed the piperidine to undergo a reversible protonation (figure 3.23), maybe using 




Scheme 3.18: Synthesis of a reversible protonatable GCase inhibitor. 
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3.2.2.4 Experimental section 
 
For the general details see paragraph 2.4. 
 
Synthesis of piperidine 101: A 0.1 M solution of dialdehyde 100 (819 mg, 4.35 mmol) in dry 
MeOH was stirred in the presence of 3Å molecular sieves powder for 15 min, under 
nitrogen atmosphere, then dodecylamine (806 mg, 4.35 mmol) was added. After 3 hours 
the reaction mixture was cooled at 0°C, NaBH3CN (820 mg, 13.05 mmol) and AcOH (500 l, 
8.70 mmol) were added and the mixture was allowed to warm to room temperature and 
stirred for two days under nitrogen atmosphere. The molecular sieves were removed by 
filtration through Celite and the filtrate was concentrated under vacuum. The residue was 
purified by flash chromatography (CH2Cl2:MeOH from 50:1 to 10:1) affording 101 in 38% 
yields (Rf = 0.32, 563 mg, 1.65 mmol) as a colourless waxy solid. [α]22D= + 11.5 (c = 0.31 in 
CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 4.31 (pq, J = 6.2 Hz, 1H, H-3), 4.07 (t, J = 4.4 Hz, 1H, 
H-4), 3.97-3.93 (m, 1H, H-5), 2.81 (dd, J = 12.0, 6.0 Hz, 1H, Ha-2), 2.57 (d, J = 2.9 Hz, 2H, H-
6), 2.42-2.34 (m, 3H, Hb-2, H-1’), 1.50-1.45 (m, 5H, CH3, H-2’), 1.35 (s, 3H, CH3), 1.31-1.25 
(m, 18H, from H-3’ to H-11’), 0.87 (t, J = 6.8 Hz, 3H, CH3) ppm; 13C-NMR (50 MHz, CDCl3): δ= 
109.2 (s, C(CH3)2), 76.9 (d, C-4), 72.1 (d, C-3), 67.5 (d, C-5), 57.8 (t, C-1’), 55.8 (t, C-2), 55.5 
(t, C-6), 31.8-26.3 (12C, t from C-2’ to C-11’, q CH3), 14.0 (q, CH3) ppm; IR (CHCl3): ν = 3458, 
2928, 2854, 1468, 1456, 1404, 1383, 1246, 1144 cm−1. MS (ESI): m/z calcd (%) for C20H39NO3 
341.29; found: 342.33 (100%, [M+ H]+). Elemental analysis: C20H39NO3 (341.53) calcd. C, 
70.33; H, 11.51; N, 4.10; found C, 70.51; H, 11.72, N, 4.22. 
Synthesis of piperidine 97: To a solution of 101 (563 mg, 1.65 mmol) in 55 mL of 
methanol, 1.38 ml of 37% HCl were added and the mixture was stirred at room temperature 
for 18 hours. After that an 1H-NMR showed disappearance of the methyl groups, the 
solvent was removed under reduced pressure. The crude was purified by FCC 
(CH2Cl2:MeOH:NH3 10:1:0.1) affording pure 97 (Rf = 0.25, 419 mg, 1.39 mmol, 84% yield) as 
a white powder. [α]22D= −19.6 (c = 0.91 in MeOH); 1H-NMR (400 MHz, CD3OD): δ= 3.90 (dt, 
J = 5.7, 2.9 Hz, 1H, H-3), 3.80 (td, J = 7.9, 4.0 Hz, 1H, H-5), 3.42-3.39 (m, 1H, H-4), 2.85-2.73 
(m, 2H, Ha-6, Ha-2), 2.44-2.17 (m, 3H, H-1’, Hb-2), 2.06-2.02 (m, 1H, Hb-6), 1.54-1.45 (m, 
2H, H-2’), 1.31-1.27 (m, 18H, from H-3’ to H-11’), 0.89 (t, J= 6.8 Hz, 3H, CH3) ppm; 13C-NMR 
(50 MHz, CD3OD): δ= 73.7 (d, C-4), 68.1 (d, C-5), 67.5 (d, C-3), 57.8 (t, C-1’), 56.5 (t, C-2), 
56.0 (t, C-6), 31.6-22.2  (12C, t from C-2’ to C-11’, q CH3), 12.9 (q, CH3) ppm; MS (ESI): m/z 
calcd (%) for C17H35N4O3 301.26; found: 302.42 (100%, [M+ H]+). Elemental analysis: 
C17H35NO3 (301.53) calcd. C, 67.73; H, 11.70; N, 4.65; found C, 67.91; H, 11.53, N, 4.40. 
Synthesis of piperidine 98 and 103: A solution of 98 (71 mg, 0.53 mmol), 1-
11,bromoundecene (187 mg, 0.80 mmol) and K2CO3 (111 mg, 0.80 mmol) in 2.3 ml of a 
mixture CH3CN/H2O 5:1 was stirred in microwave at 120°C for 2 h, until a TLC analysis 
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(CH2Cl2:MeOH:NH3 6:1:0.1) showed the disappearance of the starting material (Rf = 0.00). 
After filtration through Celite®, the solvent was removed under reduced pressure and the 
crude was purified by FCC (CH2Cl2:MeOH:NH3 from 10:1:0.1 to 8:1:0.1) affording pure 98 
(Rf = 0.24, 87 mg, 0.34 mmol, 64% yield as white waxy solid) and, as byproduct, compound 
103 (Rf = 0.18, 66 mg, 0.23 mmol, 28% yield).  
Piperidine 98: [α]21D= −30.7 (c = 0.79 in MeOH); 1H-NMR (400 MHz, CD3OD): δ= 
5.82 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H, H-10’), 5.02-4.91 (m, 2H, H-11’), 3.91 (dt, J = 5.7, 3.0 
Hz, 1H, H-3), 3.80 (td, J =7.9, 4.0 Hz, 1H, H-5), 3.41-3.40 (m, 1H, H-4), 2.83-2.77 (m, 2H, Ha-
6, Ha-2), 2.42-2.34 (m, 2H, H-1’), 2.29 (d, J = 11.3 Hz, 1H, Hb-2), 2.13-2.03 (m, 3H, Hb-6, H-
9’), 1.56-1.46 (m, 2H, H-2’), 1.41-1.32 (m, 12H, from H-3’ to H-8’) ppm; 13C-NMR (50 MHz, 
CD3OD): δ= 140.0 (d, C-10’), 114.7 (t, C-11’), 75.2 (d, C-4), 69.5 (d, C-5), 69.1 (d, C-3), 59.3 
(t, C-1’), 58.1 (t, C-2), 57.5 (t, C-6), 34.8 (t, C-9’), 30.6-28.6 (t, 6C, from C-3’ to C-8’), 27.5 (t, 
C-2’) ppm; MS (ESI): m/z calcd (%) for C16H31NO3 285.23; found: 286.42 (100%, [M+ H]+);. 
Elemental analysis: C16H31NO3 (285.43) calcd. C, 67.33; H, 10.95; N, 4.91; found C, 67.46; H, 
11.03, N, 4.78. 
Piperidine 103: [α]26D= − 5.5 (c = 1.0 in MeOH); 1H-NMR (400 MHz, CD3OD): δ= 5.83 
(ddt, J = 17.0, 10.2, 6.7 Hz, 2H, H-10’), 5.03-4.93 (m, 4H, H-11’), 3.32-4.26 (m, 1H, H-3), 4.17-
4.07 (m, 1H, H-5), 3.83 (dd, J = 5.7, 3.0 Hz, 1H, H-4), 3.69-3.39 (m, 8H, H-6, H-2, H-1’), 2.08 
(q, J = 6.9 Hz, 4H, H-9’), 1.85-1.68 (m, 4H, H-2’), 1.42-1.37 (m, 24H, from H-3’ to H-8’) ppm; 
13C-NMR (100 MHz, CD3OD): δ= 140.1 (d, 2C, C-10’), 114.7 (t, 2C, C-11’), 71.3 (d, C-4), 68.1 
(d, C-5), 64.3 (d, C-3), 64.2 (t, 2C, C-1’), 62.0 (t, C-2), 59.4 (t, C-6), 34.9 (t, 2C, C-9’), 30.4-
27.3 (t, 12C, from C-3’ to C-8’), 22.7 (t, 2C, C-2’) ppm; MS (ESI): m/z calcd (%) for C27H52NO3+ 
438.39; found: 438.51 (100%, [M]+). 
Synthesis of piperidine 104 and 105: A solution of 87 (143 mg, 0.83 mmol), 1-
11,bromoundecene (252 mg, 1.08 mmol) and K2CO3 (172 mg, 1.25 mmol) in 3.6 ml of a 
mixture CH3CN/H2O 5:1 was stirred in microwave at 120°C for 2 h, until a TLC analysis 
(CH2Cl2:MeOH:NH3 6:1:0.1) showed the disappearance of the starting material (Rf = 0.00). 
After filtration through Celite®, the solvent was removed under reduced pressure and the 
crude was purified by FCC (AcOEt:Hexane from 1:5 to 1:1) affording pure 104 (Rf = 0.31, 
121 mg, 0.37 mmol, 45% yield as white waxy solid) and, as byproduct, compound 105 (Rf = 
0.10, 67 mg, 0.14 mmol, 17% yield).  
Piperidine 104: [α]21D= + 9.97 (c = 1.0 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 5.80 
(dqd, J = 19.8, 6.7, 5.9 Hz, 1H, H-10’), 5.00-4.91 (m, 2H, H-11’), 4.29 (dd, J = 12.6, 5.9 Hz, 1H, 
H-5), 4.05 (t, J = 4.5 Hz, 1H, H-4), 3.94 (dd, J = 7.1, 4.2 Hz, 1H, H-3), 2.76 (dd, J = 11.8, 6.1 
Hz, 1H, Ha-6), 2.56 (dd, J = 11.7, 2.7 Hz, 1H, Ha-2), 2.51 (dd, J = 11.8, 4.8 Hz, 1H, Hb-2), 2.39-
2.34 (m, 3H, Hb-6, H-1’), 2.03 (q, J = 6.9 Hz, 2H, H-9’), 1.50 (s, 3H, CH3), 1.46-1.43 (m, 2H, H-
2’), 1.35 (s, 3H, CH3), 1.26 (s, 12H, from H-3’ to H-8’) ppm; 13C-NMR (50 MHz, CDCl3): δ= 
138.7 (d, C-10’), 113.6 (t, C-11’), 108.8 (s, C-(CH3)2), 75.9 (d, C-4), 71.5 (d, C-5), 66.9 (d, C-
3), 57.3 (t, C-1’), 55.4 (t, C-6), 54.9 (t, C-2), 33.3 (t, C-9’), 29.0-25.9 (q, 2C, C-(CH3)2, t, 7C, 
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from C-2’ to C-8’) ppm; IR (CHCl3): ν = 3338, 2936, 2859, 2492, 2456, 2197, 2100, 2061, 
1458, 1384, 1246, 1221, 1153 cm−1.  MS (ESI): m/z calcd (%) for C19H35NO3 325.26; found: 
326.20 (100%, [M+H]+). 
Piperidine 105: [α]21D= −10.22 (c = 1.0 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 5.81-
5.71 (m, 2H, H-10’), 4.97-4.88 (m, 4H, H-11’), 4.63 (bs, 1H, H-3), 4.49 (bs, 1H, H-4), 4.22 (bs, 
1H, H-5), 4.03 (d, J = 14.0 Hz, 1H, Ha-2), 3.92 (bs, 1H, Ha-6), 3.69-3.30 (m, 6H, Hb-2, Hb-6, 
H-1’), 2.02-1.97 (m, 4H, H-9’), 1.68 (bs, 4H, H-2’), 1.46 (s, 3H, CH3), 1.30-1.24 (m, 27H, CH3, 
from H-3’ to H-8’) ppm; 13C-NMR (100 MHz, CDCl3): δ= 139.1 (d, 2C, C-10’), 114.3 (t, 2C, C-
11’), 109.8 (s, C-(CH3)2), 72.8 (d, C-4), 70.4 (d, C-3), 65.0 (d, C-5), 63.6 (t, 2C, C-1’), 58.8 (t, 
C-6), 56.7 (t, C-2), 33.8 (t, 2C, C-9’), 29.4-22.3 (q, 2C, C-(CH3)2 t, 14C, from C-2’ to C-8’) ppm; 
IR (CHCl3): ν = 3340, 3006, 2874, 2437, 2402, 2221, 1998, 1976, 1497, 1396, 1266, 1146 
cm−1.MS (ESI): m/z calcd (%) for C30H56NO3+ 478.43; found: 478.40 (100%, [M]+). 
Synthesis of piperidine 106: A solution of 87 (60 mg, 0.35 mmol), tetraethylene 
glycol p-toluenesulfonate (181 mg, 0.52 mmol) and K2CO3 (72 mg, 0.52 mmol) in 3.6 ml of 
a mixture CH3CN/H2O 5:1 was stirred in microwave at 120°C for 2 h, until a TLC analysis 
(CH2Cl2:MeOH:NH3 5:1:0.2) showed the disappearance of the starting material (Rf = 0.37) 
and the formation of a new product (Rf = 0.73). After filtration through Celite®, the solvent 
was removed under reduced pressure and the crude was purified by FCC (Et2O:AcOEt from 
15:1 to AcOEt) affording pure 106 (Rf = 0.52, 78 mg, 0.22 mmol, 64% yield) as a yellow oil. 
[α]25D= + 12.6 (c = 0.76 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 4.32 (dd, J = 12.7, 6.2 Hz, 
1H, H-5), 4.07 (s, 1H, H-4), 3.94 (s, 1H, H-3), 3.70-3.69 (m, 2H, H-2’), 3.65 (s, 8H, from H-3’ 
to H-6’), 3.60-3.50 (m, 4H, H-7’, H-8’), 2.87 (dd, J = 11.6, 6.1 Hz, 1H, Ha-6), 2.68 (dd, J = 11.7, 
9.3 Hz, 1H, Ha-2), 2.63-2.58 (m, 3H, H-1’, Hb-2), 2.33 (dd, J = 11.5, 8.0 Hz, 1H, Hb-6), 1.49 
(s, 3H, CH3), 1.35 (s, 3H, CH3) ppm; 13C-NMR (50 MHz, CDCl3): δ=  109.2 (s, C(CH3)2), 76.5 (d, 
C-4), 72.8 (t, C-7’), 72.0 (d, C-5), 70.7-70.2 (d, 4C, from C-3’ to C-6’), 68.9 (t, C-8’), 67.3 (d, 
C-3), 61.8 (t, C-2’), 57.0 (t, C-2), 56.3 (t, C-1’), 55.8 (t, C-6), 28.4 (q, CH3), 26.5 (q, CH3) ppm; 
IR (CDCl3): ν = 3447, 3005, 2876, 1655, 1458, 1354, 1246, 1101, 1059 cm−1. MS (ESI): m/z 
calcd (%) for C16H31NO7 349.21; found: 372.49 (100%, [M+ Na]+), 350.43 (49%, [M+ H]+).  
Synthesis of piperidine 99: To a solution of 106 (71 mg, 0.20 mmol) in 8 mL of 
methanol, 15 drops of 37% HCl were added and the mixture was stirred at room 
temperature for 18 hours. After that a TLC analysis (CH2Cl2:MeOH:NH3 5:1:0.2) showed 
disappearance of the starting material (Rf = 0.73), the solvent was removed under reduced 
pressure. Piperidine 99 was obtained without further purification (Rf = 0.10, 62 mg, 0.20 
mmol, quantitative yield) as a colourless oil. [α]26D= −17.1 (c = 0.84 in MeOH); 1H-NMR (400 
MHz, CD3OD): δ= 3.98 (s, 1H, H-3), 3.58 (td, J = 8.7, 4.3 Hz, 1H, H-5), 3.72-3.71 (m, 10H, from 
H-2’ to H-6’), 3.65-3.63 (m, 4H, H-7’, H-8’), 3.49 (d, J = 10.4 Hz, 1H, H-4), 2.91 (dd, J =22.2, 
2.1 Hz, 2H, Ha-6, Ha-2), 2.66 (t, J = 5.5 Hz, 2H, H-1’), 2.40 (d, J = 12.3 Hz, 1H, Hb-2), 2.20-
2.11 (m, 1H, Hb-6) ppm; 13C-NMR (100 MHz, CD3OD): δ= 73.6 (d, C-4), 71.6 (d, C-5),69.6-
69.3 (t, 5C, from C-3’ to C-7’), 67.6 (C-8’), 67.4 (d, C-3), 60.3 (t, C-2’), 56.6 (t, C-2), 56.0 (t, C-
Chapter 3  
_________ 
101 
6), 55.8 (t, C-1’) ppm; MS (ESI): m/z calcd (%) for C13H27NO7 309.18; found: 332.45 (100%, 
[M+ Na]+). Elemental analysis: C13H27NO7 (309.36) calcd. C, 50.47; H, 8.80; N, 4.53; found 
C, 50.55; H, 8.69, N, 4.61. 
 
For the procedures of biochemical characterization with human GCase, IC50 determination 
and chaperoning activity assays, see section 3.2.1.4. 
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3.2.3 Resorcinarenes  
To extend the study of multimerization of our iminosugar onto different scaffolds, 
we started a project in collaboration with the groups of Prof. Neri from the University of 
Salerno and of Dr. Sestak from the Centre for Glycomics Slovak Academy of Sciences of 
Bratislava. Our aim was to design a new class of mannosidases inhibitors starting from 
pyrrolidine DAB-1 derivatives conjugated to resorcinarene scaffolds. Combining our 
expertise in the total synthesis of iminosugar glycomimetics and Prof. Neri experience in 
the synthesis of resorcinarenes, we wanted to obtain a new class of selective inhibitors of 
different families of mannosidase enzymes, towards whom the new glycocalyx systems 
would be tested by Dr. Sestak. We decided to multimerize onto resorcinarenic scaffolds a 
bioactive unit that contains as iminosugar skeleton, the pyrrolidine DAB-1, a well-known 
inhibitor of a wide range of mammalian glycosidases.101 Indeed, in its multivalent fashion, 
it showed very impressive results in our previous works towards different enzymes, such 
as N-acetylgalactosamine-6-sulfatase (GALNS), which is the deficient enzyme in 
mucopolysaccharidosis Morquio A syndrome (see section 1.2.4)47 and JBMan, that can be 
taken as model for other two mannosidases of therapeutic interest (Golgi -mannosidase 
GManII and lysosomal -mannosidase LManII), due to its dimeric nature and its 
commercially availability (see section 1.2.5).93 In particular this project was focused in the 
synthesis of new multivalent compounds that could selectively target GManII, in order to 
find new potential anticancer drugs, being it involved in N-glycan processing. Indeed, an 
alterated cell surface carbohydrate decoration compared to normal cells has been found 
in many types of cancer. Swainsonine is a potent inhibitor of GManII, blocking tumour 
growth and metastasis, but it is not selective towards this enzyme, because it inhibits also 
the close lysosomal -mannosidase LManII, leading to swainsonine-induced mannosidosis 
symptoms.53 However, previous work showed that the multimerization of DAB-1 
pyrrolidine iminosugar93 and DNJ,102 produced multivalent inhibitors more potent towards 
GManII than towards LManII. In other words, GManII is much more prone to accept 
multivalent inhibitors than LManII (78, 107, figure 3.24).  
 
101 Asano N., Oseki K., Kizu H., Matsui K., J. Med. Chem., 1994, 37, 3701 –3706. 
102 Brissonet Y., Ortiz Mellet C., Morandat S., Garcia-Moreno M. I., Deniaud D., Matthews S. E., Vidal S., Sestak 
S., Kirat K. El, Gouin S. G., J. Am. Chem. Soc., 2013, 135, 18427–18435. 





Figure 3.24: Multivalent GManII inhibitors 78 and 107. 
For this reason, the synthesis of multivalent compounds can help us in finding increasingly 
selective inhibitors for Golgi mannosidase without affecting the lysosomal enzyme, 
avoiding in this way undesired drawbacks such as the onset of mannosidosis. 
Among the multitude of scaffolds reported in the literature for the multimerization of 
glycosidases inhibitors, we can find bowl-shaped macrocycles called resorcinarenes, 
resorcinol-formaldehyde cyclic oligomers that furnish the opportunity to attach several 
bioactive functions on different positions thereby accessing different topologies of the 
multivalent constructs. Because of their structural resemblance to calixarenes, chalice-like 
shape compounds which are phenol-derived cyclo-oligomers, they are also called 
calix[4]resorcinarenes.103 Resorcinarenes are non-planar systems and they exist in different 
isoforms, classified by a combination of stereochemical criteria: the conformation of the 
macrocyclic ring; the relative configuration of the substituents at the methylene bridges; 





103 Gutsche C. D, Calixarenes; Monographs in Supramolecular Chemistry, 1989, 1, Ed. J F Stoddart. 
104 Högberg A. G. S., J. Am. Chem. Soc., 1980, 102, 6046-6050. 





Figure 3.25: The five highly symmetrical conformations: crown (C4v), boat (C2v), chair (C2h), 
diamond (Cs) and saddle (D2d). 
Calix[4]resorcinarenes are very versatile scaffolds because they can be functionalized at 
two, four, six, eight, twelve, sixteen or more sites depending on the reagent, aldehyde, 
resorcinol and conditions used to carry out the reaction. 
In this project, we wanted to access new selective GManII inhibitors by multimerizing our 
bioactive DAB-1 based iminosugar derivative with calix[4]resorcinarenes and 
calix[6]resorcinarenes synthesized by Prof. Neri group.  
 
3.2.3.1 Results and discussion 
 As already mentioned before, this project has been developed in collaboration with 
Prof. Neri from the University of Salerno, and our contribution involved the synthesis of the 
iminosugar azido derivatives that were then conjugated to resorcinarenes by Prof. Neri 
group. In our initial plans, we thought to multimerize onto Prof. Neri’s resorcinarenes 
pyrrolidine iminosugar 108, that we obtained starting from the same intermediate 38 used 
in the synthesis of trehalase inhibitors (see chapter 2). Compound 108 was achieved from 
D-arabinose, that once transformed to pyrrolidine 38 through a reduction with NaBH4 
followed by a N-O cleavage performed with Zn in acetic acid of nitrone 30, was first 
alkylated with 1-bromo-2-ethanol to afford alcohol 38, then exposed to a Mitsunobu 
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reaction with diphenil phosphoryl azide (DPPA) as the nucleophile to obtain the azido 
intermediate 108 (scheme 3.19).105 
 
 
Scheme 3.19: Synthetic strategy to obtain pyrrolidine derivative 108. 
The deprotection of the hydroxyl groups of the pyrrolidine was not a trivial task, indeed we 
could not perform a reductive cleavage of the benzyl groups through a catalytic 
hydrogenation due to the presence of the azido moiety that is not resistant to those strong 
conditions and would undergo the reduction to amine. Furthermore, we could not exploit 
the same route used in previous cases of piperidine iminosugars (see section 3.2.1 and 
section 3.2.2), consisting in the alkylation of pyrrolidine skeleton with 1-bromo-2-
azidoethanol, because of the explosivity of such low molecular weight azides. For this 
reason we thought to use a reduction milder than hydrogenation, using BCl3 that in a 
previous work allowed to perform a benzyl cleavage in similar conditions.105 In that way, 
we were able to obtain a sufficient amount of the final deprotected azido derivative to be 
characterized, but not enough to be ‘clicked’ to resorcinarenes (scheme 3.20).  
 
 
Scheme 3.20: Synthesis of pyrrolidine 109. 
 
105 Ferhati X., Matassini C., Fabbrini M.G., Goti A., Morrone A., Cardona F., Moreno-Vargas A. J., Paoli P., Bioorg. 
Chem., 2019, 87, 534-549. 
Multivalency in glycosidase inhibition 
__________________________________ 
106 
For this reason, we though to elongate the alkyl chain from 2 to 6 carbon atoms, whose 
synthesis had been already accomplished in our laboratories for other projects (see section 
3.3.1), and easily allows to obtain a bromo-azide chain without the risk of explosivity. 
Additionally, this longer derivative could furnish more flexible inhibitors with respect to 
those obtained using azido-pyrrolidine 109. The starting point was again nitrone 30, that 
was however hydrogenated to DAB-1, that already possesses the free hydroxyl groups, and 
successively alkylated with 1-bromo,6-hexanol 110 previously obtained from a mono-
substitution with NaN3 of 1,6-dibromohexane (scheme 3.21). 
 
 
Scheme 3.21: Synthesis of pyrrolidine 80. 
We sent bioactive iminosugar 80 to Prof. Neri’s laboratories, where the conjugation 
through a click CuAAC reaction to three different resorcinarenes was accomplished, since 
they possess a wide experience in the synthesis of this kind of multivalent systems.106 
The synthesis of monovalent pyrrolidine compound 111 (figure 3.26), necessary to 
estimate the multivalent effect of our resorcinarenes, was already reported in our previous 
work. 
 
106 (a) Talotta C., De Rosa M., Soriente A., Spinella A., Gaeta C., Neri P., Supramol. Chem., 2019, 31, 62-68. (b) 
Iuliano V., Ciao R., Vignola E., Talotta C., Iannece P., De Rosa M., Soriente A., Gaeta C., Neri P., Beilstein J. Org. 
Chem., 2019, 15, 2092–2104. (c) Concilio G., Talotta C., Gaeta C., Neri P., Monaco G., Zanasi R., Tedesco D., 
Bertucci C., J.Org.Chem., 2017, 82, 202−210. 




Figure 3.26: Monovalent reference compound 111. 
The multimeric scaffold structures are octavalent (112 and 113, scheme 3.22) and 
dodecacavalent (114) resorcinarenes, or calix[4]resorcinarenes, with different degree of 
rigidity (scheme 3.22). Indeed, while the scaffold 112 is conformationally more rigid thanks 
to the presence of methyl groups between the resorcinol units, compounds 113 and 114 
are more flexible, and this could reflect, in our hypotheses, in a different biological activity. 
Moreover, calix[6]resorcinarenes such as compound 114, much less common than 




Scheme 3.22: Resorcinarene scaffolds 112, 113 and 114. 
Once conjugated to our pyrrolidine iminosugars, we obtained the final resorcinarenes 
derivatives 115, 116 and 117 (scheme 3.23). While compound 115 results to be stable in a 
cone conformation displaying bioactive pyrrolidine units in a syn orientation, the 
conformational mobility of the resorcinol rings in derivatives 116 and 117, leads the 
pyrrolidine epitope to adopt different orientations.  






Scheme 3.23: Resorcinarene derivatives 115, 116 and 117. 
All the glycocalix- were tested in the laboratories of Dr. Sestak, with whom we collaborated 
in several projects,93 towards different mannosidases (see section 3.2.3.2). Since they 
noticed some problems in dissolving the glycoresorcinarenes in water, we wanted to find 
a method to increase the water solubility of the final compounds. Thus, we thought to 
functionalize the DAB-1 skeleton with a more polar linker to properly space the bioactive 
component from the resorcinarene scaffolds, for example exploiting a PEG-ylated chain 
similar to the one used in the synthesis of piperidine 99 (see section 3.2.2.1), but with a 
length comparable to pyrrolidine 111 (scheme 3.24). At first, we had to synthesize an 
appropriate PEG-ylated chain that could allow us to perform an alkylation using the same 
condition exploited for the piperidine (see section 3.2.1 and 3.2.2) and to obtain final 
compound 120. 




Scheme 3.24: Synthetic pathway to obtain PEG-ylated pyrrolidine 120. 
Starting from the commercial 2-[2-(2-chloroethoxy)ethoxy]ethanol 118, we transformed 
the alcohol in an azido moiety with a Mitsunobu reaction to afford the azido derivative 119, 
used in the following alkylation performed in a mixture of acetonitrile and water (1:5) in 
the presence of a base by heating with microwaves for two hours. In the case of pyrrolidine, 
we had some problems in the efficiency of alkylation reaction in fact, the first time that we 
tried, only a low amount of product was recovered (26% yield). We tried thus to avoid the 
microwave heating and to perform the reaction at reflux overnight. In this case we 
obtained an improvement in the results (38% yield, scheme 3.25), but without reaching the 
good yields obtained for the piperidines.  
 
 
Scheme 3.25: Attempt of synthesis of pyrrolidine 120 using reflux heating. 
We thought therefore that, by substituting chlorine atom with a more effective leaving 
group such as iodine, maybe we could enhance the percentage of recovered product, and 
so we decided to try this method, but unfortunately, the yield was comparable to the 
previous attempt (scheme 3.26). Anyway, we were able to obtain enough pyrrolidine azido 
derivative to send to Prof. Neri. 




Scheme 3.26: Attempt with ioduration of compound 118. 
 
3.2.3.2 Biological evaluation  
 The three resorcinarene derivatives 115, 116 and 117 bearing our pyrrolidine 80 
were tested against a panel of commercial mannosidases by Prof. Sestak and co-workers. 
Moreover, rp and rp/n with respect to the reference monovalent compound 111, were also 
evaluated. The data shown in table 3.9 show a good inhibitory profile, expressed in terms 
of IC50, for all three compounds. Indeed, they all have the IC50 values in the micromolar 
range, thus demonstrating to be good mannosidases inhibitors. In particular, towards the 
commercial JB mannosidase the best result was achieved with the dodecavalent compound 
117, that showed an IC50 value of 3.8 M. Also compounds 115 and 116, both displaying a 
valency of 8 bioactive units, are potent JBMan inhibitors, with IC50 of 5.3 M and 14.8 M 
respectively. In the case of the Golgi mannosidase GManII, that is our target enzyme due 
to its involvement in some cancer growth processes, excellent inhibition values were 
obtained, with the best IC50 of the series showed by dodecavalent compound 117 (IC50 =1.7 
M). Comparing these inhibition data with the IC50 obtained towards lysosomal 
mannosidase LManII, that ranged between 173 M and 865 M, we can affirm that our 
resorcinarene pyrrolidines are selective for Golgi mannosidase with respect to the 
lysosomal mannosidase LManII, paving the way for a potential application of these 
compounds as anticancer agent.  
 














111 1    1300  - 175 - 2450 - 
115 8 5.3 248 (31) 3.7 47 (6) 173 14 (1.8) 
117 12 3.8 342 (29) 1.7 103 (8.6) 523 4.7 (0.4) 
116 8 14.8 88 (11) 5.3 33 (4.1) 865 2.8 (0.35) 
 
Table 3.9: Relative potency (rp) and relative potency per active unit (rp/n) of compounds 115, 
116 and 117 as related to monovalent iminosugar 111. Inhibitory activity towards the three α-
mannosidases presented in IC50 [µM]. 
 
Moreover, also in terms of multivalent effect quantification we had encouraging feedback, 
considering first that the monovalent reference compound showed an IC50 value in the 
micromolar range only in one case (IC50 = 175 M towards GManII) while towards other 
mannosidases the inhibition is in the millimolar range. Moreover, all compounds had rp 
higher than 30; in particular, the best results of the series were obtained with dodecavalent 
compound 117 towards both JBman (rp = 342) and GManII (rp= 103), once again confirming 
the huge potentiality of a multivalent structure in the inhibition of some glycosidases of 
therapeutic interest. Comparing the two octavalent resorcinarenes instead, which differs 
for the conformational mobility of the pyrrolidine units, we can say that, given the same 
valency, a higher rigidity of the resorcinol rings (in derivative 115) leads to an enhancement 
of the biological activity towards all the mannosidases, with IC50 values of 5.3 M, 5.7 M 
and 173 M (towards JBMan, GManII and LManII respectively), versus 14.8 M, 5.3 M 
and 865 M (see table 3.9).  
 
3.2.3.3 Conclusions  
 Three new multivalent compounds based on pyrrolidine DAB-1 derivatives 
anchored to resorcinarene scaffolds, were synthesized and tested against some 
mannosidases of therapeutic interest, thanks to the collaborations that we have with the 
two groups of Prof. Neri and Dr. Sestak. Once obtained the pyrrolidine ligands, they were 
multimerized onto resorcarenes with different valency and conformational orientations. 
The results obtained with biological tests showed a good inhibitory profile and precious 
information about the importance to find multivalent glycosidases inhibitors. Indeed, we 
obtained excellent results in term of both inhibition potency and selectivity towards the 
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enzyme we were interested in inhibiting, due to its involvement in anticancer applications, 
as reported in table 3.9. It will be of our interest to rationalize the differences in biological 
activity between the two derivatives with the same valency 115 and 116, and in our future 
plans there will be some modelling studies, such as docking on the commercial JB 
mannosidase, considering that it was recently solved in its apo form by Prof. Compain and 
co-workers,51 to better understand the mechanism of interaction between our inhibitors 
and the target enzyme. Moreover, the grafting of the pyrrolidine ligand 120 onto the same 
resorcinarenes 112-114 is now ongoing in the laboratories of Prof. Neri, and they will be 
tested by Prof. Sestak in the near future, in order to understand if the use of a more soluble 
bioactive unit could be enhanced in someway the inhibitory potential of whole multivalent 
structure. 
 
3.2.3.4 Experimental section 
 
For the general details see paragraph 2.4. 
 
Synthesis of pyrrolidine 109: To a solution of 108 (256 mg, 0.54 mmol) in dry CH2Cl2 
(48 mL) cooled to 0 °C by means of an ice bath, 4.88 mL of BCl3 solution 1.0 M in hexane 
were added and the reaction mixture was stirred at room temperature under nitrogen 
atmosphere for 16 h. A TLC analysis (AcOEt: EP 2:1) showed the disappearance of starting 
material (Rf = 0.89) and formation of a new product (Rf = 0.50). To the reaction mixture 20 
mL of a EtOH were added, and the reaction mixture was stirred until the solution was 
transparent, subsequently 20 mL of H2O and 10 mg of basic resin Ambersep® 900-OH were 
added and left stirred for 1 hour. The mixture was filtered on cotton to remove the resin, 
washed thoroughly with MeOH. The solvent was evaporated at reduced pressure and the 
crude 109 was purified by FCC (CH2Cl2:MeOH: 12 %NH3 1:5:0.3). The hydrochloride salt 
obtained from the first fraction of the column was then passed through DOWEX 50WX8 
ion-exchange resin, by eluting sequentially with MeOH, H2O and 12 % NH4OH, affording 
free amine 109 as pale yellow oil (17 mg, 0.08 mmol, 15% yield). [α]28D= −25.1 (c = 0.84 in 
MeOH); 1H-NMR (400 MHz, D2O): δ= 4.09-4.07 (m, 1H, H-3), 3.90-3.88 (m, 1H, H-4), 3.68 
(dd, J = 5.1, 1.2 Hz, 2H, H-6), 3.45 (t, J = 6.0 Hz, 2H, H-2’), 3.07-3.01 (m, 2H, Ha-2, Ha-1’), 
2.77 (dd, J = 11.1, 5.8 Hz, 1H, Hb-2), 2.62-2.55 (m, 2H, H-5, Hb-1’) ppm; 13C-NMR (50 MHz, 
D2O): δ= 79.0 (d, C-4), 75.6 (d, C-3), 71.9 (d, C-5), 61.2 (t, C-6), 58.6 (t, C-2), 53.4 (t, C-1’), 
49.2 (t, C-2’) ppm; MS (ESI): m/z calcd (%) for C7H14N4O3 202.11; found: 225.26 (100%, [M+ 
Na]+). Elemental analysis: C7H14N4O3 (202.21) calcd. C, 41.58; H, 6.98; N, 27.71; found C, 
41.46; H, 6.89, N, 27.60. 
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Synthesis of piperidine 120: A solution of 3 (60 mg, 0.45 mmol), 2-[2-(2-
azidoethoxy)ethoxy]ethanol 119 (175 mg, 0.90 mmol) and K2CO3 (93 mg, 0.68 mmol) in 2.4 
ml of a mixture CH3CN/H2O 5:1 was stirred at reflux for 24 h, until a TLC analysis 
(CH2Cl2:MeOH:NH3 2:1:0.2) showed the disappearance of the starting material (Rf = 0.10) 
and the formation of a new product (Rf = 0.79). After filtration through Celite®, the solvent 
was removed under reduced pressure and the crude was purified by FCC 
(CH2Cl2:MeOH:NH3 from 6:1:0.1 to 2:1:0.1) affording pure 120 (Rf = 0.21, 50 mg, 0.17 mmol, 
38% yield) as a yellow oil. [α]21D= -41.5 (c = 0.68 in H2O); 1H-NMR (400 MHz, D2O): δ= 4.00 
(ps, 1H, H-3), 3.81 (ps, 1H, H-4), 3.61-3.54 (m, 10H, H-6, from H-2’ to H-5’), 3.39 (t, J = 4.7 
Hz, 2H, H-6’), 3.02-2.94 (m, 2H, Ha-2, Ha-1’), 2.71 (dd, J = 11.2, 5.7 Hz, 1H, Hb-2), 2.55-2.46 
(m, 2H, H-5, Hb-1’) ppm; 13C-NMR (50 MHz, D2O): δ= 78.9 (d, C-4), 75.5 (d, C-3), 72.0 (d, C-
5), 69.6-68.7 (t, 4C, from C-2’ to C-5’), 61.0 (t, C-6), 58.9 (t, C-2), 53.9 (t, C-1’), 50.2 (t, C-6’) 
ppm; MS (ESI): m/z calcd (%) for C11H22N4O5 290.16; found: 313.04 (55%, [M+ Na]+), 291.06 
(100%, [M+ H]+). Elemental analysis: C11H22N4O5 (290.32) calcd. C, 45.51; H, 7.64; N, 19.30; 
found C, 45.49; H, 7.48, N, 19.34. 
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3.3 Multivalent iminosugars through Copper free-methodologies 
 As mentioned before, most of the strategies used to design multivalent 
architectures require the use of the click chemistry reaction CuAAC (copper catalysed 
alkyne azide cycloaddition), that represents the most proficient way to rapidly access 
compounds with a high valency degree. Using that methodology, however, a wide range of 
scaffolds of different nature, such as dendrimers, calixarenes and recently also 
glycopolymers formed by iminosugars can be exploited. 107 Even if to date it is the 
predominant protocol to achieve the large variety of multivalent glycosidases inhibitors, 
CuAAC is associated with a general drawback consisting in the possibility of complexation 
of copper that could occur by the several triazole moieties and enhanced by the nitrogen 
atoms presents in iminosugar units, traducing in the possibility of a cytotoxicity of the final 
products if traces of copper remain as impurities. 
Trying to overcome all the possible drawbacks related to the use of copper in the synthetic 
methodologies illustrated until now, we also thought to exploit alternative strategies to 
multimerize our bioactive iminosugar warheads, in particular we focused our efforts in the 
synthesis of Au glyconanoparticles (Au GNPs), adducts formed by a gold nanometric core 
decorated with sugars. Those systems were initially projected as a survey tool for the study 
of carbohydrate-lectin interaction108 indeed, given their chemical and physical properties, 
they have all the characteristics necessary for this purpose: they are a colloidal system 
which is soluble and stable in water and able to cross the cell membrane thanks to the 
surface shell formed by carbohydrates.  One of the main features that makes GNPs 
particularly attractive for our purposes is their multi-functionality, reflecting in the 
possibility of simultaneously insert more ligand units on the gold nano-core and modulating 
their arrangement, thus making them an advantageous alternative to other dendrimeric 
scaffolds previously seen (see section 3.1). The synthesis of glyconanoparticles is provided 
by a one-step procedure described for the first time by Brust and collaborators.109 It is 
called "in situ direct synthesis", and it consists in the reduction in situ of a gold (III) salt 
(HAuCl4) in the presence of glycoconjugates functionalized with a terminal thiol group and 
of NaBH4 as a reducing agent (Figure 3.27). 
 
107 Martínez-Bailén M., Galbis E., Carmona A. T., de-Paz M.V., Robina I., Eur. Polymer J., 2019, 119, 213–221. 
108 (a) de La Fuente J. M., Barrientos A. G., Rojas T. C., Rojo J., Cañada J., Fernández A., Penadés S., Angew. 
Chem. Int. Ed. 2001, 40, 2257-2261. (b) Barrientos A. G., de La Fuente J. M., Rojas T. C., Fernández A., Penadés 
S., Chem. Eur. J., 2003, 9, 1909-1921. (c) de La Fuente J. M., Penadés S., BBA-Gen. Subjects, 2006, 1760, 636. 
109 Brust M., Walker M., Bethell D., Schiffrin D. J., Whyman R., J. Chem. Soc., Chem. Commun., 1994, 801-802. 





Figure 3.27: The direct method for the synthesis of A GNPs. 
The Au GNPs formed are made up of self-assembled mono-layers (SAMs) of 
glycoconjugates, bound to the metal surface by S-Au bonds (Figure 3.28). 
 
 
Figure 3.28: SAMs glyconanoparticles. 
The approach based on the use of carbohydrate self-assembled monolayers (SAMs) on two- 
and three-dimensional gold surfaces is termed glyconanotechnology, and it allows to 
obtain multivalent structures without employing the click CuAAC approach, thus avoiding 
the risk of finding copper residues in the final products. Since the direct synthesis allows to 
insert different ligands on the same core, it becomes possible to prepare a wide range of 
glyco-adducts with different "load" of ligands. In fact, together with the biologically active 
part of the GNPs (the active component), it is necessary to introduce components that 
modulate the rigidity and flexibility without interfering in their biological activity.110 These 
 
110 Marradi M., Chiodo F., García I., Penadés S., Chem. Soc. Rev., 2013, 42, 4728-4245. 
SAMs on gold Au Glyconanoparticle 
SAMs and Au Glyconanoparticle 
 
Multivalency in glycosidase inhibition 
__________________________________ 
116 
are called inner components, and allow to obtain a better spatial arrangement of the active 
component on the gold surface and an adequate solubility of the final system in water, and 
on the basis of previous studies, a fairly long and amphiphilic linker was the ideal to impart 
flexibility and to assist the dispersion of the glyconano-adducts in water.111  
Our group recently contributed to the field by synthesizing the first example of multivalent 
glyconanoadducts containing biologically active iminosugars as active component, and 
monosaccharides as inner component to target different glycosidases. A synthetic strategy 
that allowed the inclusion of iminosugars (pyrrolizidines and piperidines) on a very small 
gold core (the diameter is less than 2 nm) has been developed, to verify the presence of a 
positive multivalent effect. Moreover, this approach has made possible the achievement 
of multivalent iminosugars with a density modulable by simply varying the mutual 
percentage between the inner and the active component (figure 3.29).112 
 
 
Figure 3.29: General scheme of gold glyconanoparticles (GNPs). 
The obtained Au GNPs contained as inner component two kind of iminosugars previously 
synthesized in our laboratories and then properly functionalized, of piperidine and 
pyrrolizidine nature (figure 3.30). 
 
111 (a) Martínez-Ávila O., Hijazi K., Marradi M., Clevel C., Campion C., Kelly C., Penadés S., Chem. Eur. J., 2009, 
15, 9874-9888. (b) Safari D., Marradi M., Chiodo F., Th Dekker H. A., Shan Y., Adamo R., Oscarson S., Rijkers G. 
T., Lahmann M., Kamerling J. P., Penadés S., Snippe H., Nanomedicine, 2012, 7, 651-662. 
112 Matassini C., Marradi M., Cardona F., Parmeggiani C., Robina I., Moreno-Vargas A.J., Penadés S., Goti A., RSC 
Adv., 2015, 5, 95817-95822. 





Figure 3.30: Glyconanoparticles with pyrrolizidine and piperidine iminosugars. 
The glyconano-adducts 127 and 128 were prepared with different active and inner 
component percentages and then tested towards commercial glycosidases, showing only 
retention of the inhibitory activity, but any positive multivalent effect. Moreover, it was 
also observed that using 125 or 126 as inner component made no difference in the 
biological activity.  
 Following this procedure, in part of the PhD thesis we decided to apply the same 
strategy seen now to multimerize other two kind of iminosugars, already proved to be good 
inhibitors towards two glycosidase enzymes: the first one is a pyrrolidine derivative of 
natural DAB-1 (section 3.3.1), to be tested against the two sulfatases IDS and GALNS (see 
chapter 1). The other bioactive warhead is the widely envisaged DNJ piperidine iminosugar, 
available in our laboratories thanks to the collaboration with Prof. Compain from the 
University of Strasbourg, that we would like to test against JBMan (scheme 3.27). 




Scheme 3.27: Aim of this work: synthesis of gold glyconanoparticles decorated with DAB-1 and 
DNJ derivatives as active component. 
Additionally, in searching novel methodologies to avoid the use of click CuAAC 
reaction, we envisaged a strategy based on a sequence of 1,3-dipolar cycloaddition with a 
high stereo and regioselectivity (section 3.3.3). 
 
3.3.1 Hybrid Gold Glyconanoparticles (DAB-1 based)  
When multimerized on a dendrimeric scaffold, the natural DAB-1 pyrrolidine 
iminosugar was demonstrated to be an excellent inhibitor of two lysosomal sulfatases, 
namely N-acetylgalactosamine-6-sulfatase (GALNS) and iduronate-2-sulfatase (IDS), whose 
deficiency leads to lysosomal storage diseases (Morquio A and Hunter diseases, 
respectively. See section 1.2.4).47 These pathologies are currently treated by infusion of 
recombinant enzymes, which suffer from low stability in vivo. Hence, the identification of 
inhibitors of these recombinant enzymes represents the starting point for the development 
of enzyme stabilizers.113 Based on our previous findings, where we developed a 
straightforward strategy to build gold glyconanoparticles containing a bioactive iminosugar 
component, we aimed to achieve the multimerization of DAB-1 onto Au GNPs, in order to 
find new GALNS and/or IDS inhibitors. Our results are the object of this part of the PhD 
thesis and can be also found in this paper:  
 
Matassini C., Vanni C., Goti A., Morrone A., Marradi M., Cardona F. 
Multimerization of DAB-1 onto Au GNPs affords new potent and selective N-
acetylgalactosamine-6-sulfatase (GALNS) inhibitors, Org. & Biomol. Chem., 2018, 16, 
8604– 8612.  
 
113 Boyd R. E., Lee G., Rybczynski P., Benjamin E. R., Khanna R., Wustman B. A., Valenzano K. J., J. Med. Chem., 
2013, 56, 2705-2725. 
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3.3.1.1 Results and discussion 
 With the aim to synthesize the gold glyconanoparticles (Au GNPs) decorated with 
pyrrolidine iminosugars, we started with the design of the active and inner components. It 
was necessary indeed to insert in our pyrrolidine ligand a properly functionalized linker 
(129, scheme 3.28), in order to allow the formation of a Au-S bond,114 and to space the 
bioactive warhead from the gold core in order to avoid the whole system collapse. 
 
 
Scheme 3.28: Synthesis of PEG-ylated linker 129.114 
To achieve this derivative, we started from the D-arabinose derived nitrone 30, that was 
first alkylated with 1,6-bromo,azidohexane 110, then catalytically hydrogenated to afford 
the corresponding amino derivative 131 with 65% yield after basic elution over an ion 
exchange acid resin DOWEX-50WX8 (scheme 3.29).47  
 
 
Scheme 3.29: Synthesis of pyrrolidine amino derivative 131.47 
However, coupling of 131 with the linker 129 was not selective, and afforded an 
inseparable mixture of the two regioisomers: the desired amide 132 and its ester derivative 
133 (scheme 3.30). 
 
114 He S., Garcia I., Gallo J., Penadés S., CrystEngComm, 2009, 11, 2605. 





Scheme 3.30: First attempt for the synthesis of 132. 
Therefore, we thought to use an alternative strategy, which eliminated the problem of poor 
regioselectivity in the formation of the amide bond: to introduce the terminal amino 
moiety on the pyrrolidine, we first alkylated the endocyclic nitrogen of DAB-1 3 with an 
azido-terminal aliphatic chain, thus obtaining derivative 80; then, we protected the 
hydroxyl moieties with acetyl groups to give compound 134, considering that the O-acetyl 
protecting groups would be removed when liberating the thiol-ending moiety. At this point 
we reduced the azide group to amine 135 using the Staudinger reaction. However, the 
reaction was troublesome, due to problematic product isolation from the formed 
triphenylphosphine oxide. We managed to overcome this problem by using polymer-bound 
Ph3P 115 and the amine 135 was isolated in quantitative yield after refluxing for 4 h in 
THF/H2O. In this way we were able to drive the reaction towards the formation of a single 
regioisomer, thus making the coupling with 129 to give the compound 132 (Scheme 3.31).  
 
115 Ayesa S., Samuelsson B., Classon B., Synlett., 2008, 1, 97-99. 






Scheme 3.31: Synthethic patway fo the synthesis of 132. 
As inner component we used GlcC5S 125, obtained starting from β-glucose pentaacetylate 
54, which was first glycosylated at the anomeric oxygen by Fisher esterification with 4-
penten-1-ol alcohol (yield = 30%) and then thioacetylate with thioacetic acid (yield = 85%). 
Final deprotection with sodium metanoate in MeOH led to the obtainment of product 125 
in 63% yield (Scheme 3.32).116  
 
 
Scheme 3.32: Synthesis of inner component 125. 
It is worth noting that while ligand 132 has a long and amphiphilic linker to impart flexibility 
and assist the water dispersibility of the final GNPs, the sugar ligand 125 has a shorter and 
hydrophobic linker to ensure the rigidity of the nanoparticle core. 
With active and inner components in hands, we could provide the glyconanoadduct 
formation, by preliminary establishing the mutual percentage between the two 
components. In that way we built a small library of Au GNPs at different percentages of 
 
116 Love J. C., Estroff L. A., Kriebel J. K., Nuzzo R. G., Whitesides G. M., Chem. Rev. 2005, 105, 1103-1169. 
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iminosugar. As mentioned before, the in situ synthesis allows to control the growth of the 
gold cluster by simply varying the ligands mixture/Au(III) molar ratio and the simultaneous 
insertion of different ligands. Water-soluble and stable gold GNPs of 2-nm average 
diameter were obtained by adding an aqueous solution of tetrachloroauric acid (HAuCl4, 1 
equiv.) to a methanolic solution of a mixture of thiol-derivatized conjugates (active 
iminosugar conjugate and inner sugar component, 3 equiv.) in the desired proportion. The 
resulting mixture was reduced with an excess of NaBH4 (27 equiv.) as reducing agent and 
the suspension was vigorously shaken for 2 h at 25 °C. The supernatant was removed, the 
nanoparticles were washed with methanol and the residue was dissolved in milliQ water, 
purified by dialysis and characterized by 1H NMR spectroscopy, transmission electron 
microscopy (TEM), infrared spectroscopy (IR), and ultraviolet spectroscopy (UV). 
Glyconanoparticles with different density of active component were obtained by changing 
the ratio of iminosugar conjugate with respect to sugar derivative as inner component in 
the initial mixture before GNP formation. The ratio of the components was controlled by 
1H NMR. The proportion of the ligands on the gold surface was also examined by 1H NMR 
after cluster formation (analysis of the supernatant and washings) as well as performing 
qNMR of GNPs in deuterium oxide with an internal reference. This well established protocol 
employed for the quantification of different ligands onto Au GNPs,117 allowed the 
quantitative 1H NMR determination of the iminosugar on the nanoparticle by integration 
of a diagnostic signal (see the section 3.3.1.3) with respect to the internal standard signal.112 
The 1H NMR spectra of the GNPs featured broader peaks with respect to those of the 
corresponding free ligands, testifying for nanoparticle formation. Regarding the 
sugar/iminosugar ligand ratio, its uniformity was ascertained by 1H NMR performed on the 
reaction mixture (before) and, after nanoparticle formation, on both the supernatant and 
the washings (after). The Au GNPs were also characterized by UV-vis spectroscopy and 
transmission electron microscopy (TEM). Following the above procedure, Au GNPs 
decorated with 30% (138a), 40% (138b) and 50% (138c) densities of iminosugar were 
prepared (Scheme 3.33). Au GNPs 138a and 138b were dispersible in water and TEM 
images showed metallic cores with average diameters ranging from 1.7 nm to 1.9 nm. 
These nanoparticles could be freeze-dried and re-dispersed in water without flocculation. 
Conversely, 50% iminosugar-coated Au GNPs (138c) showed difficulties in isolation after 
washing with MeOH and could not be properly redispersed in water after freeze-drying. 
 
117 (a) Manea F., Bindoli C., Fallarini S., Lombardi G., Polito L., Lay L., Bonomi R., Mancin F., Scrimin P., Adv. 
Mater., 2008, 20, 4348; (b) Chiodo F., Enríquez-Navas P. M., Angulo J., Marradi M., Penadés S., Carbohydr. Res., 
2015, 405, 102.  




Scheme 3.33: Synthesis of the DAB-1-decorated Au GNPs 138. 
If on one hand the exceptionally small dimensions of the gold core have the advantage to 
give to the glyconanocomposites better biological properties (such as, for example, an 
efficient internalization in the cell), on the other side they limit the possibility to increase 
the percentage of the iminosugar beyond a certain limit. As a matter of fact, we could not 
increase the loading of the iminosugar ligand more than 40% without losing water 
dispersibility. For this reason, we also set out a strategy that would allow us to expand the 
valency of the system prior to the formation of the gold nanoparticles, by combining the 
dendrimeric technique (see section 3.1), using suitable bioactive dendrons equipped with 
a thiol-ending functionality, in order to increase the valency without affecting water 
stability properties, thanks to a more favorable balance between hydrophilic heads and 
hydrophobic chains. In that case we decided to use the same trimeric alkyne scaffold used 
in the synthesis of multimeric trihydroxypiperidines (81, see section 3.2.1.1) to multimerize 
our pyrrolidine azido derivative 134: indeed, it possesses the alkyne moieties necessary to 
click the azido active warhead, and an amine that could be coupled with the thiol-ended 
linker 129 (scheme 3.34). Moreover, the CuAAC reaction that contemplates the ‘critical’ 
use of copper as catalyst, is done several steps before the grafting of the active component 
to the gold core, reducind in this way the risk of contamination. Furthermore, compounds 
bearing the trimeric linker, have been subjected to ICP analysis to assess the absence of 
copper traces.  
 




Scheme 3.34: Trivalent scaffold to build dendrimeric ligand. 
Reaction of the azido-armed acetyl protected 134 with the trivalent amine 81118 gave the 




Scheme 3.35: Synthesis of trivalent active component 139. 
Unfortunately, reaction of the amine 139 with the acid 129 under the same conditions used 
for amine 135 (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 1–
hydroxybenzotriazole (HOBt) and diisopropylethylamine (DIPEA) in dry DMF at room 
temperature) failed to yield the desired product 140. However, coupling of 139 with the 
acid 129 in the presence of 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazine-4(3H)-one 
(DEPBT)119 and DIPEA in dry THF for 6 days at room temperature afforded the compound 
140 with a remarkable 85% yield (scheme 3.36). Based on this result, the amine 135 was 
reacted with the acid 129 using DEPBT as coupling agent (reaction conditions: DEPBT, 
DIPEA, dry THF, 6 d, r.t.), in order to verify if we could obtain a yield enhance, but no 
improvement (around 40% with respect to 38%) was observed. 
 
118 Chabre Y. M., Contino-Pépin C., Placide V., Shiao T. C., Roy R., J. Org. Chem., 2008, 73, 5602. 
119 Li H., Jiang X., Ye Y.-h., Fan C., Romoff T., Goodman M., Org. Lett., 1999, 1, 91. 






Scheme 3.36: Coupling between amine 139 and acid 129 with DEPBT. 
With trivalent ligand 140 in hand, the preparation of Au GNPs 142 decorated with 30% of 
the trivalent DAB-1 was achieved following the same protocol employed for the synthesis 




Scheme 3.37: Synthesis of tri-DAB-1-decorated Au GNPs 141. 
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After work-up (MeOH washings) and purification (dialysis), the Au GNPs 142 resulted 
dispersible and very stable in water and they were characterized analogously to the Au 
GNPs 138. 
Au GNPs functionalized with 100% of GlcC5S (100% Au Glc, 143, scheme 3.38) were also 
prepared following a reported procedure111a to be employed as control systems. 
 
 
Scheme 3.38: Au GNPs 143 functionalized with 100% of GlcC5S. 
The small library of Au GNPs synthesized in this project, is summarized in the table below, 
with all data related to them, experimentally extrapolated. In the table the estimated 
molecular weight of the Au GNP is also reported, calculated by following an empirical 
formula reported in literature that correlates the gold core diameter with the molecular 
weights of the nanoparticles.120 Moreover, in the last column of the table it is reported the 
amount of the active component DAB-1 as measured by qNMR. It is worth noting that the 
concentrations found with these two different methods (by TEM and qNMR) are quite in 
agreement (the same order of magnitude) for the GNPs 138a and 138b while, for GNPs 



















M.W. = 32775 
0.54mg 
Correspond to  
49 nmol 
0.54mg 
Correspond to  
50 nmol 
 
120 Martinez-Avila O., Hijazi K., Marradi M., Clavel C., Campion C., Kelly C., Penadés S., Chem. Eur. J., 2009, 15, 
9874-9888. 








M.W. = 34317 
0.2mg 
Correspond to  
35 nmol 
0.2mg 






















Table 3.10: Resume table of DAB-1-based Au GNPs. 
 
3.3.1.2 Biological evaluation  
 As mentioned before, the purpose of this project was to evaluate the inhibitory 
activity of the new synthesized Au GNPs towards the two sulfatases GALNS and IDS, 
involved respectively in the metabolic diseases Morquio A Syndrome and Hunter's Disease. 
The glyconanoparticles 138a-b, 142 and 143 obtained were subjected to preliminary 
inhibition tests, carried out thanks to the collaboration with the group of Prof. A. Morrone 
at the laboratory of Metabolic Diseases of the Meyer Hospital of Florence. They were 
initially evaluated at 0.2 mg/mL concentration in extracts from a pool of human leukocytes 
isolated from healthy donors by fluorimetric test. Compound 80 was used as the 
monovalent reference compound, and the percentage of inhibition towards GALNS and IDS 
was evaluated at 1 mM of inhibitor, as previously reported.121 The collected data are 
summarized in table 3.11. For percentages of inhibition higher than 70%, the corresponding 
IC50 values were evaluated by measuring human enzyme activity at different Au GNPs 
 
121 (a) Van Diggelen O. P., Zhao H., Kleijer W. J., Janse H. C., Poorthuis B. J. H. M., Van Pelt J., Kamerling J. 
P., Galjaard H., Clin. Chim. Acta, 1990, 187, 131. (b) Voznyi Y. V., Keulemans J. L., van Diggelen O. P., J. 
Inher. Metabol. Dis., 2001, 24, 675.  
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concentrations (see section 3.3.1.4). 
GNP 
Iminosugar conc. (µM) in                  
0.2 mg/mL-1 of Au GNPs 

















143 0 18% 
75% 
0.028 mg/mL‐1 
Compound Iminosugar conc. (µM) IDS GALNS 
80 1000 0% 52%c 
144 3000 n.d. 29%c 
78 9000 96%c,d (140)d 94%c,d (47)d 
 
Table 3.11: Percentage of inhibition towards human GALNS and IDS at 0.2 mg 
mL−1 in terms of Au GNPs. IC50 values were measured for inhibition percentage 
higher than 70% and are reported as mg L−1 of Au GNPs in bold and as μM 
concentration of iminosugar in parentheses. 
 
a Percentage of inhibition obtained at 0.15 mg mL−1 concentration of Au GNPs.  
b IC50 (μM) in terms of the iminosugar concentration. c Percentage of inhibition 
obtained at 1 mM concentration. d Data taken from ref. 47. The reported IC50 value 
was obtained using the same experimental protocol of this manuscript (e.g. same 
substrate concentration). 
 
The effective iminosugar component concentration of Au GNPs 138a, 138b and 142 was 
determined by qNMR. This allowed us to measure the IC50 values not only as mg L−1 of Au 
GNPs, but also as the μM concentration of the iminosugar in the nanoparticles (for 138a, 
138b and 142, values are in parentheses). Monovalent reference compound 80 showed 
around 50% inhibition of GALNS, while multivalent Au GNPs decorated with DAB-1 
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inhibited GALNS with percentages ranging from 83% to 97%. In terms of DAB-1 
concentration, these results indicate that GALNS was strongly inhibited in the low 
micromolar/high nanomolar range. In other words, the presentation of the multiple DAB-
1 units at the gold glyconanoparticle surface generates more potent GALNS inhibitors, 
confirming our previous observation reported with DAB-1 based dendrons (scheme 3.39).47 
 
 
Scheme 3.39: Trivalent DAB-1 based dendron 144 and nonavalent DAB-1 based dendrimer 78. 
A moderate enhancement of inhibitory activity was observed when the number of grafted 
active units was increased from 30% DAB-1 βGlc (138a) to 40% DAB-1 βGlc (138b), being 
the IC50 = 0.016 mg mL−1 for vs. IC50 = 0.025 (table 3.29). In terms of the iminosugar 
concentration, no enhancement of inhibitory activity was observed at all, being IC50 = 2.56 
μM vs. IC50 = 2.31 μM). This trend parallels that previously observed on Au GNPs coated 
with a pyrrolizidine iminosugar in the inhibition of a different enzymatic target, namely 
amyloglucosidase from Aspergillus niger.112 Also in this case, the inhibitory activity was 
insensitive to the increase of the percentage of the iminosugar ligand with respect to the 
sugar inner component. However, while towards amyloglucosidase from Aspergillus niger 
100% Au βGlc 143 did not show any inhibitory activity when tested at 0.2 mg mL−1, with 
GALNS an unexpected remarkable inhibition was observed (75% inhibition, IC50 = 0.028 mg 
mL−1, table 3.29). This prompted us to reflect on the role of the sugar (the inner 
component). Indeed, the sugar part, which constitutes an essential component of our 
nanoparticle/scaffold, exerts a considerable inhibitory activity itself. As a matter of fact, it 
has been recently reported that sugars, when multivalently presented on nanodiamond 
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particles122 and on magnetic nanoparticles,123 may afford a significant inhibitory activity, 
even if the monovalent sugar ligand is not an inhibitor. Also in our case, neither the thiol 
ending GlcC5SH nor its disulfide dimer showed any inhibitory activity towards GALNS when 
screened up to 2 mM inhibitor concentration (see section 3.3.1.4). The significant inhibition 
observed for 143 suggests that the GALNS enzyme is particularly prone to accept 
multivalent ligands. Moreover, these results confirm that GALNS, unlike lysosomal 
glycosidases that show exquisite specificity for the saccharide to hydrolyze, has substantial 
promiscuity in substrate recognition, as previously reported.89 Our data suggest that the 
simultaneous presentation of the sugar and the iminosugar units results in the 
enhancement of the affinity towards the GALNS enzyme, thus acting in a synergistic way. 
The greatest improvement was achieved by protruding the trivalent DAB-1 moiety 
(deprotected 141) from the glyconanoparticle core. This was achieved with the synthesis 
of Au GNPs 142 by combining the dendrimeric technique with the nanoparticle formation. 
The Au GNPs 142 decorated with 30% of trivalent DAB-1 resulted in 97% inhibition of 
GALNS with an observed IC50 value of 0.004 mg mL−1 in terms of Au GNP concentration, 
corresponding to 0.52 μM of iminosugar (table 3.29). The advantage of employing the 
glyconanoparticle strategy to afford new more potent inhibitors of GALNS based on DAB-1 
(AuGNPs 142) is clearly demonstrated. Indeed, the previously reported trivalent DAB-1 
compound 14447 (scheme 3.39) inhibited GALNS by only 29% at 1 mM concentration (table 
3.29). The inhibitory activity found for Au GNPs 142 far exceeds that previously obtained 
with nonavalent DAB-1 dendrimer 78, for which an IC50 = 47 μM was observed when tested 
under the same experimental conditions (the same substrate concentration). Indeed, Au 
GNPs 142 are two orders of magnitude more active than the nonavalent dendrimer 76. 
Regarding IDS, Au GNPs 138a, 138b and 142 did not significantly inhibit this enzyme (15–
39% inhibition at 0.2 mg mL−1), and 80 did not inhibit IDS at all. Interestingly, Au GNPs 
coated with DAB-1 (12a, 12b) or tri-DAB-1 142 showed high selectivity towards GALNS with 
respect to IDS, while the previously reported dendrimer 78 showed no substantial 
selectivity. 
 
3.3.1.3 Conclusions  
 In this project, Au GNPs decorated with the iminosugar active component DAB-1 
were synthesized, in search of new potent multivalent inhibitors of lysosomal sulfatases 
GALNS and IDS, therapeutically relevant enzymes involved in lysosomal storage diseases 
 
122 Siriwardena A., Khanal M., Barras A., Bande O., Mena-Barragán T., Ortiz Mellet C., Garcia-Fernández J. M., 
Boukherroub R., Szunerits S., RSC Adv., 2015, 5, 100568. 
123 Alvarez-Dorta D., Brissonnet Y., Saumonneau A., Deniaud D., Bernard J., Yan X., Telluer C., Daligault F., Gouin 
S., ChemistrySelect, 2017, 2, 9552. 
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(Morquio A and Hunter disease, respectively). Exploiting the nanoparticle direct synthesis 
protocol, Au GNPs decorated with different loadings of the iminosugar component were 
achieved. This methodology allows indeed to vary the mutual percentage between active 
and inner component. A remarkable inhibitory activity was found for the whole set of Au 
GNPs 138a, 138b, 142 and 143 towards GALNS, while IDS was not significantly inhibited. 
Surprisingly, a good inhibition was observed also for 100% Au-βGlu 143, prepared as a 
control system, thus suggesting a synergistic effect of the sugar component (which is a part 
of the scaffold) and the iminosugar moiety in imparting the inhibitory activity, at least 
towards this particular enzyme target. Loading higher than 40% could not be attained due 
to the small dimensions of the gold cores. To enhance the multivalent presentation of the 
iminosugar component, combination with the dendrimeric technique was used by 
synthesizing the trivalent DAB-1 ligand 139, subsequently employed in the preparation of 
Au GNPs 142. Multimerization of DAB-1 onto Au GNPs resulted in new multivalent 
inhibitors selective for GALNS in the low micromolar range in all cases, with the best result 
obtained with the Au GNPs 142 decorated with 30% of trivalent DAB-1, for which an IC50 
value of 0.52 μM was measured. This result far exceeds that obtained with a previously 
reported nonavalent dendrimer 78, for which an IC50 value of 47 μM had been obtained. 
Therefore, Au GNPs coated with DAB-1 are between 18-fold (138b, IC50 = 2.56 μM) and 90-
fold more active than 78 (142, IC50 = 0.52 μM), thus representing the most potent GALNS 
inhibitor reported so far to the best of our knowledge. Work is underway in our lab to 
deeply investigate the role of the sugar component, in order to find the best synergistic 
effect in inhibiting GALNS. 
 
3.3.1.4 Experimental section 
 
For the general details see paragraph 2.4. Additionally, UV/Vis spectra were recorded with 
a Varian CaryWin 4000 UV/Vis spectrophotometer. TEM analysis was performed with a 
Philip CM12 instrument with CRYO-GATAN UHRST 3500 Technology, digital camera and 
EDAX microanalysis and with a JEOL JEM-2100F microscope, both operating at 200 kV. ICP 
analysis was performed with a Thermo Scientific™ iCAP 7400 ICP-OES analyzer. 
 
Synthesis of pyrrolidine 131: To a solution of 2 (89 mg, 0.17 mmol) in MeOH (5 mL) 
and 12 M HCl (6 drops), Pd/C (45 mg) was added and the reaction mixture was left stirring 
at room temperature under a H2 atmosphere for three days. The catalyst was filtered 
through a Celite® pad and the filtrate was concentrated under vacuum to quantitatively 
yield the hydrochloride of 3, which was eluted through an ion-exchange resin (DOWEX® 
50XW8-100) with MeOH, H2O and 6% NH4OH to give the free amine 131 (25 mg, 0.11 mmol, 
65%). [α]20D = −49.4 (c = 0.69 in H2O); 1H-NMR (400 MHz, D2O): δ = 3.98 (dt, J = 5.4, 2.4 Hz, 
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1H, H-3), 3.80 (dd, J = 4.9, 2.9 Hz, 1H, H-4), 3.63–3.54 (m, 2H, H-6), 2.87 (dd, J = 11.2, 2.4 
Hz, 1H, Ha-2), 2.72–2.65 (m, 3H, Ha-1’, H-6’), 2.60 (dd, J = 11.2, 5.8 Hz, 1H, Hb-2), 2.39 (dd, 
J = 10.5, 5.1 Hz, 1H, H-5), 2.24 (td, J = 10.7, 5.4 Hz, 1H, Hb-1’), 1.48–1.19 (m, 8H, from H-2’ 
to H-5’) ppm; 13C-NMR (50 MHz, D2O) δ = 79.3 (d, C-4), 75.5 (d, C-3), 71.9 (d, C-5), 61.4 (t, 
C-6), 58.3 (t, C-2), 55.3 (t, C-1′), 39.8 (t, C-6′), 28.2–25.5 (t, 4C, from C2′ to C5′)ppm; MS 
(ESI): m/z calcd (%) for C11H24N2O3 232.18; found: 233.23 (100%, [M + H]+). Elemental 
analysis: (%) for C11H24N2O3 (232.32) calcd: C, 56.87; H, 10.41; N, 12.06; found C, 56.36; H, 
10.31; N 11.84. 
Synthesis of pyrrolidine 134: To a solution of 80 (336 mg, 1.3 mmol) in pyridine 
(9.6 mL), acetic anhydride (6.2 mL, 65.0 mmol) was added. The solution was stirred at room 
temperature overnight. Then, after concentration under reduced pressure, the crude 
product was purified by FCC (pentane/AcOEt from 5 : 1 to 2 : 1) to afford pure 134 (216 mg, 
0.56 mmol, Rf = 0.5, 81% yield) as a colorless oil. [α]21D = −50.8 (c = 0.91 in CHCl3). 1H-NMR 
(400 MHz, CDCl3): δ ppm = 5.07 ( pt, J = 5.3 Hz, 2H, H-3, H-4), 4.17 (dd, J = 5.6, 11.6 Hz, 2H, 
H-6), 3.26 (t, J = 6.9 Hz, 2H, H-6′), 3.14 (d, J = 11.2 Hz, 1H, Ha-5), 2.79–2.71 (m, 3H, Hb-5, H-
2, Ha-1′), 2.36–2.32 (m, 1H, Hb-1′), 2.08 (s, 9H, OAc), 1.63–1.25 (m, 8H,  from H-2′ to H-5′). 
13C-NMR (100 MHz, CDCl3): δ = 170.8–169.6 (s, 3C, –OC̲OCH3), 78.9–76.4 (d, 2C, C-3, C-4), 
67.8 (t, C-1′), 63.3 (t, C-6), 57.5 (t, C-5), 54.7 (d, C-2), 51.4 (t, C-6′), 29.7–26.6 (t, 4C, from 
C2′ to C5′), 21.0–20.6 (q, 3C, OC̲H3) ppm; IR (CDCl3): ν˜ = 2939, 2862, 2811, 2258, 2099, 
1740, 1455, 1372, 1236, 1049 cm−1; MS (ESI): calcd (%) for C17H28N4O6 384.20; found: 
407.09 (100 %, [M + Na]+). Elemental analysis: (%) for C17H28N4O6 (384.43): calcd C, 53.11; 
H, 7.34; N, 14.57; found: C, 53.61; H, 7.52; N, 14.95. 
Synthesis of pyrrolidine 135: To a solution of supported-PPh3 (Fluka, ∼3.2 mmol 
g−1 crosslinked with 2% DVB, 50 mg, 0.2 mmol) in dry THF (1 mL), a solution of 134 (30 mg, 
0.08 mmol) in dry THF (1 mL) was added. The reaction mixture was stirred under a nitrogen 
atmosphere at room temperature overnight. After a TLC control (CHCl3/MeOH = 20: 1) 
showing the presence of both the starting material (Rf = 0.8) and the product (Rf = 0.9), 4 
μL of H2O were added and the mixture was refluxed for 3 hours, until a TLC analysis showed 
the complete disappearance of the starting material 134. The obtained crude product was 
filtered over cotton and purified by FCC (from CH2Cl2/MeOH 10: 1 to CH2Cl2/MeOH/NH3 5: 
1: 0.1) to give pure 135 (17 mg, 0.05 mmol, 59% yield) as a pale-yellow oil. 1H-NMR (400 
MHz, CDCl3): δ ppm = 5.08–5.05 (m, 2H, H-3, H-4), 4.21–4.13 (m, 2H, H-6), 3.15 (d, J = 11.6 
Hz, 1H, Ha-5), 2.81–2.66 (m, 5H, Hb-5, H-2, Ha-1′, H-6′), 2.37–2.23 (m, 1H, Hb-1′), 2.08 (s, 
9H, OAc), 1.49–1.26 (m, 8H, from H-2′ to H-5′). 13C-NMR (50 MHz, CDCl3): δ ppm = 170.7–
169.9 (s, 3C, –OC̲OCH3), 79.2–76.5 (d, 2C, C-3, C-4), 67.8 (t, C-1′), 63.4 (t, C-6), 57.5 (t, C-5), 
54.7 (d, C-2), 42.2 (t, C-6′), 33.8 (t, C-5′), 28.0–26.8 (t, 3C, from C-2′ to C4′), 21.0–20.9 (q, 
3C, OC̲H3). MS (ESI): calcd (%) for C17H30N2O6 358.21; found: 359.44 (100%, [M + H]+).  
Synthesis of DAB-1 based ligand 132: A solution of compound 129 (102 mg, 234 
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μmol), 1-hydroxybenzotriazole (HOBt, 46.4 mg, 343 μmol) and N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide (EDC, 66.0 μL, 374.4 μmol) in dry DMF (2.0 mL) was stirred at room 
temperature under a nitrogen atmosphere. After 10 min, a solution of 135 (56.0 mg, 156 
μmol) and N,Ndiisopropylethylamine (DIPEA 73.0 μL, 421.0 μmol) in dry DMF (1.5 mL) was 
added. The reaction mixture was stirred at room temperature for 18 h, until a TLC analysis 
(CH2Cl2/MeOH 2: 1) confirmed the formation of a new product (Rf = 0.5) and the complete 
disappearance of compound 135 (Rf = 0.1). The reaction mixture was diluted with AcOEt 
(10 mL) and washed with H2O (1 × 8 mL) and the organic layer was then washed with a 
saturated solution of NaHCO3 (1 × 8 mL), water (1 × 8 mL) and brine (1 × 8 mL), dried over 
anhydrous Na2SO4 and concentrated under vacuum. Purification through gradient column 
chromatography (CH2Cl2/MeOH from 30: 1 to 10: 1) afforded pure 132 (46 mg, 59 μmol) as 
a pale-yellow oil, in 38% yield. [α]23D = −25.2 (c = 0.63 in CHCl3). 1H-NMR (400 MHz, CDCl3): 
δ = 5.06 (br s, 2H, H-3, H-4), 4.22–4.06 (m, 2H, H-6), 3.97 (s, 2H, H-L1), 3.74–3.55 (m, 12H, 
H-L2/L7), 3.43 (t, J = 6.8 Hz, 2H, H-L8), 3.24 (dt, J = 14.3, 6.7 Hz, 2H, H-6′), 3.14 (d, J = 12.0 
Hz, 1H, Ha-5), 2.85 (t, J = 7.4 Hz, 2H, H-L18), 2.79–2.65 (m, 3H, Hb-5, H-2, Ha-1′), 2.31 (s, 
1H, Hb-1′), 2.31 (s, 3H, SAc), 2.12–2.02 (m, 9H, OAc), 1.59–1.18 (m, 26H, from H-2′ to H-5′, 
from H-L9 to H-L17) ppm; 13C-NMR (100 MHz, CDCl3): δ = 196.1 (s, SC̲OCH3), 170.9–169.7 
(s, 4C, OAc (3), C̲ONH–), 78.8–76.4 (d, 2C, C-3, C-4), 71.6–70.6 (t, 7C, OCH2– from L1 to L7), 
67.7 (t, CH2, L-8), 63.2 (t, C-6), 57.5 (t, C-5), 54.8 (d, C-2), 39.5 (t, C-6′), 38.8 (t, C-1, O–C̲H2–
CH2–R), 30.6 (q, SCOC̲H3), 29.7–26.1 (t, 14C, CH2SAc; C from L9 to L18; form C 2′ to 5′), 21.1–
20.9 (q, 3C, OCH3) ppm; MS (ESI): calcd (%) for C38H68N2O12S 776.45; found: 799.07 (100 %, 
[M + Na]+). IR (CDCl3): ν˜ = 3690, 3422, 2930, 2856, 2256, 2245, 1737, 1669, 1601, 1535, 
1465, 1370, 1234, 1112, 1045 cm−1. Elemental analysis: (%) for C38H68N2O12S (777.02): calcd 
C, 58.74; H, 8.82; N, 3.61; found: C, 58.83; H, 8.68; N, 3.60. 
Synthesis of trivalent DAB-1 derivative 139: To a solution of 134 (52.3 mg, 140 
μmol) in 1.2 mL of THF/H2O = 2: 1 CuSO4 (1.9 mg, 12 μmol), sodium ascorbate (5 mg, 25 
μmol) and 81 (9.7 mg, 41 μmol) were added. The reaction mixture was stirred under 
microwave irradiation at 80 °C for 45 min, until a TLC analysis (AcOEt) showed the 
disappearance of the starting material (Rf = 0.75) and the formation of a new product (Rf = 
0.00). After filtration through a Celite® pad, the solvent was removed under reduced 
pressure and the crude product was purified by FCC (CH2Cl2/MeOH/NH3 from 10: 1: 0.1 to 
5: 1: 0.1) affording pure 139 (52 mg, 37.4 μmol, Rf = 0.41 in CH2Cl2/MeOH/NH3 10: 1: 0.1) 
as a colorless oil, in 91% yield. [α]23D = −37.3 (c = 0.88 in CHCl3). 1H-NMR (400 MHz, CDCl3): 
δ = 7.59 (br s, 3H, triazole), 5.06 (pd, J = 5.6 Hz, 6H, H-3, H-4), 4.63 (br s, 6H, H-β), 4.34 (t, J 
= 7.2 Hz, 6H, H-6′), 4.15 (ddd, 6H, J = 11.6, 5.6, 4.72 Hz, 6H, H-6), 3.52 (br s, 6H, H-α), 3.13 
(d, J = 11.2 Hz, 3H, H-5), 2.77–2.70 (m, 9H, Hb-5, H-2, Ha-1′), 2.34–2.31 (m, 3H, Hb-1′), 2.07 
(s, 27H, OAc), 1.95–1.85 (m, 6H, H-5′), 1.51–1.41 (m, 6H, H-2′), 1.34–1.25 (m, 12H, H-3′, H-
4′) ppm; 13C-NMR (100 MHz, CDCl3): δ = 170.8–169.6 (s, 9C, OAc), 144.9 (s, 3C, triazole), 
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122.3 (d, 3C, triazole), 78.7 (d, 3C, C-3), 76.3 (d, 3C, C-4), 72.3 (t, 3C, C-α), 67.7 (d, 3C, C-2), 
64.9 (t, 3C, C-β), 63.1 (t, 3C, C-6), 57.4 (t, 3C, C-5), 56.0 (s, HNC̲(CH2O)3–), 54.5 (t, 3C, C-1′), 
50.2 (t, 3C, C-6′), 30.2 
(t, 3C, C-5′), 27.7 (t, 3C, C-2′), 26.6 (t, 3C, C-3′), 26.3 (t, 3C, C-4′), 21.0 (q, 9C, C̲H3CO) ppm; 
MS (ESI): calcd (%) for C64H101N13O21 1364.54; found: 1387.76 (100 %, [M + Na]+); IR (CDCl3): 
ν˜ = 3675, 3148, 3029, 3005, 2938, 2863, 2813, 1739, 1465, 1438, 1372, 1218, 1210, 1143, 
1095, 1051 cm−1. Elemental analysis: (%) for C64H101N13O21 (1388.56): calcd C, 55.36; H, 
7.33; N, 13.11; found: C, 55.13; H, 7.18; N, 13.13. 
Synthesis of trivalent DAB-1 based ligand 140: To a solution of compound 129 (8.6 
mg, 19.7 μmol) in dry THF (225 μL) at 0 °C, 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-
4(3H)-one (DEPBT 13 mg, 43.2 μmol) and N,N-diisopropylethylamine (DIPEA 7.4 μL, 43.2 
μmol) were added. The mixture was stirred at 25 °C for 15 min under a nitrogen 
atmosphere, then a solution of 139 (30.0 mg, 21.6 μmol) in dry THF (225 μl) was added and 
the reaction mixture was stirred at room temperature for 6 days, until a TLC analysis 
(CH2Cl2/MeOH 20: 1) showed the formation of a new product (Rf = 0.9). The reaction 
mixture was diluted with AcOEt (5 mL), washed with NH4Cl (2 × 3 mL), NaHCO3 (2 × 3 mL) 
and H2O (2 × 3 mL), dried over anhydrous Na2SO4 and concentrated under vacuum. 
Purification through gradient column chromatography (CH2Cl2/MeOH from 20: 1 to 10: 1) 
afforded pure 140 (30 mg, 17 μmol) as a yellow oil, in 85% yield. [α]23D = −29.1 (c = 0.35 in 
CHCl3). 1H-NMR (400 MHz, CDCl3): δ = 7.56 (br s, 3H, triazole), 5.06 (t, J = 5.3 Hz, 6H, H-3, 
H-4), 4.59 (br s, 6H, H-β), 4.33 (t, J = 7.3 Hz, 6H, H-6′), 4.16 (qd, 6H, J = 16.3, 11.5, 5.5 Hz, 
6H, H-6), 3.87 (s, 2H, L-1), 3.80 (s, 6H, H-α), 3.65–3.40 (m, 14H, from L-2 to L-8), 3.13 (d, J = 
11.2 Hz, 3H, Ha-5), 2.85 (m, 2H, L-18), 2.79–2.68 (m, 9H, Hb-5, H-2, Ha-1′), 2.36–2.29 (m, 
6H, Hb-1′, SAc), 2.07 (s, 27H, OAc), 1.91 (br s, 6H, H-5′), 1.58–1.25 (m, 36H, from L-9 to L-
17, H-2′, H-3′, H-4′) ppm; 13C-NMR (100 MHz, CDCl3): δ =  196.6 (s, SC̲OCH3), 170.7–169.6 
(s, 9C, OAc), 169.5 (s, C̲ONH–), 144.9 (s, 3C, triazole), 122.4 (d, 3C, triazole), 78.9 (s, 3C, C-
3), 76.4 (d, 3C, C-4), 71.5–70.1 (t, 7C, from L-1 to L-7), 69.9 (s, L-8), 68.9 (t, 3C, C- α), 67.8 
(d, 3C, C-2), 65.0 (t, 3C, C-β), 63.2 (t, 3C, C-6), 59.7 (s, HNC̲(CH2O)3–), 57.4 (t, 3C, C-5), 54.6 
(t, 3C, C-1′), 50.2 (t, 3C, C-6′), 30.2 (q, –CH2SCOC̲H3), 29.7–26.1 (t, 22C, from L-9 to L-18, C-
2′– C-5′), 20.9, 20.8 (s, 9C, COC̲H3) ppm; MS (ESI): calcd (%) for C85H139N13O27S 1807.60; 
found: 926.25 (100%, [(M+ Na)/2]+); IR (CDCl3): ν˜ = 3690, 3396, 3029, 3007, 2930, 2858, 
1739, 1681, 1603, 1530, 1465, 1372, 1234, 1207, 1097, 1052, 1021 cm−1. Elemental 
analysis: (%) for C85H139N13O27S (1807.15): calcd C, 56.49; H, 7.75; N, 10.08; found: C, 56.64; 
H, 7.38; N, 9.85. 
General procedure for the “in situ” deprotection of S-acetyl conjugates 132 and 
140: To a solution of 132 and 140 in CD3OD (20 mg ml−1 and 10 mg ml−1, respectively), 30 
equivalents of NaOMe were added and the reaction mixture was left stirring for 2 hours at 
25 °C under a nitrogen atmosphere. The complete disappearance of the starting material 
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was confirmed via 1H-NMR and the crude product was directly used for the preparation of 
Au GNPs. 
 
Preparation and characterization of Au GNPs: The Au GNPs coated with DAB-1 
derivatives (mono- and trivalent) and simple monosaccharide βGlcC5S (DAB-1-βGlc-Au NPs 
143 and tri-DAB1-βGlc-Au NPs 142) were prepared by the reduction of an Au(III) salt using 
sodium borohydride in the presence of a mixture of thiol-ending iminosugar conjugate and 
βGlcC5S 137 as ligands, in different ratios following a reported procedure.112 For the 
analysis of the ratio between the iminosugar ligands and βGlcC5S, 1H-NMR spectra of the 
initial mixture and the supernatant after Au-GNP formation were recorded. The ligand 
loading on the Au-GNPs was also evaluated by quantitative NMR (qNMR) using 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid (TSP-d4) as an internal standard in the D2O solution 
of the Au GNPs. The prepared Au GNPs were freeze-dried and stored at 4 °C. Under these 
conditions, the Au GNPs can be stored for months maintaining their biophysical properties. 
The Au GNPs 143, coated only with the simple monosaccharide βGlcC5S, were also 
prepared as previously described.  
General procedure for the preparation of Au GNPs coated with iminosugars: An 
aqueous solution of HAuCl4 (25 mM, 1 equiv.) was added to a 12 mM methanolic solution 
of a suitable mixture of thiol-ending sugar and iminosugar conjugates (3 equiv. overall). An 
aqueous solution of NaBH4 (1 M, 27 equiv.) was then added in four portions, with vigorous 
shaking. The black suspension formed was shaken for 2 hours at 25 °C. After that, the 
supernatant was removed and analysed by 1H-NMR to study the nanoparticle ligand 
composition. The residue was washed several times with MeOH. In order to separate well 
the nanoparticles from the supernatant centrifugation (12 000 rpm, 2 min) was performed. 
The residue was dissolved in a minimal volume of HPLC gradient grade water and purified 
by dialysis (SnakeSkin® Pleated Dialysis Tubing, 10 000 MWCO and Slide-A-Lyzer® 10K 
Dialysis Cassettes, 10 000 MWCO). Iminosugar coated Au GNPs were obtained as a dark-
brown powder after freeze-drying and characterized via 1H-NMR, UV-Vis spectroscopy and 
TEM analysis. 
 
The spectra relatives to the Au GNPs 138a-c 142 can be found in the ESI of the paper cited 
before. 
 
Preparation of 30% DAB-1-βGlc NPs (138a): A 1: 2.3 mixture of thiol-ending 132 
(7.83 mg, 12.9 μmol) and βGlcC5S 137 (8.3 mg, 29.6 μmol) in CD3OD (1.4 mL) was used to 
obtain 4.7 mg of AuGNPs 138a. TEM (average diameter): 1.7 ±0.4 nm. Quantitative 1H-
NMR (400 MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, 
sodium salt as an internal standard): 0.54 mg of 138a were dissolved in 120 μL of D2O and 
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40 μL of D2O containing 0.05 wt.% TSP were added and 50 nmoles of DAB-1 conjugate were 
found. Significant peaks: δ = 4.24 (br s, from βGlcC5S), 3.95-2.95 (m), 2.82-2.70 (m, 1H, from 
DAB-1 conjugate) 2.62-2.53 (m, 1H, from DAB-1 conjugate), 1.90-1.00 ppm (m). 
Preparation of 40% DAB-1-βGlc NPs (138b): A 1: 1.5 mixture of thiol-ending 132 
(7.80 mg, 12.9 μmol) and βGlcC5S 137 (5.4 mg, 19.3 μmol) in CD3OD (2.7 mL) was used to 
obtain 0.4 mg of Au GNPs 138b. TEM (average diameter): 1.9 ±0.3 nm. Quantitative 1H-
NMR (400 MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, 
sodium salt as an internal standard): 0.20 mg of 12b were dissolved in 150 μL of D2O and 
15 μL of D2O containing 0.05 wt.% TSP were added and 32 nmoles of DAB-1 conjugate were 
found. Significant peaks: δ = 3.98 (br s, NHCOCH2- from DAB-1 conjugate), 3.81-2.98 (m), 
2.87-2.75 (m, 1H, from DAB-1 conjugate), 2.67-2.57 (m, 1H, from DAB-1 conjugate), 1.90-
1.00 ppm (m). 
Preparation of 50% DAB-1-βGlc NPs (138c): A 1: 1 mixture of thiol-ending 132 (7.80 
mg, 12.9 μmol) and βGlcC5S 137 (3.6 mg, 12.9 μmol) in CD3OD (2.1 mL) was used to obtain 
0.45 mg of Au GNPs 138c. These nanoparticles were difficult to isolate after washing with 
MeOH and they were not stable when dispersed in water; indeed flocculation was observed 
after a few hours. For this reason a qNMR was impossible to be recorded (15-18 h of 
acquisition time are usually necessary for these experiments).TEM (average diameter): 2.5 
±0.5 nm. 
Preparation of 30% tri-DAB-1-βGlc NPs (142): A 1: 4 mixture of thiol-ending 141 
(10.0 mg, 5.5 μmol) and βGlcC5S 137 (6.3 mg, 22.1 μmol) in CD3OD (2.3 mL) was used to 
obtain 2.2 mg of AuGNPs 142. TEM (average diameter): 1.7 ±0.5 nm. The 1H-NMR spectrum 
of the “before mixture” showed a 1: 2.3 ratio between 141 and 137, corresponding to 30% 
tri-DAB-1-βGlc NPs, also confirmed by the 1H NMR spectrum of the “after mixture”. 
Quantitative 1H-NMR (400 MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-
2,2,3,3-d4 acid, sodium salt as an internal standard): 0.27 mg of 142 were dissolved in 150 
μL of D2O and 15 μL of D2O containing 0.05 wt.% TSP were added and 35 nmoles of DAB-1 
conjugate were found. Significant peaks: δ = 7.85 (br s, 3H, triazole from DAB-1 conjugate), 
4.29 (br s, from βGlcC5S), 4.03 (br s, NHCOCH2-, 6H, from DAB-1 conjugate), 3.93-3.00 (m), 
2.90-2.65 (m, 9H, from DAB-1 conjugate), 2.48-2.30 (m, 6H, from DAB-1 conjugate), 1.92-
0.93 ppm (m). 
 
Determination of GALNS and IDS activity in leukocytes homogenate from healthy donors. 
For compounds 80, 138a-b, 142, 143 and 144 the percentage of inhibition (at 1 mM 
concentration for 80 and 144 and at 0.2 mg/mL for AuGNPs 138a-b, 142 and 143) towards 
GALNS and IDS, using leukocyte extracts from healthy donors, was evaluated. Leukocyte 
pellets were disrupted by sonication in water and the micro BCA protein assay kit (Sigma-
Chapter 3  
_________ 
137 
Aldrich) was used to set up the protein amount for the enzymatic assay, according to the 
manufacturer’s instructions. 
GALNS enzymatic test: Enzyme activity was measured by setting the reaction in 0.2 
ml tubes and performing the experiments in triplicates as follows. 
Step 1: Iminosugars solution (3 μl), leukocytes homogenate (7 μl) and 20 μl of 4-
methylumbelliferyl-ßgalactoside-6-sulphate.Na (Moscerdam Substrates) substrate solution 
in Na-Acetate/acetic acid buffer (0.1 M/0.1 M, pH 4.3) containing 0.1 M NaCl , 0.02% (w/v) 
NaN3 and 5 mM Pb-acetate were incubated for 17 h at 37 °C. 
Step 2: After step 1 the tubes were placed on an ice cooler and the reaction was stopped 
by addition of 5 μl of Na-phosphate buffer (0.9 M, pH 4.3) containing 0.02 % of NaN3 and 
by efficient mixing with vortex. Then, 10 μl of β-Gal-A-10U were added to each sample and 
the suspension mixed again in vortex apparatus, then samples were incubated for 2 h at 
37°C. At the end of this period the tubes were placed on an ice cooler and the samples were 
transferred in a cooled flat–bottomed 96 well plate and the reaction was immediately 
stopped with 200 μl of NaHCO3/Na2CO3 buffer (0.5M/0.5M pH 10.7) containing 0.025% 
(w/v) of Triton X-100. Fluorescence was measured in a SpectraMax M2 microplate reader 
(Molecular-Devices) using a 365 nm excitation wavelength and a 435 nm emission 
wavelength. Percentage of GALNS inhibition was given with respect to the control (without 
iminosugar). Experiments were performed in triplicate, and the mean ± S. D. was 
calculated. 
IDS enzymatic test: Enzyme activity was measured by setting the reaction in 0.2 ml 
tubes and performing the experiments in triplicates as follows. 
Step 1: Iminosugars solution (3 μl), leukocytes homogenate (7 μl) and 20 μl of 4-
methylumbelliferyl-α-LIduronide-2-sulphate.2Na (Moscerdam Substrates) substrate 
solution were incubated for 4 h at 37 °C. 
Step 2: After step 1 the tubes were placed on an ice cooler and the reaction stopped by 
addition of 20 μl of Na-Phosphate/Citrate buffer (0.2M/ 0.1M pH 4.5) and by efficient 
mixing with vortex. Then, 10 μl of LEBT (Lysosomal Enzymes purified from Bovine Testis) 
were added to each sample and the incubation was continued for 24 hours at 37°C. At the 
end of this period tubes were placed on an ice cooler and the samples were transferred in 
a cooled flat–bottomed 96 well plate and the reaction was immediately stopped by 
addition of 200 μl of NaHCO3/Na2CO3 buffer (0.5M/0.5M pH 10.7) containing 0.025% (w/v) 
of Triton X-100. Fluorescence was then measured in a SpectraMax M2 microplate reader 
(Molecular-Devices) using a 365 nm excitation wavelength and a 435 nm emission 
wavelength. Percentage of IDS inhibition was given with respect to the control (without 
iminosugar). Experiments were performed in triplicate, and the mean ± S. D. was 
calculated. 
For the IC50 determination, see section 3.2.1.4 
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3.3.2 Hybrid Gold Glyconanoparticles (DNJ based)  
The first synthesis of deoxynojirimycin DNJ (1966, Paulsen) and the discovery of its 
important biological properties,1 has prompted the interest in imino analogues of 
carbohydrates.  The first rational of the MVE observed for a trimeric DNJ derivative, ten 
years ago,81 extended the multivalency concept to carbohydrate-processing enzymes. Until 
then indeed, this phenomenon was considered an exclusive prerogative of the lectins-
carbohydrates interaction due to the multimeric nature of such enzymes. But in 2009, by 
clicking a DNJ azido derivative to some bi- and tridentate oligoetilene scaffolds, for the first 
time a systematic evaluation of multivalent iminosugar-based glycosidase inhibitors were 
furnished, paving the way for a wide research in this field (see section 3.2). The concept 
was validated in 2010, when Compain and Nierengarten, reported the synthesis of a 
fullerene-based 12-valent DNJ compound (63, section 3.2)  that showed a binding 
enhancements towards JBα-man up to three orders of magnitude over the monovalent 
counterpart (Ki = 0.15 µM vs Ki = 188 µM).82 Starting from these multivalency ‘milestones’, 
a large variety of multimeric DNJ compounds were synthesized by exploiting the CuAAC 
reaction, for example in 2011 Ortiz Mellet and Compain reported the synthesis of 
multivalent structures based on β-cyclodextrins (β-CD).84 Many other different scaffolds 
were exploited, ranging from porphyrins87 or calixarenes,88 to more complex micellar self-
assembled glycopeptides and polymeric dextrans.51 In 2016 again Compain built a series of 
cyclopeptoids of different valency (from 18 to 48 units of DNJ), including the one decorated 
with 36 DNJ units which showed the best inhibition value ever reported until now (Ki = 
0.0011 µM).85 Moreover, the recent obtainment of the first high resolution crystal structure 
of its complex with  JBα-man, allowed the rationalization of multivalent effect observed 
with this 36-valent cluster,51 revealing that the binding modes involved in the inhibition of 
JBα-man and the multivalent effect observed, strongly depend on the size and shape of the 
prepared multivalent architecture. Indeed, the crystal structure clearly confirmed the 
previously hypothesized formation of a 2:1 JBα-man:inhibitor complex, revealing a 
sandwich-type complex in which four DNJ units bind the catalytic pockets of two JBα-man 
molecules.  
Despite the large variety of studied scaffolds, until now nobody has ever grafted a DNJ 
derivative onto gold nanoparticles. Only magnetic nanoparticles coated with DNJ 
(DNJ@Fe3O4) to apply in biocatalysis123 and a nanostructured porous silicon (PS) particles 
covalently attached with DNJ to study brain tumor inhibitors,124 are reported. 
For this reason and thanks to our group’s expertise in the synthesis of Au 
glyconanoparticles,112,45b we thought to synthesized Au GNPs decorated with a DNJ 
 
124 Kleps I., Ignat T., Miu M., Craciunoiu F., Trif M., Simion M., Bragaru A., Dinescu A., J. Nanosci. Nanotechnol., 
2010, 10, 2694-2700. 
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derivative to target JBMan enzyme, to be applied in anticancer research. Indeed, Jack 
Bean mannosidase can be taken as model for Golgi α-mannosidase II, that was 
demonstrated to be involved in some cancer growth processes (see section 1.2.5). 
Moreover, being JB-Man commercially available, it is possible to use it as a model enzyme 
for structural and mechanistic studies, mostly considering that its structure was recently 
solved Prof. Compain.51 To deal with this goal, we collaborated with Prof. Compain 
(University of Strasbourg, France), who furnished us the DNJ unit that we properly 
functionalized and grafted on the gold nanometric core, following the protocol developed 
in our recent work (see section 3.3.1).45b 
 
3.3.2.1 Results and discussion 
 Aiming to target JB-Man using DNJ based Au GNPs, we followed the guidelines 
achieved in our previous work where we multimerized two kinds of DAB-1 linkers on gold 
nanosized core.45b For this reason, the strategy was to synthesized Au GNPs containing the 
monovalent ligand 145 in a percentage of 40%, since in previous case, this was the optimal 
amount of active component to insert onto the gold core. On the other hand, trying to 
expand the effective amount of iminosugar units, we wanted to vary the percentage of the 
trivalent iminosugar linker 146 to find if any implementation of the bioactive compound on 
the nanoparticle was possible (scheme 3.40). Moreover, we also investigated the 
consequence of changing the inner component, by using -mannose 147 as well as -
glucose ligand 125 (scheme 3.40). Again, it was necessary to connect our bioactive 
iminosugar derivative to a properly functionalized linker (129 scheme 3.28), in order to 
allow the formation of a Au-S bond, and to space the bioactive warhead from the gold core 
in order to avoid the whole system collapse.  




Scheme 3.40: Scheme of the ligands, active and inner components. 
In this case the azido DNJ derivative 148 (scheme 3.41) was directly furnished by prof. 
Compain and we did not need to synthesize it. Starting from the same azido key 
intermediate, we were able to get the two ligands: the monovalent 145, by reducing the 
azido to amine through the Staudinger reaction seen before, and the trivalent 146 by 
performing a simple CuAAC click reaction. For the synthesis of amine 149, we exploited the 
Staudinger reaction conditions optimized before (section 3.3.1), consisting in the use 
polymer-bound Ph3P and refluxing for 4 h in THF/H2O. With intermediate 149 in hands, a 
coupling reaction using EDC and HOBt in dry DMF, was performed, and allowed to achieve 
compound 150 in good yield (67%). Starting from the same azido intermediate 148 we also 
synthesized the trivalent dendron 151, by ‘clicking’ it onto the trivalent scaffold 81 with a 
CuAAC reaction (CuSO4 and sodium ascorbate). Subsequently we coupled it with linker 129 
to get the peracetylated ligand 152 (scheme 3.41). In this case, to reproduce the same 
coupling conditions exploited in the case of trivalent pyrrolidine-based ligand (section 
3.3.1), we used DEPBT as coupling agent (reaction conditions: DEPBT, DIPEA, dry THF, 6 d, 
r.t.) that afforded the final ligand 152 in excellent yield (94%).  





Scheme 3.41: Synthesis of two ligands 150 and 152. I) Staudinger reduction; II) CuAAC. 
As mentioned before, we also wanted to use two different inner components (125 and 147, 
scheme 3.40). GlcC5S and ManC5S conjugates 125116 (section 3.3.1, scheme 3.32) and 147125 
(Scheme 3.42) were easily prepared starting from the peracetylated sugars which are 
commercially available, according to published procedures (Scheme 3.42). Briefly, the 
pentacetylated glycoside was glycosylated with 4-penten-1-ol in Fisher conditions, 
followed by free radical mediated thioacetilation with thioacetic acid; the subsequent 
deprotection with sodium methoxide in MeOH afforded desired derivative in good overall 
yields.  
 
Scheme 3.42: Synthesis of inner component 147. 
 
125 Buskas T., Sçderberg E., Konradsson P., Fraser-Reid B., J. Org. Chem., 2000, 65, 958 – 963. 
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With active and inner components in hands, we could provide the glyconanoadduct 
formation, by preliminary establishing the mutual percentage between the two 
components, following the same protocol employed for the synthesis of Au GNPs with DAB-
1 ligands (section 3.3.1). In that way we built a small library of Au GNPs at different 
percentages of iminosugar, in its monovalent (scheme 3.43) and trimeric form (scheme 
3.44). Briefly, water-soluble and stable gold GNPs of 2-nm average diameter were obtained 
by adding an aqueous solution of tetrachloroauric acid (HAuCl4, 1 equiv.) to a methanolic 
solution of a mixture of thiol-derivatized conjugates (active iminosugar conjugate and inner 
sugar component, 3 equiv.) in the desired proportion. The resulting mixture was reduced 
with an excess of NaBH4 (27 equiv.) as reducing agent and the suspension was vigorously 
shaken for 2 h at 25 °C.  
 
Scheme 3.43: Au GNPs containing monovalent DNJ ligand as active component GlcC5S (154) 
and ManC5S (155) as inner component. 
With the same procedure, we synthesized also Au GNPs grafting on the gold core the 
trivalent ligand 146 (scheme 3.44). 





Scheme 3.44: Au GNPs containing trivalent DNJ ligand as active component and GlcC5S (156) 
and different percentages of ManC5S (157a, 157b) as inner component. 
After 2 hours, the supernatant was removed, the nanoparticles were washed with 
methanol and the residue was dissolved in milliQ water, purified by dialysis and 
characterized by 1H NMR spectroscopy, transmission electron microscopy (TEM), infrared 
spectroscopy (IR), and ultraviolet spectroscopy (UV). Glyconanoparticles with different 
density of active component were obtained by changing the ratio of iminosugar conjugate 
with respect to sugar derivative as inner component in the initial mixture before GNP 
formation. The ratio of the components was controlled by 1H NMR. The proportion of the 
ligands on the gold surface was also examined by 1H NMR after cluster formation (analysis 
of the supernatant and washings) as well as performing qNMR of GNPs in deuterium oxide 
with an internal reference. This well stablished protocol employed for the quantification of 
different ligands onto Au GNPs, allowed the quantitative 1H NMR determination of the 
iminosugar on the nanoparticle by integration of a diagnostic signal with respect to the 
internal standard signal.112 The 1H NMR spectra of the GNPs featured broader peaks with 
respect to those of the corresponding free ligands, testifying for nanoparticle formation. 
Regarding the sugar/iminosugar ligand ratio, its uniformity was ascertained by 1H NMR 
performed on the reaction mixture (before) and, after nanoparticle formation, on both the 
supernatant and the washings (after). The Au GNPs were also characterized by UV-vis 
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spectroscopy and transmission electron microscopy (TEM).  
Au GNPs functionalized with 100% of GlcC5S (100% Au Glc, 143, scheme 3.45) and with 
100% of ManC5S (100% Au Man, 158, scheme 3.45) were also prepared following a 




Scheme 3.45: Au GNPs 143 functionalized with 100% of GlcC5S and 158. 
The small library of Au GNPs synthesized in this project, is summarized in the table below, 
with all data related to them. In the table are also reported the estimated molecular weight 
of the Au GNP, calculated by following an empirical formula reported in literature that 
correlates the gold core diameter (measured with TEM) with the molecular weights of the 
nanoparticles.120 Moreover, in the last column of the table it is reported the amount of the 
active component DNJ as measured by qNMR. It is worth noting that the concentrations 
found with these two different methods (by TEM and qNMR) are quite in agreement (the 
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Table 3.12: Resume table of DNJ-based Au GNPs. 
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3.3.2.2 Biological evaluation  
 As mentioned before, the purpose of this project was to evaluate the inhibitory 
activity of newly synthesized Au GNPs towards JBMan glycosidase, taken as a model 
enzyme for Golgi mannosidase, important enzyme for anticancer applications. 
The obtained glyconanoparticles 154, 155, 156, 157a and 157b were subjected to 
preliminary inhibitory tests, carried out thanks to the collaboration with the group of Prof. 
P. Compain at the University of Strasbourg, France.  
They were evaluated at 2 mg/mL concentration towards commercially available (Sigma 
Aldrich) JBMan. Compound 62 (scheme 3.46) was used as the monovalent reference 
compound. The collected data are summarized in table 3.32.  
 
 
Scheme 3.46: Monovalent reference compound 62. 
 
GNP 
Iminosugar conc. (µM) in                    
2 mg/mL-1 of Au GNPs 
Jack-bean  mannosidase        
Ki 
154 413 8 ± 2 µM 
Competitive 
155 467 
16 ± 2 µM 
Competitive 
156 567 
0.198 ± 0.060 µM 
Competitive 
157a 450 
0.175 ± 0.171 µM 
Competitive 
157b 503 
0.084 ± 0.066 µM 
Competitive 
143 0 n.i. at 0.5 mg/mL 
158 0 n.i. at 0.5 mg/mL 
Compound Iminosugar conc. (µM) 
Jack-bean  mannosidase        
Ki 
62 1000 322 µM 
 
Table 3.13: IC50 values measured for Au GNPs towards JBMan. 
Chapter 3  
_________ 
147 
The effective iminosugar component concentration of Au GNPs 154, 155, 156, 157a and 
157b was determined by qNMR. This allowed us to measure the IC50 values as the μM 
concentration of the iminosugar in the nanoparticles. Monovalent reference compound 62 
showed an IC50 value of 322 M, while all the multivalent Au GNPs bearing DNJ iminosugar 
derivatives display IC50 in the low micromolar range, thus validating that a multivalent 
presentation of the iminosugar generates a real advantage in the biological activity. The 
best activity of the series was that obtained for Au GNPs 157b, decorated with 40% of tris-
DNJ and 60% of α-mannose as inner component (0.084 M). This is also the best result 
obtained with a glyconanoadduct towards JBMan, considering that it is twice better than 
the best result obtained with some glycopeptides self-assembled in micelles synthesized 
by Compain in 2014, also glyconanoclusters but with another NP size and loading (among 
30 nm).126 Moreover, it is the first DNJ-based NP evaluated on JBMan.  
The effective advantage of an additional synthetic step, consisting in the trimerization of 
the bioactive ligand before the formation of AuGNPs, could be justified by comparing the 
biological activities of GNPs 155 and 157a which display the same number of active 
component (i.e. approximately 9 DNJ units). Indeed, from qNMR (measured at 2mg/mL in 
terms of nanoparticles) the concentration of DNJ was confirmed to be 467 M and 450 M 
for GNPs 155 and 157a respectively. Despite the comparable DNJ concentrations, GNPs 
157a showed a much lower Ki with respect to 155 (0.175 M vs 16 M). While the 
multivalent effect in 155 arises exclusively from the multimerization of monovalent DNJ on 
the gold nanoparticle platform, in 157a we can ascribe the much higher biological activity 
to the multivalent synergy of the platform (AuGNPs) and the previous trimerization of DNJ 
units, suggesting that the preorganization of the ligand in trimeric heads plays a 
fundamental role.   
Activities of Au GNPs displaying mono DNJ ligands 154 and 155 and -glucose and -
mannose respectively, were active in a similar range, as we previously observed for 
pyrrolizidine-based Au GNPs 127a-127c and 127b-127d.112 Moreover, their activity is 
comparable to the glycopeptides reported by Compain in 2014.126 The same comparison in 
terms of inner component can be done also for compounds bearing the tripod tris-DNJ 156 
and 157a-b, confirming that the biological activity depends only from the iminosugar part 
of the glyconanoadducts. It is worth noting that this aspect is not always glaring, given the 




126 Bonduelle C., Huang J., Mena-Barragan T., Ortiz Mellet C., Decroocq C., Etame E., Heise A., Compain P., 
Lecommandoux S., Chem. Commun., 2014, 50, 3350-3352. 
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3.3.2.3 Studies by TEM  
 To better rationalize the binding interactions largely enhanced by a multimeric 
presentation of our DNJ ligand, we aim to analyse the complexes JBMan-ligands through 
Transmission Electron Spectroscopy (TEM) with negative staining. This kind of studies are 
now ongoing in our laboratories, in collaboration with the laboratory of 
GLycoNanoTechnology of CIC biomaGUNE in San Sebastian, Spain. 
JBMan is a high molecular weight metalloenzyme of about 220 KDa, which comprises two 
pairs of subunits that have molecular weights of 66 and 44 KDa, respectively,127 and is 
visible by TEM. By exploiting the technique of TEM with negative staining, we will be able 
to see how our glyconanoparticles interact with the enzyme and how the enzyme will 
display its conformation in the presence of such inhibitors. Those experiments will enrich 
this study about the multimerization of DNJ onto gold nanoparticles as scaffolds, that until 
now, were not still reported in literature. 
 
3.3.2.4 Conclusion  
 In this project, Au GNPs decorated with the iminosugar active component DNJ were 
synthesized, in searching for new potent inhibitors of JBMan enzyme. Following the in situ 
direct synthesis protocol reported in 1994 by Brust and co-workers,109 that we 
demonstrated to be successful to graft on a gold nanoparticle surface ligands of iminosugar 
nature,112 Au GNPs decorated with different loadings of DNJ component were obtained. 
Being not possible to overcharge the percentage of iminosugar component onto gold 
surface, we trimerized the bioactive compound before grafting it on the nanoparticle, 
following the procedure already performed in the previous work with DAB-1 Au GNPs.45b A 
remarkably inhibitory activity was found for both Au GNPs 154 and 155. By grafting onto 
the gold core the DNJ tripod 146, Au GNPs 156, 157a and 157b was achieved and they 
showed the best activity of the series. In particular, 157b with a Ki of 0.084 M, is the best 
among multivalent nanosized DNJ inhibitors ever reported in literature to the best of our 
knowledge. 
Given the excellent results achieved with these Au GNPs and being DNJ a potent GCase 
inhibitor (see section 1.2.2), in the next future we would like to test these derivatives also 
against the GCase enzyme, in order to find new selective inhibitors/chaperones to be apply 
in the treatment of Gaucher Disease. Additionally, we are also planning to follow the same 
synthetic protocol to multimerize our bioactive trihydroxypiperidine already multimerized 
with dendrimeric scaffolds, onto gold glyconanoparticles, in order to study the effect of 
another type of scaffold on the GCase inhibition. 
 
127 Gnanesh Kumar B. S., Pohlentz G., Schulte M., Mormann M., Kumar N. S., Glycobiology, 2014, 24, 252–261. 




3.3.2.4 Experimental section 
 
For the general details see paragraph 3.3.1.4. TEM analysis was performed with a Philip 
CM12 instrument with CRYO-GATAN UHRST 3500 Technology, digital camera and EDAX 
microanalysis and with a JEOL JEM-2100F microscope, both operating at 200 kV. ICP 
analysis was performed with a Thermo Scientific™ iCAP 7400 ICP-OES analyzer. 
 
Synthesis of piperidine 149: To a solution of 148 (36 mg, 79 μmol) in 4.6 mL of THF/H2O = 
2:1, PPh3 (25 mg, 75 mol) was added. The reaction mixture was then refluxed for 5.30 h, 
until a TLC analysis (CH2Cl2/MeOH 10: 1) showed the disappereance of the starting material 
(Rf= 0.91) and the formation of a new product (Rf= 0.10). The solvent was removed under 
reduced pressure and the crude was purified by FCC (CH2Cl2/MeOH/NH3 from 10: 1 to 5: 1: 
0.2) affording pure 149 (25 mg, 58.1 μmol, Rf = 0.10 in CH2Cl2/MeOH 10: 1) as colourless oil 
in 74% yield. [α]D22 = + 4.75 (c = 0.59 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ = 5.05 (dt, J = 
17.1, 9.2 Hz, 2H, H-3, H-4), 4.94 (td, J = 10.0, 5.0 Hz, 1H, H-5), 4.19-4.09 (m, 2H, H-7), 3.18 
(dd, J = 11.5, 5.1 Hz, 1H, Ha-6), 2.75-2.68 (m, 1H, Ha-1’), 2.62 (dt, J = 11.6, 2.5 Hz, 1H, H-2), 
2.57-2.50 (m, 1H, Hb-1’), 2.43 (bs, 2H, H-6’), 2.30 (t, J = 10.5 Hz, 1H, Hb-6), 2.06 (s, 3H, OAc), 
2.01 (s, 6H, OAc), 2.00 (s, 3H, OAc), 1.48-1.22 (m, 8H, H-2’, H-3’, H-4’, H-5’) ppm; 13C-NMR 
(100 MHz, CDCl3): δ = 171.0-169.9 (s, 4C, -OCOCH3), 74.8 (d, C-5), 69.7 (C-3), 69.6 (d, C-4), 
61.7 (d, C-2), 59.7 (t, C-7), 53.0 (t, C-6), 51.8 (t, C-1’), 27.1-26.8 (t, 4C, from C2’ to C5’), 24.9 
(t, C-6’), 21.0-20.8 (q, 4C, -COCH3) ppm; MS (ESI): m/z 431.04 (100, H+). IR (CDCl3): 𝜈 = 2935, 
2860, 2255, 1744, 1664, 1601, 1508, 1369, 1234, 1061, 1032 cm−1. Elemental analysis (%) 
for C20H34N2O8 (430.49): calcd C, 55.80; H, 7.96; N, 6.51; found: C, 55.74; H, 7.87; N, 6.60. 
Synthesis of DNJ based ligand 150: A solution of EDC.HCl (1-Ethyl-3-(3-
dimethylaminopropyl) carbodimide hydrochloride (18.2 mg, 95 µmol), 1–
hydroxybenzotriazole (HOBt, 11.7 mg, 87 µmol) and 129 (25.9 mg, 59 µmol) in dry DMF 
(0.2 mL) was left stirring for 10 min. and then added to a solution of DNJ derivative 149 
(17.0 mg, 40 µmol) and N,N-diisopropylethylamine (19 µL, 107 µmol) in DMF (0.9 mL). The 
reaction mixture was left stirring at room temperature, under nitrogen atmosphere, for 6 
hours, then diluted with AcOEt (10 mL) and washed with H2O (2 x 3 mL). The organic layer 
was then washed with a satured solution of NaHCO3 (1 x 3 mL) and brine (1 x 4 mL), dried 
over anhydrous Na2SO4 and concentrated under vacuum. The crude was purified by column 
chromatography (DCM/MeOH from 30:1 to 10:1) affording 22 mg of 150 (26 µmol, 67% 
yield). Rf = 0.32 (CH2Cl2/MeOH 10: 1). [α]D26 = 3.33 (c = 0.69 in CHCl3). 1H-NMR (400 MHz, 
CDCl3): δ = 5.06 (dt, J = 9.2, 2.8 Hz, 2H, H-3, H-4), 4.99-4.92 (m, 1H, H-5), 4.17-4.13 (m, 2H, 
H-7), 3.98 (s, 2H, L-1), 3.69-3.56 (m, 12H, from L-2 to L-7), 3.44 (t, J = 6.8 Hz, 2H, L-8),  3.29-
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3.16 (m, 3H, H-6’, Ha-6), 2.85 (t, J = 3.6 Hz, 2H, L-18), 2.77-2.69 (m, 1H, Ha-1’), 2.64-2.61 
(m, 2H, H-2), 2.58-2.52 (m, 1H, Hb-1’), 2.32 (bs, 4H, SAc, Hb-6), 2.08 (s, 3H, OAc), 2.02 (s, 
6H, OAc), 2.01 (s, 3H, OAc), 1.59-1.51 (m, 4H, L-9, L-17), 1.36-1.25 (m, 22H, from H-2’ to H-
5’, from L-10 to L-16) ppm; 13C-NMR (50 MHz, CDCl3): δ = 195.9 (s, SCOCH3), 170.8-170.0 (s, 
4C, -OCOCH3), 169.7 (s, CONH-), 74.7 (d, C-5), 71.6-70.0 (t, 8C, from L-1 to L-8), 69.5 (C-3), 
69.4 (d, C-4), 61.5 (d, C-2), 59.2 (t, C-7), 52.9 (t, C-6), 51.7 (t, C-1’), 38.7 (t, C-6’), 30.6 (q, -
SCOCH3), 29.6-28.9 (t, 11C, from L-9 to L-18, C-5’), 26.9-26.1 (t, 3C, C-2’, C-3’, C-4’), 20.8-
20.7 (q, 4C, -COCH3) ppm; MS (ESI): m/z 871.35 (100, M+Na+). IR (CDCl3): 𝜈 = 3005, 2929, 
2856, 1744, 1673, 1540, 1466, 1370, 1237, 1107, 1033 cm−1; Elemental analysis (%) for 
C41H72N2O14S (849.08): calcd C, 58.00; H, 8.55; N, 3.30; found: C, 57.94; H, 8.50; N, 3.39. 
Synthesis of trivalent piperidine  151: To a solution of 148 (63 mg, 138 μmol) in 3 
mL of THF/H2O = 2:1 CuSO4 (2.1 mg, 13 μmol), sodium ascorbate (5 mg, 25 μmol) and 81128 
(9.9 mg, 42 μmol) were added. The reaction mixture was stirred in microwave at 80 °C for 
45 min, until a TLC analysis (CH2Cl2/MeOH 10: 1 ) showed the disappearance of the starting 
material (Rf = 0.46) and the formation of a new product (Rf = 0.00). The solvent was 
removed under reduced pressure and the crude was purified by FCC (CH2Cl2/MeOH/NH3 
from 30: 1 to 5: 1: 0.1) affording pure 151 (57 mg, 35.4 μmol, Rf = 0.33 in CH2Cl2/MeOH/NH3 
10: 1: 0.1) as a pale yellow oil, in 85% yield. [α]D22 = + 7.47 (c = 0.91 in CHCl3). 1H-NMR (400 
MHz, CDCl3): δ = 7.58 (br s, 3H, triazole), 5.09-5.01 (m, 6H, H-3, H-4), 4.96-4.91 (m, 3H, H-
5), 4.60 (s, 6H, H-β), 4.34 (t, J = 7.2 Hz, 6H, H-6’), 4.18-4.10 (m, 6H, H-7), 3.44 (s, 6H, H-), 
3.18 (dd, J = 11.4, 5.0 Hz, 3 H, Ha-6), 2.76-2.69 (m, 3H, Ha-1’), 2.63-2.60 (m, 3H, H-2), 2.56-
2.49 (m, 3H, Hb-1’), 2.29 (t, J = 10.8 Hz, 3H, Hb-6), 2.07-1.84 (m, 36H, OAc), 1.45-1.25 (m, 
24H, H-2’, H-3’, H-4’, H-5’) ppm; 13C-NMR (100 MHz, CDCl3): δ = 170.8-169.7 (s, 12C, -
OCOCH3), 145.1 (s, 3C, triazole), 122.4 (s, 3C, triazole), 74.7 (d, 3C, C-5), 72.3 (t, 3C, C-), 
69.6 (d, 3C, C-3), 69.4 (d, 3C, C-4), 65.1 (t, 3C, C-), 61.8 (d, 3C, C-2), 59.7 (t, 3C, C-7), 52.9 
(t, 3C, C-6), 51.6 (t, 3C, C-1’), 50.2(t, 3C, C-6’), 30.3 (t, 3C, C-5’), 26.7 (t, 3C, C-2’), 26.4 (t, 3C, 
C-3’), 25.0 (t, 3C, C-4’), 20.9 (q, 12C, CH3CO) ppm; MS (ESI): m/z 1626.58 (100, Na+); IR 
(CDCl3): 𝜈 = 3690, 3606, 2937, 2862, 2257, 1745, 1602, 1438, 1370, 1234, 1097, 1052, 1032 
cm−1. Elemental analysis (%) for C73H113N13O27 (1604.75): calcd C, 54.64; H, 7.10; N, 11.35; 
found: C, 54.60; H, 7.25; N, 11.37.  
Synthesis of trivalent DNJ based ligand 152: To a solution of compound 151 (56.8 
mg, 35.4 mol) in dry THF (570 μL) at 0 °C, 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-
4(3H)-one (DEPBT 21.2 mg, 70.8 μmol) and N,N-diisopropylethylamine (DIPEA 12.0 μL, 70.8 
μmol) were added. The mixture was stirred at 25 °C for 15 min under a nitrogen 
atmosphere, then a solution of 129 (30.0 mg, 21.6 μmol) in dry THF (225 μl) was added and 
the reaction mixture was stirred at room temperature for 6 days, until a TLC analysis 
 
128 Y. M. Chabre, C. Contino-Pépin, V. Placide, T. C. Shiao and R. Roy, J. Org. Chem., 2008, 73, 5602. 
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(CH2Cl2/MeOH 6: 1) showed the formation of a new product (Rf = 0.7). The reaction mixture 
was diluted with AcOEt (5 mL), washed with NH4Cl (2 × 3 mL), NaHCO3 (2 × 3 mL) and H2O 
(2 × 3 mL), dried over anhydrous Na2SO4 and concentrated under vacuum. Purification 
through gradient column chromatography (CH2Cl2/MeOH from 20: 1 to 10: 1) afforded pure 
152 (61 mg, 30.1 μmol) as a yellow oil, in 94% yield. [α]D18 = + 5.29 (c = 0.87 in CHCl3). 1H-
NMR (400 MHz, CDCl3): δ = 7.54 (br s, 3H, triazole), 6.81 (s, 1H, CON-H), 5.06-4.98 (m, 6H, 
H-3, H-4), 4.94-4.88 (m, 3H, H-5), 4.57 (s, 6H, H-), 4.31 (t, J = 7.2 Hz, 6H, H-6’), 4.15-4.07 
(m, 6H, H-7), 3.84 (s, 2H, L-1), 3.77 (s, 6H, H-), 3.63-3.51 (m, 12 H, from L-2 to L-7), 3.39 (t, 
J = 6.8 Hz, 2H, L-8), 3.15 (dd, J = 11.5, 5.1 Hz, 3H, Ha-6), 2.82 (t, J = 7.4 Hz, 2H, L-18), 2.74-
2.67 (m, 3H, Ha-1’), 2.60-2.58 (m, 3H, H-2), 2.53-2-46 (m, 3H, Hb-1’), 2.28-2.24 (m, 6H, Sac, 
Hb-6), 2.03 (s, 9H, OAc), 1.99 (s, 18H, OAc), 1.98 (s, 9H, OAc), 1.91-1.84 (m, 6H, H-5’), 1.48 
(quint., J = 14.1, 6.8 Hz, 4H, L-9, L-17),  1.33-1.22 (m, 32H, H-2’, H-3’, H-4’, from L-10 to L-
16) ppm; 13C- NMR (50 MHz, CDCl3): δ = 196.0 (s, SC̲OCH3), 170.8–169.7 (s, 12C, -OCOCH3), 
169.6 (s, C̲ONH–), 144.9 (s, 3C, triazole), 122.5 (d, 3C, triazole), 74.7 (d, 3C, C-5), 71.6-70.0 
(t, 8C, from L-1 to L-8), 69.6 (d, 3C, C-3), 69.4 (d, 3C, C-4), 68.9 (t, 3C, C-), 65.0 (t, 3C, C-), 
52.9 (t, 3C, C-6), 51.6 (t, 3C, C-1’), 50.2 (t, 3C, C-6’), 30.3 (q, 30.2 (q, –CH2SCOC̲H3), 29.6–
24.9 (t, 22C, from L-9 to L-18, C-2’- C-5’), 20.8, 20.7 (s, 12C, COC̲H3) ppm; MS (ESI): m/z 
1033.92 (100, (m/z) + 2Na+); IR (CDCl3): 𝜈  = 3022, 2932, 2858, 1744, 1675, 1525, 1369, 
1220, 1098, 1032 cm−1. Elemental analysis (%) for C94H151N13O33S (2023.34): calcd C, 55.80; 
H, 7.52; N, 9.00; found: C, 55.76; H, 7.62; N, 8.92. 
General procedure for the “in situ” deprotection of S-acetyl conjugates 150 and 
152: To a solution of 150 and 152 in CD3OD (20 mg ml−1 and 10 mg ml−1, respectively), 30 
equivalents of NaOMe were added and the reaction mixture was left stirring for 2 hours at 
25 °C under a nitrogen atmosphere. The complete disappearance of the starting material 
was confirmed via 1H-NMR and the crude product was directly used for the preparation of 
Au GNPs. 
Preparation and characterization of Au GNPs: The Au GNPs coated with DNJ 
derivatives (mono- and trivalent) and simple monosaccharides βGlcC5S and aManC5S (DNJ-
βGlc-Au NPs 154,  DNJ-Man-Au NPs 155 and tri-DAB1-βGlc-Au NPs 156, and tri-DNJ-Man 
-Au NPs 157a-b) were prepared by the reduction of an Au(III) salt using sodium borohydride 
in the presence of a mixture of thiol-ending iminosugar conjugate and βGlcC5S 125 and 
ManC5S 147 as ligands, in different ratios following a reported procedure.112 For the 
analysis of the ratio between the iminosugar ligands and βGlcC5S or ManC5S, 1H-NMR 
spectra of the initial mixture and the supernatant after Au-GNP formation were recorded. 
The ligand loading on the Au-GNPs was also evaluated by quantitative NMR (qNMR) using 
3-(trimethylsilyl)propionic-2,2,3,3-d4 acid (TSP-d4) as an internal standard in the D2O 
solution of the Au GNPs. The prepared Au GNPs were freeze-dried and stored at 4 °C. Under 
these conditions, the Au GNPs can be stored for months maintaining their biophysical 
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properties. The Au GNPs 143, coated only with the simple monosaccharide βGlcC5S, and 
158, coated only with the simple monosaccharide ManC5S were also prepared as 
previously described.  
General procedure for the preparation of Au GNPs coated with iminosugars: An 
aqueous solution of HAuCl4 (25 mM, 1 equiv.) was added to a 12 mM methanolic solution 
of a suitable mixture of thiol-ending sugar and iminosugar conjugates (3 equiv. overall). An 
aqueous solution of NaBH4 (1 M, 27 equiv.) was then added in four portions, with vigorous 
shaking. The black suspension formed was shaken for 2 hours at 25 °C. After that, the 
supernatant was removed and analysed by 1H-NMR to study the nanoparticle ligand 
composition. The residue was washed several times with MeOH. In order to separate well 
the nanoparticles from the supernatant centrifugation (12 000 rpm, 2 min) was performed. 
The residue was dissolved in a minimal volume of HPLC gradient grade water and purified 
by dialysis (SnakeSkin® Pleated Dialysis Tubing, 10 000 MWCO and Slide-A-Lyzer® 10K 
Dialysis Cassettes, 10 000 MWCO). Iminosugar coated Au GNPs were obtained as a dark-
brown powder after freeze-drying and characterized via 1H-NMR, UV-Vis spectroscopy and 
TEM analysis. 
Preparation of 40% DNJ-βGlc NPs (154): A 1: 2.3 mixture of thiol-ending 145 (4.5 
mg, 2.65 μmol) and βGlcC5S 125 (1.0 mg, 3.72 μmol) in CD3OD (1.1 mL) was used to obtain 
0.35 mg of AuGNPs 154. TEM (average diameter): 1.8 ±0.4 nm. Quantitative 1H-NMR (400 
MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt 
as an internal standard): 0.15 mg of 154 were dissolved in 200 μL of D2O and 15 μL of D2O 
containing 0.05 wt.% TSP were added and 31 nmoles of DNJ conjugate were found.129 




129 In the quantitative NMR (qNMR) a mediated value of the multiplet corresponding to Ha-1’ proton signal (δ 
= 2.84 ppm, 1H) of DNJ conjugate and the multiplet corresponding to H-6 (δ = 2.60-2.45 ppm, 2H) was selected 
for integration as it falls in a spectral region free of other signals. 




1H NMR of sugar/iminosugar ligands mixture before (left) and after (right) formation of Au GNPs 
154 (400 MHz, CD3OD). 
 
 
1H NMR and 1H qNMR with TSP-d4 of Au GNPs 154 (400 MHz, D2O). 
 
 
TEM micrograph in H2O and size-distribution histogram obtained by measuring 300 
nanoparticles (average diameter double distribution: 1.8 ±0.4 nm). 
 




UV/vis spectrum of H2O solution of Au GNPs 154 recorded at concentration of 0.1 mg/mL. 
 
Preparation of 40% DNJ-Man NPs (155): A 1: 2.3 mixture of thiol-ending 145 (3.8 
mg, 5.89 μmol) and ManC5S 147 (4.2 mg, 14.73 μmol) in CD3OD (1.2 mL) was used to 
obtain 1.33 mg of AuGNPs 155. TEM (average diameter): 2.1 ±0.6 nm. Quantitative 1H-
NMR (400 MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, 
sodium salt as an internal standard): 0.60 mg of 155 were dissolved in 200 μL of D2O and 
40 μL of D2O containing 0.05 wt.% TSP were added and 140 nmoles of DNJ conjugate were 
found.130 Significant peaks: δ = 2.89 (m, 1H, from DNJ conjugate). 
 
 
1H NMR of sugar/iminosugar ligands mixture before (left) and after (right) formation of Au GNPs 
155 (400 MHz, CD3OD). 
 
 
130 In the quantitative NMR (qNMR) the multiplet corresponding to Ha-1’ proton signal (δ = 2.89 ppm, 1H) of 
DNJ conjugate, was selected for integration as it falls in a spectral region free of other signals. 




1H NMR and 1H qNMR with TSP-d4 of Au GNPs 155 (400 MHz, D2O). 
 
 
TEM micrograph in H2O and size-distribution histogram obtained by measuring 300 
nanoparticles (average diameter double distribution: 2.1 ±0.6 nm). 
 
 
UV/vis spectrum of H2O solution of Au GNPs 155 recorded at concentration of 0.1 mg/mL. 
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Preparation of 20% DNJ-βGlc NPs (156): A 1: 2.3 mixture of thiol-ending 152 (10.9 
mg, 7.41 μmol) and βGlcC5S 125 (8.4 mg, 29.64 μmol) in CD3OD (3.1 mL) was used to obtain 
4.5 mg of AuGNPs 156. TEM (average diameter): 2.1 ±0.5 nm. Quantitative 1H-NMR (400 
MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt 
as an internal standard): 0.60 mg of 156 were dissolved in 180 μL of D2O and 40 μL of D2O 
containing 0.05 wt.% TSP were added and 170 nmoles of DNJ conjugate were found.131 
Significant peaks: δ = 7.83 (br s, 3H, triazole from DNJ derivative) ppm. 
 
 
1H NMR of sugar/iminosugar ligands mixture before (left) and after (right) formation of Au GNPs 
156 (400 MHz, CD3OD). 
 
 
1H NMR and 1H qNMR with TSP-d4 of Au GNPs 156 (400 MHz, D2O). 
 
 
131 In the quantitative NMR (qNMR) the multiplet corresponding to the triazole signal (δ = 7.83 ppm, 3H) of 
DNJ conjugate, was selected for integration as it falls in a spectral region free of other signals. 




TEM micrograph in H2O and size-distribution histogram obtained by measuring 300 
nanoparticles (average diameter double distribution: 2.1 ±0.5 nm). 
 
 
UV/vis spectrum of H2O solution of Au GNPs 156 recorded at concentration of 0.1 mg/mL. 
 
Preparation of 20% DNJ-Man NPs (157a): A 1: 2.3 mixture of thiol-ending 152 
(10.9 mg, 7.41 μmol) and ManC5S 147 (8.3 mg, 29.64 μmol) in CD3OD (3.1 mL) was used 
to obtain 3.7 mg of AuGNPs 157a. TEM (average diameter): 2.0 ±0.4 nm. Quantitative 1H-
NMR (400 MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, 
sodium salt as an internal standard): 0.60 mg of 157a were dissolved in 180 μL of D2O and 
40 μL of D2O containing 0.05 wt.% TSP were added and 135 nmoles of DNJ conjugate were 
found.132 Significant peaks: δ = 7.84 (br s, 3H, triazole from DNJ derivative) ppm. 
 
132 In the quantitative NMR (qNMR) the multiplet corresponding to the triazole signal (δ = 7.84 ppm, 3H) of 
DNJ conjugate, was selected for integration as it falls in a spectral region free of other signals. 





1H NMR of sugar/iminosugar ligands mixture before (left) and after (right) formation of Au GNPs 
157a (400 MHz, CD3OD). 
 
 
1H NMR and 1H qNMR with TSP-d4 of Au GNPs 157a (400 MHz, D2O). 
 
 
TEM micrograph in H2O and size-distribution histogram obtained by measuring 300 
nanoparticles (average diameter double distribution: 2.0 ±0.4 nm). 
 




UV/vis spectrum of H2O solution of Au GNPs 157a recorded at concentration of 0.1 mg/mL. 
 
Preparation of 40% DNJ-Man NPs (157b): A 1: 2.3 mixture of thiol-ending 152 
(6.9 mg, 4.70 μmol) and ManC5S 147 (1.27 mg, 4.51 μmol) in CD3OD (0.97 mL) was used 
to obtain 1.7 mg of AuGNPs 157b. TEM (average diameter): 2.1 ±0.5 nm. Quantitative 1H-
NMR (400 MHz, D2O containing 0.05 wt. % of 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, 
sodium salt as an internal standard): 0.60 mg of 157b were dissolved in 180 μL of D2O and 
40 μL of D2O containing 0.05 wt.% TSP were added and 151 nmoles of DNJ conjugate were 
found.133 Significant peaks: δ = 7.81 (br s, 3H, triazole from DNJ derivative), 2.57-2.44 (m, 
6H, from DNJ conjugate) ppm. 
 
 
1H NMR of sugar/iminosugar ligands mixture before (left) and after (right) formation of Au GNPs 
157b (400 MHz, CD3OD). 
 
 
133 In the quantitative NMR (qNMR) a mediated value of the multiplet corresponding to the triazole signal (δ = 
7.84 ppm, 3H) of DNJ conjugate and the multiplet corresponding to H-6 (δ = 2.57-2.44 ppm, 6H) was selected 
for integration as it falls in a spectral region free of other signals. 




1H NMR and 1H qNMR with TSP-d4 of Au GNPs 157b (400 MHz, D2O). 
 
 
TEM micrograph in H2O and size-distribution histogram obtained by measuring 300 
nanoparticles (average diameter double distribution: 2.1 ±0.5 nm). 
 
 
UV/vis spectrum of H2O solution of Au GNPs 157b recorded at concentration of 0.1 mg/mL. 
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3.3.3 1,3-dipolar cycloadditions 
 Aiming to find new methods that do not comprehend the use of copper in synthetic 
procedures, we developed a strategy that totally avoids the CuAAC reaction, by using the 
iteration of three selective and high-yielding steps (1,3-dipolar cycloaddition to nitrone 30, 
N-O bond cleavage of the adduct and selective N- and/or O-allylation), that allows the 
preparation of different multivalent clusters iminosugars based on the natural DAB-1 
moiety as the bioactive epitope. The 1,3-DC of nitrones with alkenes, like the CuAAC 
reaction, is a 100% atom economy reaction. Moreover, it does not need the presence of 
any additive or metal catalyst and requires only heating as the energy source. However, a 
major problem arises, since the 1,3-DC of cyclic nitrones to non-symmetric alkenes affords, 
in principle, two bicyclic isomeric isoxazolidines, each one possessing up to three new 




Figure 3.31: Schematic representation of 1,3-DC of pentaatomic cyclic nitrones to alkenes. 
In order to represent an advantageous method, one must be sure that the 1,3-DC is highly 
stereoselective, reducing drastically the number of the possible diasteroisomers that may 
results from the reaction. In previous work we have proved that the peculiar all-trans 
relative stereochemistry of the D-arabino derived nitrone 30 allows it to undergo highly 
regio- and stereoselective 1,3-DC with mono- and disubstituted alkenes.134 
We envisaged that the high selectivity shown by nitrone 30 may be exploited in a stepwise 
strategy with iteration of the 1,3-DC reaction, expecting formation of a single 
diastereoisomer (or a largely prevalent one) in each cycloaddition step. The proof of 
concept of this strategy for the building of new multivalent iminosugars based on DAB-1 is 
demonstrated in this work with the synthesis of dimeric and trimeric DAB-1 based 
architectures. This procedure, despite its lengthening compared to usual click techniques, 
allows placement of the bioactive units with different topologies, thus increasing the 
chance of achieving optimal interaction with the biological target. 
 
 
134 Martella D., D’Adamio G., Parmeggiani C., Cardona F., Moreno-Clavijo E., Robina I., Goti A., Eur.  
J. Org. Chem., 2016, 1588-1598. 
 




Our results are object of this part of PhD thesis and can be also found in this paper:  
 
Matassini C., D’Adamio G., Vanni C., Goti A., Cardona F. 
Studies for the Multimerization of DAB-1-Based Iminosugars through Iteration of the 




3.3.3.1 Results and discussion 
 Nitrone 30 was synthesized from commercially available tribenzylated D-
arabinose134 and allyl benzyl ether 159 was obtained from benzyl alcohol as previously 
reported.135 We envisaged that the iteration of the whole sequence (N-O bond cleavage, 
N- or O-allylation and 1,3-DC) would afford a growing linear oligomer chain with controlled 
size that contains the pyrrolidine bioactive unit either within the chain (structure A) or as a 
pendant (structure B), or mixed. The first step was the cycloaddition of 30 to 159, 
performed by heating a toluene solution in a closed vial at 110 °C either with an oil bath 
for 2.5 h or using a MW reactor (1.5 h) affording, after purification by flash column 
chromatography (FCC), similar yield (85-86%, scheme 3.47) of the exo-anti isoxazolidine 
160. In both cases, a mixture of two other inseparable stereoisomers was isolated in a very 
small amount (15% and 8% yield). The structure of 160 was assigned on the basis of 
analogies of the 1H NMR spectrum with other cycloadducts obtained with different 
dipolarophiles, and ascertained through 1D NOESY experiments, which showed correlation 
peaks between H-2, H-4 and H-6 protons that are located on the same side of the 
pyrrolizidine ring. Indeed, the dipolarophiles approach anti with respect to the vicinal 
benzyloxy group, and the exo mode is preferred to avoid repulsive steric interactions with 
substituent at C-4 placed on the opposite face, due to the nitrone trans-trans relative 
configuration.69 Reductive cleavage of the N-O bond with 10 equiv of Zn in a 1:1 mixture of 
AcOH/H2O at room temperature for 1.5 h gave quantitatively the amino alcohol 161, which 
did not require further purification (scheme 3.47), then a selective N-allylation of 161 to 
the new dipolarophile 162 was performed using allyl bromide as the electrophile heating 
at 150 °C for 2 h under MW irradiation. In these conditions, N-allyl pyrrolidine 162 was 
obtained in 86% yield (Scheme 2). To confirm the selective N-allylation, compound 162 was 
acetylated to 163 in 66% yield. 
 
135 Ilardi E. A., Stivala C. E., Zakarian A., Org. Lett. 2008, 10, 1727-1730. 





Scheme 3.47: 1,3-DC reaction of nitrone 30 to allyl benzyl ether 159, N-O bond cleavage 
reduction and selective N-allylation. 
Although it is known that selective O-allylation in the presence of a free amine is 
troublesome, we initially employed a hard base such as NaH to verify if satisfactory 
amounts of the desired compound 165 might be afforded avoiding lengthy protecting 
groups strategies. Under these conditions, a mixture of N-allylated 163, O-allylated 165 and 
the N,O-bis allylated pyrrolidines 166 was obtained (scheme 3.48). The selectivity in favor 
of the O-allylated compound 165 was improved considerably (from 8 to 39%) when the less 




Scheme 3.48: Attempted selective O-allylation of amino alcohol 161. 
For this reason, we tried a different methodology, consisting in reacting 161 with benzyl 
bromide in CH3CN with K2CO3 under MW irradiation at 150 °C for 2 h. The N-benzyl 
protected pyrrolidine 166 was then obtained in 81% yield (scheme 3.49), and it was 
expected to be less prone to undergo N-allylation and would be easily deprotected in the 
final debenzylation step. Indeed, allylation of 166 with allyl bromide (3 equiv) and NaH (4 
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equiv) in dry DMF at room temperature afforded the allyl ether 167 in 88% yield (scheme 
3.49). Moreover, direct treatment of 161 with a high excess of allyl bromide (6 equiv) and 
NaH (8 equiv) in dry DMF at room temperature for 16 h afforded exclusively the N,O-bis 
allylated pyrrolidine 165 (81% yield), which was employed as a bivalent dipolarophile in the 
1,3-DC strategy. 
 
Scheme 3.49: Selective O-allylation of amino alcohol 161 and N,O-bis allylation. 
With the three new dipolarophiles 162, 167 and 165 in hand, we investigated their 1,3-
dipolar cycloaddition reactions with nitrone 30. Reaction of N-allylated 162 with 30, 
performed in toluene under MW irradiation at 110 °C for 2.5 h, afforded the exo-anti 
adduct 168 as a single diastereoisomer in 94% yield (Scheme 3.50). The deprotection of the 
perbenzylated adduct 168 was not a trivial task, due to the high basicity and hydrophilicity 
of the final products. When I began this work, a new strategy to obtain the final free amines 
had to be found, and here my contribution to this works inserts. I started with a catalytic 
hydrogenation with Pd/C in MeOH with a few drops of 37% aqueous HCl caused also the 
isoxazolidine ring opening and afforded the bis-pyrrolidinium hydrochloride 169 in 
quantitative yield. By passing the hydrochloride salt 169 through the ion exchange resin 
Dowex 50WX8-200 and eluting successively with MeOH, H2O and 12% aqueous ammonia, 
the free amine 170 was recovered in the ammonia fraction with low yield (13%). However, 
further free amine 170 was obtained by treatment of the MeOH fraction with the strongly 
basic Ambersep 900-OH resin, to reach 40% overall yield of 170.  





Scheme 3.50: Synthesis of the dimeric pyrrolidine 170. Reaction conditions: a) Toluene, MW, 
110 °C, 2.5 h, 94%; b) H2, Pd/C, MeOH, HCl, rt, 16 h, 100%; c) Dowex 50WX8-200, and Ambersep 
900-OH, 40%. 
The cycloaddition of 167 with nitrone 30 was performed by heating in toluene under MW 
irradiation at 110 °C for 2.5 h. The reaction afforded the exo-anti adduct 171 as a single 
diastereoisomer in 87% yield (scheme 3.51). Subsequent catalytic hydrogenation with Pd/C 
in MeOH with some drops of 37% aqueous HCl gave the hydrochloride salt 172 in 
quantitative yield. Treatment with Dowex 50WX8-200 and eluting successively with MeOH, 




Scheme 3.51: Synthesis of the dimeric pyrrolidine 173. Reaction conditions: a) Toluene, MW, 
110 °C, 2.5 h, 87%; b) H2, Pd/C, MeOH, HCl, rt, 16 h, 100%, c) Dowex 50WX8-200, 95%. 
The cycloaddition of 165 to yield the bis-isoxazolidine adduct was finally undertaken. To 
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our delight, a single stereoisomer 174 was recovered in 53% yield, which derived from the 
exo-anti approach of the nitrone to both dipolarophile moieties. Catalytic hydrogenation 
with Pd/C in MeOH with some drops of 37% aqueous HCl gave the trimeric pyrrolidinium 
hydrochloride 175 in quantitative yield. Treatment with Dowex 50WX8-200 and with 




Scheme 3.52: Synthesis of the trimeric pyrrolidine 176. Reaction conditions: a) Toluene, MW, 
110 °C, 1.5 h, 53%; b) H2, Pd/C, MeOH, HCl, rt, 16 h, 100%; c) Dowex 50WX8-200 and Ambersep 
900-OH, 60%. 
 
3.3.3.2 Biological evaluation  
 All the three free amines 170, 173 and 176 were tested against GALNS enzyme, 
that we recently demonstrated to be particularly prone to accept multivalent 
iminosugars45b due to its dimeric nature.44 No inhibition was showed by DAB-1 at 1 mM 
inhibitor concentration, however both dimer 170 and trimer 176 showed IC50 in the low 
micromolar range (0.3 and 0.2 M, respectively), thus confirming that multimerization of 
DAB-1 epitopes generates potent GALNS inhibitors. On the contrary, the dimer 173 
possesses only a 55% inhibitory activity against GALNS, thus suggesting that the ligand 
topology strongly affects the affinity of the oligomeric constructs towards this enzyme, 
indeed, with type B oligomers, presenting the bioactive DAB-1 units more exposed and 
accessible, it could better interact with GALNS (scheme 3.53). 
 





3.3.3.3 Conclusions  
 In conclusions, in this project we explored an alternative synthetic pathway to 
achieve multimeric iminosugars without the use of copper mediated azide alkyne 
cycloaddition. This study could be used as proof of concept for the iteration of 1,3-dipolar 
cycloaddition, N-O-ring opening and selective N-allylation, or O-allylation, or both. The 
synthesis relies on the highly regio- and stereoselective of the 1,3-DC step that allows to 
obtain the new dipolarophiles 162, 165 and 167 which were added again to nitrone 30 and 
finally converted to divalent DAB-1 based pyrrolidines 170 and 173 and trivalent 176, 
respectively. This new strategy for the preparation of multimeric iminosugars involves the 
100% atom economic 1,3-DC in the key steps, it does not employ homogeneous metals nor 
additives, and allows to access three different types of ligand topologies of the final DAB-1 
clusters. 
 
3.3.3.4 Experimental section 
For the general details see paragraph 2.4. 
 
Here are reported data dealing with the synthesis of the free amines 170, 173, 175, 176. 
The other experimental procedures can be found in this paper:   
 
 
Scheme 3.53: Type A andtype B oligomers obtained by the iterative strategy.  
Multivalency in glycosidase inhibition 
__________________________________ 
168 
Matassini C., D’Adamio G., Vanni C., Goti A., Cardona F. 
Studies for the Multimerization of DAB-1-Based Iminosugars through Iteration of the 




Synthesis of bis-pyrrolidine 170: The free amine was obtained by passing the 
hydrochloride salt 169 (35 mg, 0.075 mmol) through a Dowex 50WX8 ion-exchange resin, 
by eluting sequentially with MeOH, H2O and 12% NH4OH. The fraction eluted with 12% 
ammonia afforded the free base 170 (4 mg, 0.010 mmol, 13%). However, the fraction 
eluted with MeOH contained the unaltered hydrochloride salt 169, which after treatment 
with the strongly basic Ambersep 900-OH resin afforded further 8 mg (0.020 mmol) of the 
free amine 170. Compound 170 (12 mg, 0.030 mmol) was therefore obtained as a waxy 
white solid with a 40% overall yield. [α]D25 = +5.7 (c = 0.14 in MeOH); 1H-NMR (400 MHz, 
D2O):  = 3.99-3.96 (m, 2H, H-3 and H-4’), 3.90-3.80 (m, 3H, H-4, H-8 and H-8’), 3.78-3.71 
(m, 4H, H-3’, H-9 and Ha-6’), 3.68 (dd, J = 11.7, 5.9 Hz, 1H, Hb-6’), 3.60 (dd, J = 11.7, 3.9 Hz, 
1H, Ha-6), 3.48 (dd, J = 11.7, 6.3 Hz, 1H, Hb-6), 3.24-3.18 (m, 1H, H-2’), 3.16-3.11 (m, 1H, H-
5), 3.06 (dt, J = 7.8, 3.4 Hz, 1H, H-2), 3.00 (q, J = 4.4 Hz, 1H, H-5’), 2.83 (dd, J = 13.7, 2.5 Hz, 
1H, Ha-9’), 2.63 (dd, J = 13.7, 8.5 Hz, 1H, Hb-9’), 1.86 (dt, J = 14.1, 3.9 Hz, 1H, Ha-7), 1.76 
(ddd, J = 13.7, 9.3, 4.4 Hz, 1H, Ha-7’), 1.72-1.65 (m, 1H, Hb-7’), 1.55 (dt, J = 14.2, 8.3 Hz, 1H, 
Hb-7) ppm; 13C-NMR (50 MHz, D2O):  = 80.7 (d, C-3), 80.3 (d, C-3’), 78.9 (d, C-4’), 76.5 (d, 
C-4), 70.0 (d, C-8’), 67.6 (d, C-5), 65.5 (d, C-8), 65.1 (t, C-6), 65.0 (d, C-2), 61.5 (d, C-5’), 60.0 
(t, C-6’), 59.1 (t, C-9), 57.2 (d, C-2’), 52.3 (t, C-9’), 37.0 (t, C-7’), 30.7 (t, C-7) ppm; MS (ESI): 
m/z calcd for C16H32N2O9 + H+ 396.99; found: 397.22 (100, [M+H]+); Elemental analysis calcd 
(%) for C16H32N2O9 (396.43): C 48.48, H 8.14, N 7.07; found: C 48.46, H 8.10, N 7.06. 
Synthesis of bis-pyrrolidine 173: The free amine 173 was obtained by passing the 
hydrochloride salt 172 (15 mg, 0.032) through a Dowex 50WX8 ion-exchange resin eluting 
sequentially with MeOH, H2O and 12% NH4OH. Elution with ammonia 12% afforded the 
free base 173 (12 mg, 0.030 mmol, 94% yield) as a white waxy solid, that tends to 
spontaneously form the corresponding mono-carbonate salt. [α]D22= + 51.6 (c = 0.45 in 
MeOH); 1H-NMR (400 MHz, D2O):  = 3.97-3.94 (m, 1H, H-8’), 3.91-3.86 (m, 2H, H-3, H-4’), 
3.81-3.66 (m, 9H, H-4, H-3’, H-6’, H-6, Ha-9’, H-9), 3.61-3.56 (m, 1H, H-8), 3.49-3.44 (m. 1H, 
Hb-9’), 3.23-3.07 (m, 4H, H-2, H-2’, H-5’, H-5), 2.02-1.90 (m, 1H, Ha-7), 1.84-1.76 (m, 1H, 
Ha-7’), 1.72-1.61 (m, 2H, Hb-7, Hb-7’) ppm; 13C-NMR (50 MHz, D2O):  = 160.3 (q, 1C, HCO3-
), 80.8, 77.8, 77.1, 77.0 (d, 4C, C-3, C-3’, C-4, C-4’), 73.6 (t, 1C, C-9’), 67.9 (d, 1C, C-8’), 62.6-
61.4 (6C, C-5, C-5’, C-6, C-6’, C-8, C-9), 57.0, 56.8 (2C, C-2’, C-2), 36.0 (t, 1C, C-7’), 34.1 (t, 
1C, C-7) ppm; MS (ESI): m/z calcd for C17H34N2O12+ 397.22; found: 397.28 (100, [M]+); 
Elemental analysis calcd (%) for C17H34N2O12+ (458.46): C 44.54, H 7.48, N 6.11; found: C 
45.05, H 7.44, N 5.84. 
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Synthesis of trimeric pyrrolidinium hydrochloride 175: To a solution of 174 (58 
mg, 0.039 mmol) in 20 mL of MeOH, 29 mg of 10% Pd on carbon and four drops of HCl 37% 
were added while stirring under nitrogen atmosphere, then the mixture was stirred under 
hydrogen atmosphere at room temperature for 16 h. After TLC analysis (PE:AcOEt 2:1) 
showed the disappearance of the starting material (Rf = 0.21) and formation of a new 
product, the mixture was filtered through Celite® and the solvent was removed under 
reduced pressure affording the trimeric pyrrolidinium hydrochloride 175 (27 mg, 0.039 
mmol, 100% yield) as a yellow waxy solid. [α]D24 = + 2.1 (c = 0.43 in MeOH); 1H-NMR (400 
MHz, D2O):  =  4.34 (bs, NH), 4.13-4.03 (m, 7H), 3.99-3.88 (m, 7H), 3.73-3.57 (m, 8H), 3.46-
3.39 (m, 5H), 2.20-2.08 (m, 6H) ppm; 13C-NMR (50 MHz, D2O):  = 77.8, 77.3, 76.3, 74.1 (d, 
7C), 69.0 (d, 2C), 65.3, 63.0, 62.7, 58.2, 58.0, 56.5, 53.1 (11C), 49.2 (t, 1C), 34.6 (t, 2C), 28.2 
(t, 1C) ppm; MS (ESI): m/z calcd for C24H49N3O13 293.67; found: (100, [M]2+). 
Synthesis of trimeric pyrrolidine 176: The free amine was obtained by passing the 
hydrochloride salt 175 (67 mg, 0.096 mmol) through a Dowex 50WX8 ion-exchange resin, 
by eluting sequentially with MeOH, H2O and 12% NH4OH. The fraction eluted with 12% 
ammonia afforded free base 176 (11 mg, 0.019 mmol, 20%). However, the fraction eluted 
with MeOH contained the unaltered hydrochloride salt 175, which after treatment with the 
strongly basic Ambersep 900-OH resin afforded further 23 mg (0.039 mmol) of the free 
amine 176. Compound 176 (34 mg, 0.058 mmol) was therefore obtained as a waxy white 
solid with a 60% overall yield. [α]D24 = + 7.0 (c = 0.70 in MeOH); 1H-NMR (400 MHz, D2O):  
=  3.98 (bs, 1H), 3.93-3.84 (m, 1H), 3.82-3.54 (m, 16H), 3.46 (dd, J = 10.2, 7.0 Hz, 1H), 3.09-
2.96 (m, 5H), 2.86-2.79 (m, 2H), 2.61-2.56 (m, 1H), 1.88-1.81 (m, 1H), 1.76-1.56 (m, 5H) 
ppm; 13C-NMR (50 MHz, D2O):  = 81.8 (1C), 81.7 (1C), 80.6 (1C), 79.8 (1C), 79.4 (1C), 78.1 
(1C), 77.9 (1C), 73.5 (1C), 68.3 (1C), 68.1 (1C), 66.2 (1C), 64.6 (1C), 62.5, 62.3, 61.8, 61.7 
(4C), 59.5 (1C), 57.8 (1C), 57.2 (1C), 52.1 (1C), 49.0 (1C), 38.6, 36.9 (t, 2C), 27.8 (t, 1C) ppm; 
MS (ESI): m/z calcd for C24H47N3O13 585.31; found: 586.38 (100, [M+H]+); Elemental 
analysis calcd (%) for C24H47N3O13 (585.64): C 49.22, H 8.09, N 7.18; found: C 48.95, H 8.32, 
N 9.95. 
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3.3.4 Multimeric trihydroxypiperidines through DRA 
 In the context of the multimerization techniques without the involvement of click 
CuAAC strategy, we are dealing with the development of a new strategy based on the 
double amination reaction (DRA) of the D-mannose derived intermediate 73, whose 
condition were previously developed by our research group,91,136 with different branched 
amines (scheme 3.54), in order to access new multivalent trihydroxypiperidines.  
 
 
Scheme 3.54: Schematic representation of DRA strategy to obtain multivalent 
trihydroxypiperidines. 
This strategy, once set up the optimal conditions to be used in the DRA, which is not as 
trivial as CuAAC, can represent another alternative pathway to those analyzed in chapter 
3. We started the study of this strategy by using ethylenediamine 177 as amine dimeric 
scaffold. We envisaged two synthetic strategies: the first one consisting in the previous 
deprotection of the hydroxyl group in anomeric position of dialdehyde 73 to afford 
intermediate 100, followed by reaction with diamine 177 in the presence of NaBH3CN as 
the reducing agent. Compound 100 indeed was treated with ethylenediamine 177 and 
NaBH3CN (3.0 equiv.) in dry methanol, in the presence of 3Å molecular sieves and AcOH 
(2.0 equiv.) for 5-7 days (scheme 3.55), affording dimeric trihydroxypiperidine 178.    
 
 
Scheme 3.55: Scheme of DRA to access dimeric trihydroxypiperidine 178. 
 
136 Matassini C., Mirabella S., Ferhati X., Faggi C., Robina I., Goti A., Moreno-Clavijo E., Moreno-Vargas A. J., 
Cardona F., Eur. J. Org. Chem. 2014, 5419–5432. 
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However, compound 178 was recovered in low yields (16%) after purification by FCC, 
probably due to the difficulties encountered in the extraction from the aqueous phase, in 
which it remains trapped due to its hydrophilic nature. For this reason, we tried an 
alternative strategy, in which we directly performed the DRA on the benzylated aldehyde 
73, that, in slight excess (1.2 equiv.), was reacted with ethylenediamine 177 (0.5 equiv.) in 
dry methanol and in the presence of 3 Å molecular sieves. After about 2 hours, Pd(OH)2 /C 
was added and the reaction mixture was left stirring under H2 atmosphere for 6 days 
(scheme 3.56); after purification by FCC, compound 179 was obtained in good yield (69%). 
The final deprotection in acidic conditions and treatment with strongly basic resin 
Ambersep 900-OH, afforded compound 178 in 86% overall yield. 
 
  
 Scheme 3.56: Synthesis of dimeric piperidine 178 starting from protected dialdehyde 73. 
Having found these optimal reaction conditions for DRA with protected dialdehyde 73, we 
are now planning to apply them to a list of ‘polibranched’ amines (for example we have 
started with 1,6-hexanediamine) that could allow the synthesis of a small library of 
multimeric trihydroxypiperidines without the use of copper mediated azide alkyne 
cycloaddition CuAAC with all the drawbacks related to it. 
Preliminary inhibition tests were effectuated on a panel of six different human lysosomal 
glycosidases, in collaboration with Prof. Morrone from the Metabolic Diseases laboratory 
of the Meyer Pediatric Hospital of Florence. In particular, the activity of compound 178 was 
tested on the following glycosidases: α-fucosidase (α-Fuc), α- and β-galactosidase (α- and 
β-Gal), α- and β-mannosidase (α- and β-Man) and β-glucosidase (β-Glu or GCase). 
 
  -Fuc -Gal β-Gal  -Man β-Man β-Glu  
178 12 (%) 3 (%) 34 (%) - 3 (%) 17 (%) 
Table 3.33: Inhibitory activity (%) towards a panel of six glucosidases 
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The inhibitory activity of compound 178 towards the lysosomal glycosidases was evaluated 
in leukocytes isolated from healthy donors by measuring enzymatic activity by means of a 
fluorimetric assay: compound 178 (1 mM), leukocyte homogenate and specific synthetic 
substrate (buffered at an appropriate pH) were incubated at 37 ° C for 1 hour. The reaction 
was stopped with pH 10.7 buffer and the fluorescence measured in a SpectraMax M2 
microplate reader. Glycosidase inhibition was calculated with respect to the corresponding 
control. 
A weak inhibition was observed for all the glycosidases towards it was tested: the α-
fucosidase and β-glucosidase enzymes were inhibited in a range lower than 20% (12% and 
17%, respectively), while β-galactosidase was inhibited by 34%. In the case of -Gal and -
Man the inhibition values are lower than 10%. A particular behaviour was observed for α-
mannosidase, whereby compound 178 appears to function as an activator (increase in 
activity by 28%). Few examples are reported in literature of glycosidases activators, but 
they represent a great opportunity in therapeutics, allowing the modulation of the 
biological activity from inhibition to activation.137 We thought that maybe the reason of 
low biological activity of dimeric piperidine 178 is related to the shortness of tether length 
between the two hydroxypiperidine polar heads that could hamper the dimer flexibility. 
For this reason, attempts to synthesize a dimeric piperidine bearing a longer spacer than 
two carbon atoms, are now ongoing in our laboratories, in particular we are synthesizing a 
178 analogue with a six-atom tether length (180, scheme 3.57). 
 
 




137 Alvarez-Dorta D., Brissonnet Y., Saumonneau A., Deniaud D., Bernard J., Yan X., Tellier C., Daligault F., G. 
Gouin S., Chem. Sel., 2017, 2, 9552 – 9556. 
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3.3.4.1 Experimental section 
For the general details see paragraph 2.4. 
Strategy A for the synthesis of piperidine 178: A solution of dialdehyde 100 (107 
mg, 0.57 mmol) in dry MeOH (1 mL) was stirred in the presence of 3Å molecular sieves 
powder for 15 min, under nitrogen atmosphere, NaBH3CN (107 mg, 1.71 mmol), AcOH (65 
L, 1.14 mmol) and ethylenediamine (19 L, 0.28 mmol) were added. The mixture was 
stirred for five days under nitrogen atmosphere. The molecular sieves were removed by 
filtration through Celite and the filtrate was concentrated under vacuum. The residue was 
purified by flash chromatography (CH2Cl2: MeOH: NH3 from 20:1:0.1 to 10:1:1) affording 
178 (27 mg, 0.09 mmol) in 16% as waxy white solid.  
Strategy B for the synthesis of piperidine 179: A solution of dialdehyde 73 (240 
mg, 0.86 mmol) in dry MeOH (10 mL) was stirred in the presence of 3Å molecular sieves 
powder for 15 min, under nitrogen atmosphere and then ethylenediamine (24 L, 0.36 
mmol) was added. Reaction mixture was stirred for 1 hour under nitrogen atmosphere, 
then Pd(OH)2/C (260 mg, in two portions) was added and left stirring under H2 atmosphere 
for six days. The molecular sieves were removed by filtration through Celite and the filtrate 
was concentrated under vacuum. The residue was purified by flash chromatography 
(CH2Cl2: MeOH: NH3 5:1:0.1) affording 179 (93 mg, 0.25 mmol) in 69% as waxy white solid. 
[α]D23 = -14.9 (c= 0.80 in MeOH); 1H NMR (400 MHz, CD3OD) δ = 4.30-4.25 (m, 2H, H-3 e H-
3’), 4.87-4.82 (m, 2H, H-4 e H-4’), 4.82-4.77 (m, 2H, H-5 e H-5’), 2.97 (dd, J= 12.8, 2.6 Hz, 
2H, Ha-2 e Ha-2’), 2.75 (dd, J = 11.9, 2.8 Hz, 2H, Ha-6 e Ha-6’), 2.59 (br s, 4H, H-7 e H-7’), 
2.56 (dd, J = 12.9, 3.3 Hz, 2H, Hb-2 e Hb-2’), 2.19-2.11 (m, 2H, Hb-6 e Hb-6’), 1.48 (s, 6H, 
Me), 1.33 (s, 6H, Me) ppm; 13C NMR (100 MHz, CD3OD) δ = 108.8 (s, 2C, -C(CH3)2), 78.5 (d, 
2C, C-4 e C-4’), 73.0 (d, 2C, C-3 e C-3’), 68.8 (d, 2C, C-5 e C-5’), 56.3 (t, 4C, C-6 e C-6’), 54.2 
(t, 2C, C-7 e C-7’), 54.0 (t, 2C, C-2 e C-2’), 27.1 (q, 2C, Me), 25.2 (q, 2C, Me) ppm; MS (ESI) 
m/z (%) = 373.26 (100, [M+H]+), 395.31 (71, [M+Na]+); IR (CD3OD): 3345, 2990, 2938, 2630, 
1595, 1564, 1462, 1379, 1244, 1221. 
Synthesis of piperidine 178: To a solution of 179 (15 mg, 0.04 mmol) in 2 mL of 
methanol, 4 drops of 1M HCl were added and the mixture was stirred at room temperature 
for 20 hours. The solvent was removed under reduced pressure, and the crude was treated 
with strongly basic resin Ambersep 900-OH and triturated with CH2Cl2: MeOH: NH3 10:1:0.1 
to afford pure piperidine 178 (10 mg, 0.03 mmol) as a waxy white solid in 86% yield. [α]D23 
= -30.1 (c= 0.40 in MeOH). 1H NMR (400 MHz, D2O) δ =3.81-3.77 (m, 2H, H-3 e H-3’), 3.68-
3.61 (m, 2H, H-5 e H-5’), 3.32-3.26(m, 2H, H-4 e H-4’), 2.75-2.60 (m, 4H, Ha-2, Ha-2’, Ha-6 
e Ha-6’), 2.41-2.34 (m, 4H, H-7 e H-7’), 2.14 (m, 2H, Hb-2 e Hb-2’), 1.98-1.87 (m, 2H, Hb-6 e 
Hb-6’) ppm; 13C NMR (100 MHz, D2O) δ = 73.7 (d, 2C, C-4 e C-4’), 67.7 (d, 2C, C-3 e C-3’), 
67.6 (d, 2C, C-5 e C-5’), 56.8 (t, 2C, C-2 e C-2’), 56.0 (t, 2C, C-6 e C-6’), 53.5 (t, 2C, C-7 e C-7’) 






















The carbonic anhydrases (CA, EC 4.2.1.1) are ubiquitous zinc(II) metalloenzymes 
that are found in higher vertebrates, green plants, algae, bacteria, and archaea.138 CA 
catalyzes the reversible hydration of carbon dioxide (CO2) to give bicarbonate (HCO3-) and 
a proton (H+), a fundamental physiological reaction that underpins a multitude of essential 
cellular processes associated with respiration and transport of CO2/HCO3- between 
metabolizing tissues and the lungs, photosynthesis in higher plants, provision of HCO3- for 
biosynthetic pathways (gluconeogenesis, lipogenesis and ureagenesis), pH regulation and 
CO2 homeostasis, electrolyte and fluid secretion.139 In all organisms, this reaction occurs 
very slowly at physiological pH, and for this reason, CAs have the primary function of 




Figure 4.1: Interconversion catalyzed by the carbonic anhydrase. 
There are 7 families known to date, (from  to -CAs), which differ in their preference for 
metal ions used within the active site for performing the catalysis, but most importantly for 
the three-dimensional folding of the protein. 15 Different isozymes are present in humans, 
designated as hCA1, several of which are cytosolic (hCA I-III, hCA VII, hCA XIII), four are 
membrane bound or transmembrane proteins (hCA IV, IX, XII and XIV), two are 
mitochondrial (hCA VA and VB), and one is secreted into the saliva and milk (hCA VI).140 The 
hCAs I and II isoforms are used in humans for the treatment of edema and glaucoma, the 
IV isoform is involved in the extracellular regulation of pH in neurons and in glial cells, hCA 
IX has instead a fundamental role in tumor progression, in acidification and metastasis in 
numerous types of tumors, such as carcinomas of the lungs, colon, breast, esophagus and 
cervix.141 The modulation of CA activity through inhibition (or activation) is therefore a 
promising avenue for the treatment of a wide range of acquired and inherited diseases. 
Moreover, due to the presence of different hCAs isoforms, it is necessary to increase the 
selectivity of the inhibitory activity in order to avoid the side effects connected to the 
inhibition of isoforms not involved in certain pathologies.142 
The most important class of compounds used in the design of such inhibitors are 
 
138 Maren, T. H. Physiol. Rev. 2017, 47, 595–781. 
139 Supuran, C. T.; Casini, A.; Scozzafava, A. Med. Res. Rev. 2003, 535–558. 
140 Lolak N., Akocak S., Bua S., Koca M., Supuran C. T., Bioorg. Chem. 2018, 77, 542–547. 
141 Sapegin A., Kalinin S., Angeli A., Supuran C. T., Krasavin M., Bioorg. Chem., 2018, 76, 140–146. 
142 D'Ambrosio K., Smaine F.-Z., Carta F., De Simone G., Winum J.-Y., Supuran C. T., J. Med. Chem., 2012, 55, 
6776-6783. 
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sufonamides (R-SO2NH2), the most effective zinc binding moiety.143 Indeed, in all the 
investigated enzyme-inhibitor complexes, the binding of the sulfonamide derivatives is 
mainly driven by the coordination of the deprotonated sulfonamide nitrogen to the 
catalytic Zn2+ ion, with consequent substitution of the zinc-bound water molecule, and by 
two H-bonds of the sulfonamide moiety with residue Thr199 of the enzyme (figure 4.2).144  
 
 
Figure 4.2: Binding mechanism of sulfonamides. 
Nevertheless, we have to consider that the substituents linked to -SO2NH2 also play a key 
role, in fact they are carefully selected to be able to interact both with one of the pockets 
of the active site and with the amino acid residues around the prosthetic group,141 and they 
are necessary to improve the interaction between sulfonamide scaffold and CA (Figure 4.3). 
 
 
Figure 4.3: Schematic representation of the interaction between the sulfonamide scaffold and 
the active site of the CA. 
The first sulfonamide studied in 1940 by Mann and Keilin was the simple 
benzenesulfonamide (figure 4.4).145 
 
143 Vullo D., Kumar R. S. S., Scozzafava A., Ferry J. G., Supuran C. T., J. Enz. Inhib. Med. Chem., 2017, 33, 31–36. 
144 Alterio V., Di Fiore A., D’Ambrosio K., Supuran C. T., De Simone G., Chem. Rev. 2012, 112, 4421–4468. 





Figure 4.4: Benzensulfonamide, the first CAs inhibitor studied. 
In later years it was of great interest to note that in almost all the adducts studied, the 
interaction of the benzene sulfonamide fraction with the active site of the enzyme is rather 
similar, i.e. the sulfonamide group is involved in the coordination of the Zn2+ catalytic ion 
and the benzene ring establishes different Van der Waals interactions with amino acid 
residues of the active site (figure 4.5). On the contrary, the substituents on the aromatic 
ring can establish different types of interaction that involve the hydrophobic / hydrophilic 
regions of the active site.144 
 
Figure 4.5: Benzenesulfonamide interactions in the active site. 
Targeting slight differences in active site topology and structure of CAs, has become a 
relevant challenge in this research field, since it would allow to selectively inhibit/activate 
the CAs of interest, depending on the therapeutic application. 
 
4.2 The sugar approach and MVE in CAs modulation   
In recent years, a promising new strategy to differentiate transmembrane hCA IX 
from the physiologically dominant cytosolic isozymes hCA I and II has emerged. It consists 
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in the development of inhibitors with polar or charged tails, thus impairing them the ability 
to diffuse through lipid membranes. The site active of the hCA IX indeed, is outside the cell 
membrane and by binding polar tails to the sulfonamide group makes these inhibitors 
selective for this isoform. This is defined by Winum et al. as the "tail approach".142 
Sugars represent the best candidates for this function. The innovation of sugar approach 
relies in carbohydrates natural occurrence, that is often a prerequisite for biological activity 
and can influence the pharmacokinetics and the mechanism of action and also their good 
solubility in water. Moreover, the variety in the stereochemistry of those compounds can 
be exploited to improve the selectivity and affinity towards a particular isozyme of CA. 
Once understood the importance of the sugar tail, the anomeric sulfonamides, a class of 
glycosides where the sulfonamide function is directly linked to the anomeric carbon of the 
carbohydrate, have been studied. In the figure below (figure 4.6) the different interactions 
of the "tail" with the various amino acid residues of the active site of the hCA II are visible.146 
 
 
Figure 4.6: Interactions of the sugar fraction in the active site of hCA II. 
Another relevant example concerns the synthesis of a class of glycosides where the 
sulfonamide moiety is anchored to sugar by a triazole ring obtained by reaction 
of CuAAC (Copper catalyzed Azide-Alkyne Cycloaddition). In particular Wilkinson and 
collaborators report the formation of a class of glycoconjugate benzenesulfonamides by 
 




reaction between a benzenesulfonamide with an alkyne and an O-glycoside with an azido 
group (figure 4.7).147 
 
 
Figure 4.7: Class of glycoconjugate benzenesulfonamides. 
Among the different approaches reported in literature to obtain more potent and selective 
CAs inhibitors/activators, it has been recently reported those based on the synthesis of 
multivalent structures.148 Indeed, crystallographic studies performed on the CAII isoform 
have shown that more than one molecule can bind in the enzymatic cavity, paving the way 
for a new generation of multivalent inhibitors/activators.142 The first studies in this sense 
date back to 2012, the year in which Whiteside et al. for the first time they used a bivalent 
benzenesulfonamide in the interaction with CA.149 
Among the platforms/ scaffolds that have been explored for the synthesis of new 
multivalent inhibitors/ activators of CA enzymes, there are systems based on gold 
nanoparticles,150 silica,151 dendrimers,152 and peptides (figure 4.8).153  
 
147 Wilkinson B. L., Innocenti A., Vullo D., Supuran C. T., Poulsen S.-A., J. Med. Chem. 2008, 51, 1945–1953. 
148 Kanfar N., Bartolami E., Zelli R., Marra A., Winum J.-Y., Ulrich S., Dumy P., Org. Biomol. Chem. 2015, 13, 9894.   
149 Mack E. T., Snyder P. W., Perez-Castillejos R. P., Bilgicer B. B., Moustakas D. T., Butte M. J., Whiteside G., J. 
Am. Chem. Soc., 2012, 134, 333-345.  
150 M. Stiti, A. Cecchi, M. Rami, M. Abdaoui, V. Barragan-Montero, A. Scozzafava, Y. Guari, J.-Y. Winum, C. T. 
Supuran, J. Am. Chem. Soc. 2008, 130, 16130.   
151 Touisni N., Kanfar N., Ulrich S., Dumy P., Supuran C. T., Mehdi A., Winum J.-Y., Chem. Eur. J. 2015, 21, 10306.   
152 Carta F., Osman S. M., Vullo D., AlOthman Z., Supuran C. T., Org. Biomol. Chem. 2015, 13, 6453   
153 Kanfar N., Tanç M., Dumy P., Supuran C. T., Ulrich S., Winum J.-Y., Chem. Eur. J. 2017, 23, 6788.   




Figure 4.8: Peptide scaffold with ArSO2NH2 moieties. 
Furthermore, the research groups of Prof Supuran and Dr Ratto have reported the 
formulation of hybrid nanoparticle gold and sulfonamide constructs for the recognition and 
inhibition of the CAIX and CAXII isoforms expressed in hypoxic cells.154 
While the importance of the sugar component has been already investigated, the 
effect of an iminosugar-sulfonamide conjugated on CAs has never been studied. Moreover, 
until now, the multivalent effect against the enzyme carbonic anhydrase has been 
investigated exclusively with reference to the sulfonamide function.  
Our project inserts in this context. Our first aim was to examine the effects of 
inhibitors/activators based on iminosugars (in whom synthesis we are expertise) on 
carbonic anhydrases modulation, by synthesizing a small library of monovalent compounds 
containing sugar and iminosugars and to compare their activity in order to identify a new 
class of modulators with a new selectivity profile with respect to the different isozymes of 
CAs. Secondly, we also aimed to design multivalent structures, containing both sugars and 
iminosugars, to evaluate the multivalent effect (MVE) on CAs inhibition.   
This part of PhD project was achieved in collaboration with the group of Prof. 
Supuran of the NEUROFARBA Department of the University of Florence, and, as previously 
announced, aims to synthesize monovalent and multivalent systems based on sugars and 
iminosugars, in order to identify a new class of inhibitors activators with selectivity towards 
different isozymes of CAs. First, we had to synthesize the iminosugar/sugar unities to 
conjugate with the benzene sulfonamide scaffold, that we then linked exploiting the CuAAC 
click reaction, a versatile and very efficient strategy in the construction of multivalent 
iminosugars (see section 3.1). In particular, we performed the reaction on 
benzenesulfonamides with the terminal alkyne-end and a linker amino or thiourea, 
 
154 Ratto F., Witort E., Tatini F., Centi S., Lazzeri L., Carta F., Lulli M., Vullo D., Fusi F., Supuran C.T., Scozzafava 




synthesized in the group of Prof. Supuran and the appropriate sugar/iminosugar derivatives 




Scheme 4.1: Schematic representation of aim of the project. 
In this way we initially built a small library of monovalent compounds containing the 
iminosugar function and the benzene sulfonamide (in addition to the triazole group which 
is formed in the Click Chemistry reaction). In this phase, the aim was to study the role of 
chain length between triazole and iminosugar in order to obtain the best biological 
response in terms of activity / selectivity. Then, for the design of the multivalent 
architectures, we wanted first of all to understand if the multimerization of the sugar unit 
of the whole glycosulfonamide conjugate was possible and then if it would carry some 
advantages in the biological response towards CAs. To do that, we selected as first attempt 
a -glucose properly functionalized, that is compound 182 (scheme 4.2). 
 
 
Scheme 4.2: -glucose unit to conjugate with sulfonamide scaffold. 
Once defined the better synthetic pathway, and once verified if effectively exists a positive 
MVE, the further aim was to multimerize onto dendrimeric scaffold and to link to 
benzenesulfonamide our iminosugars. 
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4.3 Results and discussion 
  
First of all, we dealt with the synthesis of the monovalent ‘glycosylsulfonamide’ 
derivatives containing sugar and iminosugar tails, to have, in the case of the sugar a 
monovalent refence compound to compare with the multivalent structure that we aimed 
to synthesize in a second step of the project. Secondly, by conjugating iminosugars to 
benzenesulfonamide scaffolds, we wanted to evaluate the role of a sugar mimetic on the 
selectivity of the inhibitor towards the different isoforms of hCAs.  
 
Synthesis of monovalent sugar-benzenesulfonamide adduct: 
We started with the synthesis of the sugar derivative, choosing as sugar unit a -glucose 
derivative properly functionalized with a two carbon atoms chain bearing an azido moiety 
in the terminal position to allow the performing of CuAAC reaction with the 
benzenesulfonamide scaffold (182, scheme 4.4). Starting from O-acetyl protected 1-α-
trichloroacetimidate 57 (see chapter 2, scheme 4.3), obtained from tetraacylated D-
glucopyranose, we obtained the azido derivative 183 after a glucosylation reaction 
performed in dry dichloromethane at -76°C in the presence of a Lewis acid to favor the 
formation of the -anomer, and a substitution of the chlorine using sodium azide.155 
 
 
Scheme 4.3: Synthesis of azido derivative 183. 
The subsequent CuAAC reaction was carried out with the azido sugar derivative to form the 
monovalent compound with the benzenesulfonamide scaffold 184. The development of 
the conditions took a long time and several attempts; indeed it was necessary to adapt the 
procedures found in the literature to our specific substrate to efficiently afford compound 
 




185. The first attempt to obtain compound 185 was effectuated by performing the CuAAC 
between azide 183 and the thiourea scaffold 184 (scheme 4.4). 
 
 
Scheme 4.4: Scheme of CuAAC to afford compound 185. 
Unfortunately, the yield was lower than 10%, and for this reason we tried different 
conditions reported in table 4.1, in which we made gradual changes on all the parameters 














time T (°C) yield 
a) 





b) 22 h r.t. <10% 
c) 0.5 0.1 3 1 1 44 h 50 <10% 
d) 0.1 0.001 - 0.35 0.35 18 h r.t. <10% 
 Table 4.1: CuAAC conditions used to afford compound 185. 
 
In all the cases we did not recovered the product in amounts higher than 10% yield. The 
difficulties encountered led us to hypothesize that the problem could derive from the 
particular reagents used, in particular from the use of alkyne 184. Since, despite various 
attempts, none of these changes led to the desired result, we formulated the hypothesis 
that the thiourea function contained in 184 was responsible for these failures. Probably, 
the presence of such copper-coordinating groups hampered the catalytic role of the copper 
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by sequestrating it from the reaction environment. This hypothesis was also confirmed by 
the bad results obtained with other two substrates: the pyrrolidine iminosugar that will be 
illustrate later, and with the deprotected sugar derivative 182 (scheme 4.5). 
 
Scheme 4.5: Attempt with deprotected sugar 182. 
Again, performing the reaction without heating, we did not afford the desired product. 
Based on these results, we then chose to change the synthetic strategy (scheme 4.6). 
According to this new strategy (Strategy B and B’), the thiourea bond is formed in the last 




Scheme 4.6: Alternative strategy to afford compound 186. 
With this new procedure the problem related to the presence of thiourea in the click step 
has been eliminated since this is only subsequently formed by reaction between amine and 
isocyanate; we then chose to perform the click reaction first and finally the coupling. In this 
case, the best yield could be obtained by performing the CuAAC reaction at room 




use of the copper scavenger resin Quadrasil MP® results necessary to efficiently reach the 
desired purity degree.  
 
Synthesis of multivalent sugar-benzenesulfonamide adduct: 
Once the best conditions have been defined for the monovalent adduct, we were able to 
apply this synthetic protocol to our multivalent derivative. We decided to start the study 
of MVE applied to CAs inhibitors with the trimeric scaffold already exploited in other works 
(see section 3.1), the tris-propargylated amine TRIS 81 (scheme 4.7). In this case, we 
performed the reaction using the microwaves heating, and we afforded trivalent adduct in 
45% yield.  
 
Scheme 4.7: Synthesis of trivalent glycosulfonamide 190. 
As final step, we treated compound 190 with strongly basic resin Ambersep 900-OH to 
afford deprotected 191 in quantitative yield (scheme 4.8). 





Scheme 4.8: Deprotection of trivalent 190 to afford final product 191. 
With 191 trivalent compound in hand and following the procedure used in the case of 
monovalent adduct, we performed the coupling reaction with isothiocyanate 189 (scheme 
4.9), but obtaining the final product 192 with a yield lower than 20%. Anyway, we 
recovered it in a sufficient amount to perform the biological assays. 
 
 
Scheme 4.9: Coupling with isothiocyanate. 
Synthesis of monovalent piperidine iminosugar-benzenesulfonamide adducts: 
The first iminosugar that we decide to conjugate to sulfonamide is a trihydroxypiperidine 
iminosugar (192, scheme 4.9). It is synthesized starting from D-mannose derived 
intermediate 80, that was subjected to a double reductive amination with an azido-amino 






Scheme 4.11: Piperidine iminosugar 75 to conjugate with benzenesulfonamide scaffolds. 
Product 75 was obtained with an overall yield of 47%. With the azido derivative in hands, 
in analogy with the sugar monovalent adduct 185, we performed the click reaction with 
propargylamine to afford amino derivative 193 (85% yield), that was first deprotected with 
strongly basic resin Ambersep 900-OH with a quantitative yield, then coupled with 
isothiocyante 189 to afford final benzenesulfonamide conjugate 195 (scheme 4.10). In this 
case the yield of reaction was lower than 20%, but we recovered a sufficient amount of 




Scheme 4.10: Synthesis of compound 195. 
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Synthesis of monovalent pyrrolidine iminosugar-benzenesulfonamide adducts: 
Since our initial project was to compare the biological activity of pyrrolidine and piperidine 
iminosugar, another part of this thesis was dedicated to the synthesis of the pyrrolidine-
benzenesulfonamide glycoconjugates. To do that, we initially chose to use a pyrrolidine 
iminosugar derivative with a comparable chain length of the piperidine compound. 
The iminosugar that we decide to conjugate to sulfonamide is the pyrrolidine 108, whose 
synthesis has already been developed in our group (see chapter 3, scheme 4.11). 
 
 
Scheme 4.11: Synthetic strategy to obtain pyrrolidine derivative 108. 
Starting from commercially available D-arabinose and passing through nitrone key 
intermediate 30, we afforded azido pyrrolidine derivative 108, as already described in 
section 3.2.3. We planned to ‘click’ this azido derivative through CuAAC reaction to the 
three different sulfonamide scaffolds 196, 197 and 184 in order to afford the 







Scheme 4.12: Click reaction of pyrrolidine 108 with the three sulfonamide scaffolds. 
While the synthesis of amino derivative 198 and 199 proceeded without any problems by 
using the click conditions applied in the synthesis of multimeric iminosugars (see section 
3.1), even if the yield of 199 could be improved, the synthesis of thiourea adduct 200 was 
not a trivial task. Indeed, as expected from the results obtained with the sugar adducts, 
performing the cycloaddition in the ‘standard’ conditions used in previous cases (80°C 
heating with microwaves for 45’ minutes and room temperature for 16 hours), we did not 
recover the desired product. Moreover, we tried to change strategy by effectuating the 
click reaction to form the triazole linker, before the formation of thiourea linkage, using 
propargylamine as alkyne to click with pyrrolidine 108 in analogy of strategy used for sugar 
adduct 185 and piperidine iminosugar 201 (scheme 4.13). 
 
Scheme 4.13: Click reaction with propargylamine. 
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Although, after purification by FCC in this case, it was impossible to recover the desired 
product 201. For this reason, we could not afford the final thiourea adduct 200. 
It was no possible to remove the benzyl protecting groups of derivatives 198 and 199 by 
means of catalytic hydrogenation (H2, Pd(OH)2/C). Again, we suspected that the problem is 
related to the presence of the sulfonamide group. We therefore decided to test those 
compounds with benzyl protected hydroxy groups. 
In order to evaluate the effect of a pyrrolidine iminosugar linked to the 
benzenesulfonamide scaffold avoiding the problems related to the deprotection step, we 
decide to elongate the carbon chain on the endocyclic nitrogen of pyrrolidine, as previously 
done in the case of resorcinarene adducts (section 3.2.3). In this case we could efficiently 
perform the deprotection of iminosugar moiety before to conjugate it to the scaffolds. The 
first attempt was effectuated with scaffold 196, since in the previous case gave the best 
yield (scheme 4.14).  
 
 
Scheme 4.14: Conjugation of pyrrolidine 80 to benzenesulfonamide scaffold 202. 
In this case we were able to afford adduct 202 (in a percentage yield that could be improve 
in the future) that we finally tested. Applying the same strategy to obtain the adduct with 
scaffold bearing the sulphur atom (197, scheme 4.12), we did not observe the formation of 
any product, from the FCC we recovered all the starting material. Further investigation to 
better understand those problematics related to CuAAC with benzenesulfonamide 
scaffolds, are now ongoing in our laboratories.  
Aiming to synthesize also the thiourea derivative bearing the longer spacer (203, scheme 
4.15), we tried to apply the same strategy used in the case of sugar adducts, and to perform 
the coupling amine-isothiocyanate. To do that, we first needed to reduce the azido moiety 






Scheme 4.15: Synthesis of thiourea adduct 203. 
In the preliminary attempt the product 203 was obtained with excellent yield (higher than 
90%), and the purification step is now ongoing.  
 
4.4 Biological evaluation  
  
All the synthesized compounds were tested thanks to the collaboration with Prof. 
Supuran of the department of NEUROFARBA (University of Florence). Compounds 186, 192, 
195, 198, 199 and 202 were investigated for their inhibitory effects against four 
physiological relevant isoforms, (hCA I, II, IX and XII) by means of a stopped flow CO2 
hydrase assay.156 The data are shown in table 4.2 with the AAZ (acetazolamide) as reference 
compound, that is the compound sulfonamide based used in the market in the treatment 
of some forms of glaucoma.157  
 
 
Figure 4.9: AAZ, acetazolamide, the reference compound. 
 
156 Khalifah RG., J. Biol. Chem., 1971, 246, 2561–73. 
157 Supuran CT., Expert Rev. Neurother., 2015, 15, 851–6. 






Inhibitors hCA I hCAII hCA IX hCA XII 
186 64.1 148.2 2.3 4.8 
192 759.7 579.3 143.3 207.2 
195 322.2 427.3 135.6 21.7 
198 >10000 >10000 >10000 >10000 
199 >10000 9755 3135 906.0 
202 3228 89.1 2202 438.0 
AAZ 250.0 12.1 25.8 5.7 
 
*Mean from 3 different assays, by a stopped flow technique (errors were in the range of  5-10 % 
of the reported values). 
 
The monovalent sugar adduct 186 resulted a good inhibitor towards all the human CAs, 
showing inhibition percentages comparable to those of the reference compound, that 
results even less potent in the case of hCA IX, one of the isoforms involved in tumoral 
growth. Comparing it with the inhibitory activity of the trivalent compound 192, we can 
notice no enhancement in inhibition percentage, and no selectivity profile towards any 
isoforms. Trying to rationalize those results, we thought that the reason of the lower 
activity with respect to the monovalent analogue may rely in the scaffold structure, also 
considering the excellent inhibitory value obtained with the monovalent sugar derivative 
186. Probably the distance between the sulfonamide moiety and the polar tail, which is 
necessary to impart the selectivity towards the transmembrane forms (IX and XII), is too 
short, hampering in this way the sulfonamide to reach the catalytic site. For this reason, we 
are planning to elongate the tether’s length to obtain a more flexible adduct (see section 
4.4). The activity of the piperidine iminosugar 195 was better than the trivalent sugar 
glycoconjugate, but lower than the monovalent sugar adduct. Indeed, it is a quite good 
inhibitor (remaining in the nanomolar range) but, more interestingly, selective towards 
isoform XII, again important for anticancer applications. It would be interest, once 
improved the reaction conditions and the design of the multimeric scaffold, to evaluate the 
potentiality of the piperidine iminosugar compound when presented in a multimeric 
fashion. Moving to the pyrrolidine derivatives, for those separated from the 




biological activities. In particular, compound 198 did not show inhibition towards any CA 
isoform, while a partial activity was shown by pyrrolidine adduct 199, which resulted even 
quite selective, partially inhibiting isoform XII. Probably those results can be ascribed to the 
benzyl protecting groups that impart hydrophobicity to the whole system. By elongating 
the tether’s length between the tail and the scaffold, an increment of the inhibitory 
potency was observed. Indeed, adduct 202 resulted in a better inhibition with respect to 
the adducts 198 and 199 with the shorter linker. In particular, derivative 202 showed some 
selectivity towards hCAII enzyme, which is involved in some forms of glaucoma.  
 
4.5 Conclusions  
  
In conclusion, in order to identify a class of inhibitors/activators with a new 
selectivity profile towards different isozymes of CAs, we synthesized mono- and multivalent 
systems based on sugar (a -glucose derivative) and iminosugars (piperidine and 
pyrrolidine derivatives), thanks to the collaboration with Prof. Supuran (NEUROFARBA 
department, University of Florence). All new derivatives were tested against four different 
isoforms of human carbonic anhydrases (hCAs I, II, IX and IXX) involved in some forms of 
glaucoma (I and II) and in the processes of tumoral growth (IX and XII), respectively. The 
adducts showed interesting inhibitory potentiality in the cases of monovalent sugar 
glycosulfonamide conjugate 186, the monovalent piperidine adduct 192 and the pyrroline 
derivative bearing a longer tether length 202 (6-C atoms chain). The inactivity (for 
compound 198) and the low inhibition values (for compound 199) of the pyrrolidine 
conjugates with the 2-carbon atom chain linker can be ascribed to the protection of the 
iminosugar hydroxyl groups. Indeed, the presence of free hydroxyl groups seems necessary 
to impart a good solubility in water and to favour the interactions of the inhibitor with the 
enzymatic active site of the carbonic anhydrases. As a matter of fact, pyrrolidine-based 
adduct 202 resulted a quite good inhibitor and, most importantly, was selective towards 
only one isoform, hCAII showing a Ki= 89.1 nM. An unexpected result is that one related to 
the multivalent derivative 192, that lost the inhibitory activity showed by its monovalent 
counterpart against all of the carbonic anhydrase isoforms. Indeed, while monovalent 
sugar derivative 186 showed a remarkably inhibitory potency towards all the four CAs, the 
trivalent analogue 192 resulted to be less potent and selective. Our hypothesis is related 
to the linker’s length between the sulfonamide moiety and the trivalent scaffold, that 
probably is too short resulting in a higher steric hindrance. This feature, indeed, could 
influence the multivalent selective recognition of the sugar tails. For this reason, we 
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designed a new trivalent inhibitor in which the benzenesulfonamide is more distant from 




Scheme 4.15: Synthetic pathway to obtain compound 206 with a longer spacer. 
Starting from trivalent alkyne scaffold 81, we introduced a 4-carbon atoms acid linker 
exploiting the free amino moiety of the TRIS with a coupling reaction, affording compound 
205 (67% yield), that we will click to 183, and deprotect to obtain final compound 207. If 
the biological data will be promising, we will apply the same strategy to the iminosugar-






Scheme 4.16: Deprotection of 206 to afford final 207. 
 
4.6 Experimental section  
  
For the general details see paragraph 2.4. Additionally, the biological inhibition 
tests were performed as it follows:  
An Applied Photophysics stopped-flow instrument has been used for assaying the CA 
catalyzed CO2 hydration activity. Phenol red (at a concentration of 0.2 mM) has been used 
as indicator, working at the absorbance maximum of 557 nm, with 20mM Hepes (pH 7.5) 
as buffer, and 20mM Na2SO4 (for maintaining constant the ionic strength), following the 
initial rates of the CA-catalyzed CO2 hydration reaction for a period of 10–100 s. Stock 
solutions of inhibitor (0.1 mM) were prepared in distilled–deionized water and dilutions up 
to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions 
were preincubated together at room temperature (15 min) prior to assay, in order to allow 
for the formation of the E–I complex. Data from Table 1 were obtained after 15 min 
incubation of enzyme and inhibitor, as usual protocol for all sulfonamides.158 The inhibition 
constants were obtained by non-linear least-squares methods using PRISM 3 and the 




158 Mishra C.B., Kumari S., Angeli A., Monti S.M., Buonanno M., Prakash A., Tiwari M., Supuran C.T., J. Enzyme 
Inhib. Med. Chem., 2016, 31, 174–9. 
159 Chohan Z.H., Scozzafava A., Supuran C.T., J. Enzyme Inhib. Med. Chem., 2002, 17, 261–6. 
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Synthesis of monovalent sugar derivative 186: To a suspension of 188 (62 mg, 0.20 
mmol) in EtOH (3 mL) 189 (86 mg, 0.40 mmol) was added, and the reaction mixture was 
stirred at room temperature for 20 hours. Then, the crude was evaporated under reduced 
pressure and purified by FCC (CH2Cl2:MeOH from 10:1 to 5:1) affording pure 186 (Rf = 0.32, 
15 mg, 0.03 mmol, 14% yield) as a yellow oil. 1H-NMR (400 MHz, CD3OD): δ= 8.12 (s, 1H, H-
triazoleo), 7.83 (AB system, J = 7.0 Hz, 2H, H-Ar), 7.67 (AB system, J = 7.1 Hz, 2H, H-Ar), 4.87 
(s, 2H, H-9), 4.63 (t, J = 4.9 Hz, 2H, H-8), 4.29 (dd, J = 7.8; 1.1 Hz, 1H, H-1), 4.23 (q, J = 5.6 
Hz, 1H, Ha-7), 4.00 (q, J = 6.4, 5.2 Hz, 1H, Hb-7), 3.85 (d, J = 11.9 Hz, 1H, Ha-6), 3.64 (dd, J = 
11.6 Hz; 4.3, 1H, Hb-6), 3.31-3.25 (m, 3H, H-3, H-4, H-5), 3.17 (t, J = 7.8 Hz, 1H, H-2) ppm; 
13C-NMR (100 MHz, CD3OD): δ= 181.6 (s, 1C, C=S), 144.0 (s, 1C, triazole), 142.7 (s, 1C, NH-
C-Ar), 126.6 (d, 1C, triazole), 124.3 (s, 1C, SO2NH2-C-Ar), 122.0 (d, 4C, C-Ar), 103.1 (d, 1C, C-
1), 76.5 (d, 1C, C-2), 73.4 (d, 2C, C-3, C-5), 70.1 (t, 1C, C-6), 67.6 (d, 1C, C-4), 61.2 (t, 1C, C-
7), 50.2 (t, 1C, C-8), 39.1 (t, 1C, C-9) ppm; MS (ESI): m/z calcd (%) for C18H26N6O8S2 518.13; 
found: 541.05 (100%, [M+ Na]+). 
Synthesis of monovalent sugar derivative 190: To a solution of 183 (313 mg, 0.75 
mmol) in 3 ml of a 2:1 THF:H2O mixture were added CuSO4 (30 mol%), sodium ascorbate 
(60 mol%) and TRIS-alkyne 81 (1 equiv.). The reaction mixture was stirred at 80°C (MW 
irradiation) for 45 min until TLC analysis (DCM: MeOH 10:1) showed the disappearance of 
the starting material (Rf = 0.59) and formation of a new product (Rf = 0.00). After filtration 
through Celite®, the solvent was removed under reduced pressure and the crude was first 
treated with Quadrasil® MP resin then purified by FCC (CH2Cl2:MeOH:NH3 from 20:1 to 
10:1:0.1) affording pure 190 (Rf = 0.39, 161 mg, 0.11 mmol, 43% yield) as an orange waxy 
solid. 1H-NMR (400 MHz, CDCl3): δ= 7.63 (s, 3H, H-triazole), 5.16 (t, J = 9.5 Hz, 3H, H-2), 5.05 
(t, J = 9.6 Hz, 3H, H-3), 4.97 (t, J = 9.1 Hz, 3H, H-4), 4.57-4.48 (m, 15H, H-7, H-β, H-1), 4.26-
4.22 (m, 6H, H1-8, Ha-6), 4.11 (d, J = 12.2 Hz, 3H, Hb-6), 3.94-3.90 (m, 3H, Hb-8), 3.71-3.68 
(m, 3H, H-5), 3.45 (ps, 6H, Hα), 2.08 (s, 12H, OAc), 2.01 (s, 12H, OAc), 1.98 (s, 12H, OAc), 
1.93 (s, 12H, OAc)  ppm; 13C-NMR (50 MHz, CDCl3): δ= 170.5, 170.1, 169.4, 169.3 (s, 12C, 
C=O), 144.8 (s, 3C, triazolo), 123.9 (d, 3C, triazolo),100.6 (d, 3C, C-1), 77.7 (s, 3C, C-2), 77.0 
(d, 3C; C-3), 76.4 (s, 3C, C-4), 72.5 (t, 3C; Cα), 72.1 (d, 3C, C-5) 71.0 (t, 3C,C-7) 68.4 (t, 3C, 
Cβ), 67.7 (t, 3C, C-6), 61.8 (s, 1C, HNC(CH2O)3-), 50.0 (t, 3C, C-8), 20.7, 20.6 (q, 12C, CH3) 
ppm; IR (CDCl3): ν = 3684, 2954, 2875, 2360, 2254, 1751, 1431, 1373, 1224, 1043, 931  cm-
1. MS (ESI): m/z calcd (%) for C61H86N10O33 1486.54; found: 755.50 (100%, [(M+ Na)/2]+).  
Synthesis of trivalent sugar derivative 191: Compound 190 was dissolved in MeOH 
(20 mL) and left stirring overnight at room temperature with the strongly basic resin 
Ambersep 900-OH. The reaction mixture was filtered and evaporated under reduced 




90% yield) as a waxy white solid. 1H-NMR (400 MHz, CD3OD): δ= 8.10 (s, 3H, H-triazole), 
4.63 (t, J = 4.5 Hz, 6H, H-8), 4.55 (s, 6H, Hβ), 4.30 (dd, J = 7.8 Hz; 0.8, 3H, H-1), 4.26-4.20 (m, 
3H, Ha-7), 4.00-3.95 (m, 3H, Hb-7), 3.85 (d, J = 11.9 Hz, 3H, Ha-6), 3.66-3.62 (m, 3H, Hb-6), 
3.40 (s, 6H, Hα), 3.31-3.30 (m, 3H, H-3), 3.27-3.26 (m, 6H, H-4, H-5), 3.19 (t, J = 8.2 Hz, 3H, 
H-2) ppm; 13C-NMR (100 MHz, CD3OD): δ= 144.3 (s, 3C, C-triazole), 124.8 (s, 3C, C-triazole), 
103.1 (s, 3C, C-1), 76.6 (d, 6C, C-3, C-4), 76.5 (t, 3C, Cα), 73.5 (d, 2C, C-2), 71.1 (t, 3C, 
HNC(CH2O)3-), 70.1 (d, 3C, C-5), 67.6 (d, 3C, C7), 63.9 (s, 3C, Cβ), 61.3 (s, 1C, C-6), 50.1 (t, 
3C, C-8) ppm; MS (ESI): m/z calcd (%) for C37H62N10O21 982.41; found: 1005.23 (100%, [(M+ 
Na)]+), 983.21 (76%, [(M+ Na)]+). 
Synthesis of trivalent sugar derivative 192: To a suspension of 191 (59 mg, 0.06 
mmol) in EtOH (1 mL) 189 (13 mg, 0.06 mmol) was added, and the reaction mixture was 
stirred at 50°C for 20 hours. Then, the crude was evaporated under reduced pressure and 
purified by FCC (CH2Cl2:MeOH from 10:1 to 1:2) affording pure 192 (Rf = 0.27, 12 mg, 0.01 
mmol, 17% yield) as coulorless oil. 1H-NMR (400 MHz, CD3OD): δ= 8.11 (s, 3H, H-triazole), 
7.75 (AB system, J = 8.8 Hz, 2H, H-Ar), 7.49 (AB system, J = 8.4 Hz, 2H, H-Ar), 4.62 (ps, 12H, 
H-β, H-8), 4.29 (d, J = 7.8 Hz; 1.1, 3H, H-1), 4.25-4.19 (m, 3H, Ha-7), 4.00-3.96 (m, 3-H, Hb-
7), 3.85 (pd, J = 11.8 Hz, 3H, Ha-6), 3.67-3.62 (m, 3H, Hb-6), 3.03 (q, J = 1.6 Hz, 9H, H-3, H-
4, H-5), 3.27-3.26 (m, 6H, Hα), 3.20-3.16 (m,3H, H-2) ppm; 13C-NMR (100 MHz, CD3OD): δ= 
143.9 (s, 3C, C-triazole), 126.4 (s, 3C, C-triazole), 125.1 (s, 1C, SO2NH2-C-Ar), 122.5 (d, 4C, C-
aromatic), 103.1 (s, 3C, C-1), 76.6 (t, 6C, C-3, C-4), 76.5 (d, 3C, Cα), 73.5 (s, 3C, C-2), 70.1 (s, 
6C, C-5), 67.6 (s, 3C, C-7), 63.8 (t, 3C, Cβ), 61.3 (s, 1C, C-6), 50.2 (t, 3C, C-8) ppm; MS (ESI): 
m/z calcd (%) for C44H68N12O23S2 1196.40; found: 1194.96 (100%, [M-H]+). 
Synthesis of monovalent piperidine iminosugar derivative 195: To a suspension 
of 194 (23 mg, 0.08 mmol) in EtOH (1 mL) 189 (17 mg, 0.08 mmol) was added, and the 
reaction mixture was stirred at 50°C for 20 hours. Then, the crude was evaporated under 
reduced pressure and purified by FCC (CH2Cl2:MeOH from 10:1 to 5:1) affording pure 195 
(Rf = 0.33, 6 mg, 0.01 mmol, 15% yield) as yellow waxy solid. 1H-NMR (400 MHz, CD3OD): 
δ= 8.03 (s, 1H, H-triazole), 7.83 (AB system, J = 8.9 Hz, 2H, H-Ar), 7.68 (AB system, J = 8.8 
Hz, 2H, H-Ar), 4.72 (t, J = 6.8 Hz, 2H, H-3’), 3.89-3.86 (m, 1H, H-3), 3.75 (dt, J = 8.0 Hz; 4.1, 
1H, H-4), 3.40-3.30 (m, 3H, H-5, CH2NH2), 2.79-2.69 (m, 2H, Ha-2, Ha-6), 2.36-2.24 (m, 3H, 
Hb-2, H-1’), 2.11-2.01 (m, 3H, Hb-6, H-2’) ppm; 13C-NMR (50 MHz, CD3OD): δ= 144.3 (s, 1C, 
triazole), 126.6 (s, 1C, triazole), 123.8 (s, 2C, aromatic), 122.3 (s, 2C, aromatic), 74.0 (t?, 1C, 
C-4), 68.3 (s, 1C, C-5), 67.9 (s, 1C, C-3), 56.7 (s, 1C, C-6), 56.3 (s, 1C, C-2), 53.8 (s, 1C, C-1’), 
39.1 (s, 1C, C-3’), 29.4 (s, 1C, CH2NH2), 27.0(s, 1C, C-2’) ppm; MS (ESI): m/z calcd (%) for 
C18H27N7O5S2 485.15; found: 508.12 (100%, [M+Na]+). 
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Synthesis of monovalent pyrrolidine iminosugar derivative 198: To a solution of 
108 (103 mg, 0.22 mmol) in 3 ml of a 2:1 THF:H2O mixture were added CuSO4 (30 mol%), 
sodium ascorbate (60 mol%) and alkyne 196 (1 equiv.). The reaction mixture was stirred at 
80°C (MW irradiation) for 45 min until TLC analysis (DCM: MeOH 10:1) showed the 
disappearance of the starting material (Rf = 0.59) and formation of a new product (Rf = 
0.00). After filtration through Celite®, the solvent was removed under reduced pressure 
and the crude was first treated with Quadrasil® MP resin then purified by FCC (AcOEt: 
Hexane = 1:1) affording pure 198 (Rf = 0.10, 125 mg, 0.18 mmol, 82% yield) as a yellow oil. 
[α]D20 = -5.96 (c= 0.57 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 7.60 (d, J = 6.7 Hz, 3H, AB 
system, H-triazole), 7.35-7.21 (m, 15H, H-Ar), 6.48 (d, J = 8.6 Hz, 2H, A’B’ system), 4.80 (d, J 
= 6.3 Hz, 1H, Ha-3’), 4.54-4.29 (m, 8H, H-2’, CH2-OBn), 4.26 (d, J = 5.6 Hz, 1H, Hb-3’), 3.95 
(d, J = 5.0 Hz, 1H, H-3), 3.79 (d, J = 3.7 Hz, 1H, H-4), 3.43 (dd, J = 9.9, 5.2 Hz, 1H, Ha-1’), 3.36 
(dd, J = 9.9, 6.0 Hz, 1H, Ha-6), 3.29 (dd, J = 13.4, 8.0 Hz, 1H, Hb-6), 3.13 (d, J = 10.3 Hz, 1H, 
Ha-2), 2.83 (dq, J = 10.1, 5.1 Hz, 2H, H-5, Hb-1’), 2.66 (dd, J = 10.3, 5.1 Hz, 1H, Hb-2) ppm; 
13C-NMR (100 MHz, CDCl3): δ= 151.0 (s, NH-CAr), 144.4 (s, C-SO2NH2), 138.1 (s, C-triazole), 
129.5-127.8 (d, 16C, C-Ar), 123.1 (d, C-triazole), 112.1 (s, 6C, C-Ar), 85.1 (d, C-4), 81.7 (d, C-
3) 71.7-71.2 (t, 3C, C-Ar), 71.6 (t, C-6), 69.1 (d, C-5), 57.3 (t, C-2), 54.0 (t, C-1’), 49.0 (t, C-2’), 
39.9 (t, C-3’) ppm; IR (CDCl3): ν = 3424, 3273, 3032, 2864, 2249, 1954, 1890, 1811, 1730, 
1599, 1516, 1454, 1335, 1055 cm-1. MS (ESI): m/z calcd (%) for C37H42N6O5S 682.29; found: 
705.28 (100%, [M+ Na]+). 
Synthesis of monovalent pyrrolidine iminosugar derivative 199: To a solution of 
108 (57 mg, 0.12 mmol) in 3 ml of a 2:1 THF:H2O mixture were added CuSO4 (30 mol%), 
sodium ascorbate (60 mol%) and alkyne 197 (1 equiv.). The reaction mixture was stirred at 
80°C (MW irradiation) for 45 min until TLC analysis (DCM: MeOH 10:1) showed the 
disappearance of the starting material (Rf = 0.59) and formation of a new product (Rf = 
0.00). After filtration through Celite®, the solvent was removed under reduced pressure 
and the crude was first treated with Quadrasil® MP resin then purified by FCC (AcOEt: 
Hexane = from 1:5 to 2:1) affording pure 199 (Rf = 0.26, 48 mg, 0.07 mmol, 62% yield) as a 
yellow oil. [α]D22 = -9.93 (c= 0.87 in CHCl3); 1H-NMR (400 MHz, CDCl3): δ= 7.68 (d, J = 8.4 Hz, 
2H, AB system), 7.58 (s, 1H, H-triazole), 7.35-7.20 (m, 17H, H-Ar, A’B’ system), 4.52-4.26 (m, 
8H, H-2’, CH2-OBn), 4.13 (s, 2H, H-3’), 3.92 (d, J = 4.1 Hz, 1H, H-3), 3.74 (d, J = 4.0 Hz, 1H, H-
4), 3.39 (dd, J = 9.8, 5.3 Hz, 1H, Ha-1’), 3.33-2.78 (m, 2H, H-6), 3.10 (d, J = 10.0 Hz, 1H, Ha-
2), 2.83-2.78 (m, 2H, H-5, Hb-1’), 2.60 (dd, J = 10.3, 5.1 Hz, 1H, Hb-2) ppm; 13C-NMR (50 
MHz, CDCl3): δ= 143.6 (s, C-SO2NH2), 143.1 (s, C-triazole), 139.1 (s, S-CAr), 138.2-138.1 (s, 
6C, C-Ar), 128.6-127.0 (d, 16C, C-Ar), 123.4 (d, C-triazole), 85.2 (d, C-4), 81.8 (d, C-3) 73.4-
71.3 (t, 3C, C-Ar), 71.1 (t, C-6), 69.1 (d, C-5), 57.3 (t, C-2), 54.2 (t, C-1’), 49.2 (t, C-2’), 27.4 (t, 
C-3’) ppm; IR (CDCl3): ν = 3433, 3345, 3032, 2920, 2864, 2247, 1584, 1454, 1344, 1167, 1103 




Synthesis of monovalent pyrrolidine iminosugar derivative 202: To a solution of 
81 (35 mg, 0.14 mmol) in 3 ml of a 2:1 THF:H2O mixture were added CuSO4 (30 mol%), 
sodium ascorbate (60 mol%) and alkyne 196 (1 equiv.). The reaction mixture was stirred at 
room temperature for 3 days until TLC analysis (DCM: MeOH 10:1) showed the 
disappearance of the starting material (Rf = 0.63) and formation of a new product (Rf = 
0.00). After filtration through Celite®, the solvent was removed under reduced pressure 
and the crude was first treated with Quadrasil® MP resin then purified by FCC 
(CH2Cl2:MeOH:NH3 from 10:1:0.1 to 7:1:0.1) affording pure 202 (Rf = 0.60, 25 mg, 0.06 
mmol, 43% yield) as a white waxy solid. [α]D23 = -6.25 (c= 0.87 in CHCl3);  1H-NMR (400 MHz, 
CD3OD): δ= 7.82 (s, 1H, H-triazole), 7.57 (d, J = 8.8 Hz, 2H, AB system), 6.65 (d, J = 8.9 Hz, 
2H, A’B’ system), 4.41 (s, 2H, H-7’), 4.32 (t, J = 7.0 Hz, 2H, H-6’), 3.99 (d, J = 4.6 Hz, 1H, H-3), 
3.87 (d, J = 2.4 Hz, 1H, H-4), 3.75-3.67 (m, 2H, H-6), 3.18 (d, J = 10.9 Hz, 1H, Ha-2), 3.02-2.95 
(m, 1H, Ha-1’), 2.92-2.88 (m, 1H, Hb-2), 2.76 (bs, 1H, H-5), 2.60-2.53 (m, 1H, Hb-1’), 1.87-
1.79 (m, 2H, H-5’), 1.51 (t, J = 15.0 Hz, 2H, H-2’), 1.32-1.23 (m, 4H, H-3’, H-4’) ppm; 13C-NMR 
(50 MHz, CD3OD): δ= 152.8 (s, NH-CAr), 147.1 (s, C-SO2NH2), 131.5 (s, C-triazole), 128.9 (d, 
2C, AB system), 124.0 (d, C-triazole), 112.8 (s, 2C, A’B’ system), 79.7 (d, C-4), 76.7 (d, C-3), 
76.0 (d, C-5), 61.8 (t, C-6), 60.6 (t, C-2), 57.2 (t, C-1’), 51.2 (t, C-6’), 39.5 (t, C-7’), 31.0 (t, C-
5’), 27.7-27.1 (t, 3C, from C-2’ to C-4’) ppm; MS (ESI): m/z calcd (%) for C20H32N6O5S 468.22; 
found: 491.36 (100%, [(M+ Na]+), 469.37 (94%, [(M+ Na]+). 
Synthesis of trivalent scaffold 205: A solution of EDC.HCl (1-Ethyl-3-(3-
dimethylaminopropyl) carbodimide hydrochloride (56 µL, 0.31 mmol), 1–
hydroxybenzotriazole (HOBt, 42 mg, 0.31 mmol) and 204 (58 mg, 0.29 mmol) in DCM (29 
mL) was left stirring for 1 hour. and then added to a solution of 81 (67 mg, 0.29 mmol) and 
N,N-diisopropylethylamine (55 µL, 0.31 mmol). The reaction mixture was left stirring at 
room temperature, for 4 days, then diluted with DCM (7 mL) and washed with KHSO4 (2 x 
15 mL), with a satured solution of NaHCO3 (2 x 15 mL) and brine (2 x 15 mL), dried over 
anhydrous Na2SO4 and concentrated under vacuum. The crude was purified by column 
chromatography (DCM: Et2O 2:1) affording pure 205 (Rf = 0.48, 80 mg, 0.19, 67% yield). 1H-
NMR (400 MHz, CDCl3): δ = 5.94 (s, 1H, H-NC=O), 4.78 (s, 1H, Boc-NH), 4.12 (d, J = 2.4 Hz, 
6H, H-), 3.82 (s, 6H, H-), 3.17-3.12 (m, 2H, H-4), 2.43 (t, J = 2.3 Hz, 3H, H-alkyne), 2.7 (t, J 
= 7.1 Hz, 2H, H-2), 1.76 (p, J = 6.9 Hz, 2H, H-3), 1.41 (s, 9H, CH3 Boc) ppm; 13C-NMR (50 MHz, 
CDCl3): δ = 172.8 (s, HN-C=O), 156.3 (s, HN-C=O Boc), 79.7 (s, C-CH3 Boc), 79.3 (s, 3C, C-CH), 
74.7 (d, 3C, C-alkyne), 68.7 (t, 3C, C-), 59.4 (s, C-C-), 58.8 (t, 3C, C-), 40.0 (t, C-4), 34.5 
(t, C-2), 28.6 (q, 3C, C-CH3 Boc), 26.2 (d, C-3) ppm; MS (ESI): m/z calcd (%) for C22H32N2O6 
420.23; found: 443.20 (100%, [M+ Na]+).IR (CDCl3): 𝜈 = 2429, 3306, 2936, 2253, 1703, 1508, 
1470, 1364, 1256, 1219, 1167, 1098, 945 cm−1.
 
 
